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These guidelines were developed jointly by the Ameri-can Society of Health-System Pharmacists (ASHP), the
Infectious Diseases Society of America (IDSA), the Surgical
Infection Society (SIS), and the Society for Healthcare Epide-
miology of America (SHEA). This work represents an update
to the previously published ASHP Therapeutic Guidelines on
Antimicrobial Prophylaxis in Surgery [1], as well as guide-
lines from IDSA and SIS [2,3]. The guidelines are intended to
provide practitioners with a standardized approach to the
rational, safe, and effective use of antimicrobial agents for the
prevention of surgical site infections (SSIs) based on currently
available clinical evidence and emerging issues.
Prophylaxis refers to the prevention of an infection and can
be characterized as primary prophylaxis, secondary prophy-
laxis, or eradication. Primary prophylaxis refers to the pre-
vention of an initial infection. Secondary prophylaxis refers to
the prevention of recurrence or reactivation of a preexisting
infection. Eradication refers to the elimination of a colonized
organism to prevent the development of an infection. These
guidelines focus on primary perioperative prophylaxis.
Guidelines development and use
Members of ASHP, IDSA, SIS, and SHEA were appointed
to serve on an expert panel established to ensure the validity,
reliability, and utility of the revised guidelines. The work of
the panel was facilitated by faculty of the University of
Pittsburgh School of Pharmacy and University of Pittsburgh
Medical Center Drug Use and Disease State Management
Program who served as contract researchers and writers for
the project. Panel members and contractors were required to
disclose any possible conflicts of interest before their ap-
pointment and throughout the guideline development pro-
cess. Drafted documents for each surgical procedural section
were reviewed by the expert panel and, once revised, were
available for public comment on the ASHP website. After
additional revisions were made to address reviewer com-
ments, the final document was approved by the expert panel
and the boards of directors of the above-named organizations.
Strength of evidence and grading of recommendations
The primary literature from the previous ASHP Therapeutic
Guidelines on Antimicrobial Prophylaxis in Surgery [1] was
reviewed together with the primary literature published be-
tween the date of the previous guidelines, 1999, and June 2010,
identified by searches of MEDLINE, EMBASE, and the Co-
chrane Database of Systematic Reviews. Particular attention
was paid to study design, with greatest credence given to
randomized, controlled, double-blind studies. There is a lim-
ited number of adequately powered randomized controlled
trials evaluating the efficacy of antimicrobial prophylaxis in
surgical procedures. Guidelines development included con-
sideration of the following characteristics: validity, reliability,
clinical applicability, flexibility, clarity, and a multidisciplinary
nature as consistent with ASHP’s philosophy on therapeutic
guidelines [4]. The limitations of the evidence base are noted
within each individual procedure section of the guidelines.
Published guidelines with recommendations by experts in a
procedure area (e.g., American College of Obstetricians and
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Gynecologists [ACOG]) and noted general guidelines (e.g., U.S.
Centers for Disease Control and Prevention [CDC], Scottish
Intercollegiate Guidelines Network,Medical Letter, SIS, SHEA/
IDSA) were also considered [2,3,5–11].
Recommendations for the use of antimicrobial prophylaxis
are graded according to the strength of evidence available. The
strength of evidence represents only support for or against
prophylaxis anddoes not apply to the antimicrobial agent, dose,
or dosage regimen. Studies supporting the recommendations
for the use of antimicrobial therapy were classified as follows:
 Level I (evidence from large, well-conducted, random-
ized, controlled clinical trials or a meta-analysis),
 Level II (evidence from small, well-conducted, ran-
domized, controlled clinical trials),
 Level III (evidence from well-conducted cohort studies),
 Level IV (evidence from well-conducted case–control
studies),
 Level V (evidence from uncontrolled studies that were
not well conducted),
 Level VI (conflicting evidence that tends to favor the
recommendation), or
 Level VII (expert opinion or data extrapolated from
evidence for general principles and other procedures).
This system has been used by the Agency for Healthcare
Research and Quality, and ASHP, IDSA, SIS, and SHEA
support it as an acceptable method for organizing strength of
evidence for a variety of therapeutic or diagnostic recom-
mendations [4]. Each recommendation was categorized ac-
cording to the strength of evidence that supports the use or
nonuse of antimicrobial prophylaxis as category A (levels
I–III), category B (levels IV–VI), or category C (level VII).
When higher-level data are not available, a category C
recommendation represents a consensus of expert panel
members based on their clinical experience, extrapolation
from other procedures with similar microbial or other clinical
features, and available published literature. In these cases, the
expert panel also extrapolated general principles and evi-
dence from other procedures. Some recommendations in-
clude alternative approaches in situations in which panel
member opinions were divided.
A major limitation of the available literature on antimi-
crobial prophylaxis is the difficulty in establishing significant
differences in efficacy between prophylactic antimicrobial
agents and controls (including placebo, no treatment, or other
antimicrobial agents) due to study design and low SSI rates
for most procedures. A small sample size increases the like-
lihood of a Type II error; therefore, there may be no apparent
difference between the antimicrobial agent and placebo when
in fact the antimicrobial has a beneficial effect [12]. A valid
study is placebo-controlled and randomized with a sufficient
sample in each group to avoid a Type II error. Of note, pro-
phylaxis is recommended in some cases due to the severity of
complications of postoperative infection (e.g., an infected
device that is not easily removable) necessitating precau-
tionary measures despite the lack of statistical support.
Summary of key updates
These guidelines reflect substantial changes from the
guidelines published in 1999 [1]. Highlights of those changes
are outlined here.
Preoperative-dose timing. The optimal time for admin-
istration of preoperative doses is within 60 min before surgi-
cal incision. This is a more-specific time frame than the
previously recommended time, which was ‘‘at induction of
anesthesia.’’ Some agents, such as fluoroquinolones and
vancomycin, require administration over one to two hours;
therefore, the administration of these agents should begin
within 120 min before surgical incision.
Selection and dosing. Information is included regarding
the approach to weight-based dosing in obese patients and the
need for repeat doses during prolonged procedures [13–18].
Obesity has been linked to an increased risk for SSI. The
pharmacokinetics of drugs may be altered in obese patients, so
dosage adjustments based on body weight may be warranted
in these patients. For all patients, intraoperative redosing is
needed to ensure adequate serum and tissue concentrations of
the antimicrobial if the duration of the procedure exceeds two
half-lives of the drug or there is excessive blood loss during the
procedure (Table 1). Recommendations for selection of anti-
microbial agents for specific surgical procedures and alterna-
tive agents (e.g., for patients with allergies to b-lactam
antimicrobials) are provided in Table 2.
Duration of prophylaxis. New recommendations for a
shortened postoperative course of antimicrobials involving a
single dose or continuation for less than 24 hours are pro-
vided. Further clarity on the lack of need for postoperative
antimicrobial prophylaxis based on the presence of indwell-
ing drains and intravascular catheters is included.
Common principles. A section addressing concepts that
apply to all types of surgical procedures has been added.
Expanded and new recommendations are provided for plas-
tic, urology, cardiac, and thoracic procedures, as well as
clarity on prophylaxis when implantable devices are inserted.
The latest information on the use of mupirocin and on the role
of vancomycin in surgical prophylaxis is summarized in these
updated guidelines.
Application of guidelines to clinical practice
Recommendations are provided for adult (age 19 years or
older) and pediatric (age 1–18 years) patients. These guide-
lines do not specifically address newborn (premature and full-
term) infants.While the guidelines do not address all concerns
for patients with renal or hepatic dysfunction, antimicrobial
prophylaxis often does not need to be modified for these pa-
tients when given as a single preoperative dose before sur-
gical incision.
The recommendations herein may not be appropriate for
use in all clinical situations. Decisions to follow these recom-
mendations must be based on the judgment of the clinician
and consideration of individual patient circumstances and
available resources.
These guidelines reflect current knowledge of antimicrobial
prophylaxis in surgery. Given the dynamic nature of scientific
information and technology, periodic review, updating, and
revisions are to be expected.
Special patient populations
Pediatric patients. Pediatric patients undergo a num-
ber of procedures similar to adults that may warrant
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Table 1. Recommended Doses and Redosing Intervals for Commonly Used Antimicrobials
for Surgical Prophylaxis
Recommended Dose
Antimicrobial Adultsa Pediatricsb
Half-life in Adults
With Normal Renal
Function, h [19]
Recommended Redosing
Interval (From Initiation
of Preoperative Dose), hc
Ampicillin–
sulbactam
3 g (ampicillin
2 g/sulbactam 1g)
50mg/kg of the
ampicillin
component
0.8–1.3 2
Ampicillin 2 g 50mg/kg 1–1.9 2
Aztreonam 2g 30mg/kg 1.3–2.4 4
Cefazolin 2 g, 3 g for pts
weighing ‡ 120 kg
30mg/kg 1.2–2.2 4
Cefuroxime 1.5 g 50mg/kg 1–2 4
Cefotaxime 1 gd 50mg/kg 0.9–1.7 3
Cefoxitin 2 g 40mg/kg 0.7–1.1 2
Cefotetan 2 g 40mg/kg 2.8–4.6 6
Ceftriaxone 2 ge 50–75mg/kg 5.4–10.9 NA
Ciprofloxacinf 400mg 10mg/kg 3–7 NA
Clindamycin 900mg 10mg/kg 2–4 6
Ertapenem 1g 15mg/kg 3–5 NA
Fluconazole 400mg 6mg/kg 30 NA
Gentamicing 5mg/kg based on
dosing weight
(single dose)
2.5mg/kg based
on dosing weight
2–3 NA
Levofloxacinf 500mg 10mg/kg 6–8 NA
Metronidazole 500mg 15mg/kg 6–8 NA
Neonates weighing
< 1,200 g should
receive a single
7.5-mg/kg dose
Moxifloxacinf 400mg 10mg/kg 8–15 NA
Piperacillin–
tazobactam
3.375 g Infants 2–9 mo:
80mg/kg of the
piperacillin
component
0.7–1.2 2
Children > 9 mo and
£ 40 kg: 100mg/kg
of the piperacillin
component
Vancomycin 15mg/kg 15mg/kg 4–8 NA
Oral antibiotics for
colorectal surgery
prophylaxis (used
in conjunction
with a mechanical
bowel preparation)
Erythromycin base 1 g 20mg/kg 0.8–3 NA
Metronidazole 1 g 15mg/kg 6–10 NA
Neomycin 1 g 15mg/kg 2–3 (3% absorbed
under normal
gastrointestinal
conditions)
NA
aAdult doses are obtained from the studies cited in each section. When doses differed between studies, expert opinion used the most-often
recommended dose.
bThe maximum pediatric dose should not exceed the usual adult dose.
cFor antimicrobials with a short half-life (e.g., cefazolin, cefoxitin) used before long procedures, redosing in the operating room is
recommended at an interval of approximately two times the half-life of the agent in patients with normal renal function. Recommended
redosing intervals marked as ‘‘not applicable’’ (NA) are based on typical case length; for unusually long procedures, redosing may be needed.
dAlthough FDA-approved package insert labeling indicates 1 g,14 experts recommend 2g for obese patients.
eWhen used as a single dose in combination with metronidazole for colorectal procedures.
fWhile fluoroquinolones have been associated with an increased risk of tendinitis/tendon rupture in all ages, use of these agents for single-
dose prophylaxis is generally safe.
gIn general, gentamicin for surgical antibiotic prophylaxis should be limited to a single dose given preoperatively. Dosing is based on the
patient’s actual body weight. If the patient’s actual weight is more than 20% above ideal body weight (IBW), the dosing weight (DW) can be
determined as follows: DW= IBW+ 0.4(actual weight- IBW).
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antimicrobial prophylaxis. Although pediatric-specific pro-
phylaxis data are sparse, available data have been evaluated
and are presented in some of the procedure-specific sections
of these guidelines. Selection of antimicrobial prophylactic
agents mirrors that in adult guidelines, with the agents of
choice being first- and second-generation cephalosporins, re-
serving the use of vancomycin for patients with documented
b-lactam allergies [19,20]. While the use of a penicillin with a
b-lactamase inhibitor in combination with cefazolin or van-
comycin and gentamicin has also been studied in pediatric
patients, the number of patients included in these evaluations
remains small [20–23]. As with adults, there is little evidence
supporting the use of vancomycin, alone or in combination
with other antimicrobials, for routine perioperative antimi-
crobial prophylaxis in institutions that have a high prevalence
of methicillin-resistant Staphylococcus aureus (MRSA). Van-
comycin may be considered in children known to be colo-
nized with MRSA and, in one retrospective historical cohort
study, was shown to decrease MRSA infections [21]. Mupir-
ocin use has been studied in and is efficacious in children
colonized with MRSA, but there are limited data supporting
its use perioperatively [24–30]. However, there is little reason
to think that the impact and effect would be any different in
children, so its use may be justified. Additional studies in this
setting are needed to establish firm guidelines.
Unless noted in specific sections, all recommendations for
adults are the same for pediatric patients, except for dosing. In
most cases, the data in pediatric patients are limited and have
been extrapolated from adult data; therefore, nearly all
pediatric recommendations are based on expert opinion. In
some sections, pediatric efficacy data do not exist and thus are
not addressed in these guidelines. Fluoroquinolones should
not be routinely used for surgical prophylaxis in pediatric
patients because of the potential for toxicity in this popula-
tion. The same principle of preoperative dosing within 60 min
before incision has been applied to pediatric patients [20–23].
Additional intraoperative dosing may be needed if the dura-
tion of the procedure exceeds two half-lives of the antimi-
crobial agent or there is excessive blood loss during the
procedure [19,21]. As with adult patients, single-dose pro-
phylaxis is usually sufficient. If antimicrobial prophylaxis is
continued postoperatively, the duration should be less than
24 h, regardless of the presence of intravascular catheters or
indwelling drains [19,22,23,31,32]. There are sufficient phar-
macokinetic studies of most agents to recommend pediatric
dosages that provide adequate systemic exposure and, pre-
sumably, efficacy comparable to that demonstrated in adults.
Therefore, the pediatric dosages provided in these guidelines
are based largely on pharmacokinetic data and the extrapo-
lation of adult efficacy data to pediatric patients. Because
few clinical trials have been conducted in pediatric surgical
patients, strength of evidence criteria have not been applied to
these recommendations. With few exceptions (e.g., ami-
noglycoside dosages), pediatric dosages should not exceed
the maximum adult recommended dosages. Generally, if
dosages are calculated on a milligram-per-kilogram basis for
children weighingmore than 40 kg, the calculated dosage will
exceed the maximum recommended dosage for adults; adult
dosages should therefore be used.
Patients with prosthetic implants. For patients with ex-
isting prosthetic implants who undergo an invasive proce-
dure, there is no evidence that antimicrobial prophylaxis
prevents infections of the implant. However, updated
guidelines from the American Heart Association (AHA)
suggest that prophylaxismay be justified in a limited subset of
patients for the prevention of endocarditis [11].
Common principles and procedure-specific guidelines
The Common Principles section has been developed to
provide information common to many surgical procedures.
These principles are general recommendations based on cur-
rently available data at the time of publication that may
change over time; therefore, these principles need to be ap-
plied with careful attention to each clinical situation. Detailed
information pertinent to specific surgical procedures is in-
cluded in the procedure-specific sections of these guidelines.
In addition to patient- and procedure-specific consider-
ations, several institution-specific factors must be considered
by practitioners before instituting these guidelines. The
availability of antimicrobial agents at the institution may be
restricted by local antimicrobial-use policy or lack of approval
for use by regulatory authorities. Medications that are no
longer available or not approved for use by the U.S. Food and
Drug Administration (FDA) are so noted. Local resistance
patterns should also be considered in selecting antimicrobial
agents and are discussed in the colonization and resistance
patterns section of the Common Principles section.
Requirements for effective surgical prophylaxis
Appendix A lists the wound classification criteria currently
used by the CDC National Healthcare Safety Network
(NHSN) and Healthcare Infection Control Practices Advisory
Committee (HICPAC) [33–35]. Criteria for defining an SSI
have also been established by NHSN (Appendix B) [8,36].
These definitions assist in evaluating the importance of pro-
viding antimicrobial prophylaxis and the potential conse-
quences of infection, including the need for treatment. Some
criteria vary slightly by procedure.
Although antimicrobial prophylaxis plays an important
role in reducing the rate of SSIs, other factors such as attention
to basic infection-control strategies [37], the surgeon’s expe-
rience and technique, the duration of the procedure, hospital
and operating-room environments, instrument-sterilization
issues, preoperative preparation (e.g., surgical scrub, skin
antisepsis, appropriate hair removal), perioperative manage-
ment (temperature and glycemic control), and the underlying
medical condition of the patient may have a strong impact on
SSI rates [5,8]. These guidelines recognize the importance of
these other factors but do not include a discussion of or any
recommendations regarding these issues beyond the optimal
use of prophylactic antimicrobial agents. Patient-related fac-
tors associated with an increased risk of SSI include extremes
of age, nutritional status, obesity, diabetes mellitus, tobacco
use, coexistent remote body-site infections, altered immune
response, corticosteroid therapy, recent surgical procedure,
length of preoperative hospitalization, and colonization with
microorganisms. Antimicrobial prophylaxis may be justified
for any procedure if the patient has an underlying medical
condition associated with a high risk of SSI or if the patient is
immunocompromised (e.g., malnourished, neutropenic, re-
ceiving immunosuppressive agents).
80 SURGICAL PROPHYLAXIS GUIDELINES
Antimicrobial prophylaxis may be beneficial in surgical
procedures associated with a high rate of infection (i.e., clean-
contaminated or contaminated procedures) and in certain
clean procedures where there are severe consequences of in-
fection (e.g., prosthetic implants), even if infection is unlikely.
While prophylactic antimicrobials are not indicated for some
clean surgical procedures [8], available data suggest that the
relative risk reduction of SSI from the use of antimicrobial
prophylaxis is the same in clean and in higher-risk procedures
[38]. The decision to use prophylaxis depends on the cost of
treating and the morbidity associated with infection compared
with the cost andmorbidity associatedwith using prophylaxis.
Antimicrobial prophylaxis is justified for most clean-contami-
nated procedures. The use of antimicrobial agents for dirty
procedures (Appendix A) or established infections is classified
as treatment of presumed infection, not prophylaxis. See the
procedure-specific sections for detailed recommendations.
Quality improvement efforts
National, state, local, and institutional groups have devel-
oped and implemented collaborative efforts to improve
the appropriateness of surgical antimicrobial prophylaxis.
Various process and outcomes measures are employed, and
results are disseminated. Institutional epidemiology and
infection-control programs, state-based quality-improvement
campaigns (e.g., the Michigan Surgical Quality Collaborative,
the Washington State Surgical Clinical Outcomes Assessment
Program [39,40]), CDC, NHSN, the National Surgical Quality
Improvement Program, The Joint Commission, and the Na-
tional Quality Forum have been instrumental in developing
programs to prevent SSIs.
Over the past decade or more, several organizations, pay-
ers, and government agencies, including the Centers for
Medicare and Medicaid Services (CMS), have established
national quality-improvement initiatives to further improve
the safety and outcomes of health care, including surgery
[41–47]. One area of focus in these initiatives for patients un-
dergoing surgical procedures is the prevention of SSIs. The
performance measures used, data collection and reporting
requirements, and financial implications vary among the
initiatives. The Surgical Care Improvement Project (SCIP)
began in 2002 as the Surgical Infection Prevention (SIP) pro-
ject, focusing on the timing, selection, and duration of pro-
phylactic antimicrobial agents [41,42]. The SIP project was
expanded to SCIP to include additional process measures
surrounding patient safety and care during surgical proce-
dures, including glucose control, venous thromboembolism
prophylaxis, hair removal, and temperature control. Similar
measures have been adopted by The Joint Commission [43].
The Physicians Quality Reporting System was established in
2006 to provide financial incentives to physicians meeting
performance standards for quality measures, including sur-
gery-related measures similar to those reported for SCIP and
the Joint Commission [44]. Data are required to be collected by
institutions and reported to payers [42,44,46]. Data for CMS
and the Physicians Quality Reporting System measures are
displayed on public websites to allow consumers to compare
performance among hospitals. Institutional data collection and
reporting are required, with financial incentives tied to per-
formance to varying degrees, including payment for reporting,
payment increases formeeting or exceedingminimum levels of
performance, payment reduction for poor performance, and
lack of payment for the development of surgical complications,
such as mediastinitis.
Quality improvement initiatives and mandated perfor-
mance reporting are subject to change, so readers of these
guidelines are advised to consult their local or institutional
quality-improvement departments for new developments in
requirements for measures and data reporting that apply to
their practice.
Cost containment
Few pharmacoeconomic studies have addresed surgical
antimicrobial prophylaxis; therefore, a cost-minimization
approach was employed in developing these guidelines. The
antimicrobial agent recommendations are based primarily on
efficacy and safety. Individual institutions must consider their
acquisition costs when implementing these guidelines.
Additional cost savings may be realized through collabo-
rative management by pharmacists and surgeons to select the
most cost-effective agent and minimize or eliminate postop-
erative dosing [48–50]. The use of standardized antimicrobial
order sets, automatic stop-order programs, and educational
initiatives has been shown to facilitate the adoption of
guidelines for surgical antimicrobial prophylaxis [51–58].
Common principles
Ideally, an antimicrobial agent for surgical prophylaxis
should (1) prevent SSI, (2) prevent SSI-related morbidity and
mortality, (3) reduce the duration and cost of health care (when
the costs associatedwith themanagement of SSI are considered,
the cost-effectiveness of prophylaxis becomes evident) [51,52],
(4) produce no adverse effects, and (5) have no adverse conse-
quences for themicrobial flora of the patient or the hospital [53].
To achieve these goals, an antimicrobial agent should be (1)
active against the pathogens most likely to contaminate the
surgical site, (2) given in an appropriate dosage and at a time
that ensures adequate serum and tissue concentrations during
the period of potential contamination, (3) safe, and (4) admin-
istered for the shortest effective period to minimize adverse ef-
fects, the development of resistance, and costs [8,59,60].
The selection of an appropriate antimicrobial agent for a
specific patient should take into account the characteristics of the
ideal agent, the comparative efficacy of the antimicrobial agent
for the procedure, the safety profile, and the patient’smedication
allergies. A full discussion of the safety profile, including adverse
events, drug interactions, contraindications, and warnings, for
each antimicrobial agent is beyond the scope of these guidelines.
Readers of these guidelines should review the FDA-approved
prescribing information and published data for specific antimi-
crobial agents before use. For most procedures, cefazolin is the
drug of choice for prophylaxis because it is the most widely
studied antimicrobial agent, with proven efficacy. It has a de-
sirable duration of action, spectrumof activity against organisms
commonly encountered in surgery, reasonable safety, and low
cost. There is little evidence to suggest that broad-spectrum an-
timicrobial agents (i.e., agents with broad in vitro antibacterial
activity) result in lower rates of postoperative SSI comparedwith
older antimicrobial agents with a narrower spectrum of activity.
However, comparative studies are limited by small sample sizes,
resulting in difficulty detecting a significant difference between
antimicrobial agents; therefore, antimicrobial selection is based
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on cost, safety profile, ease of administration, pharmacokinetic
profile, and bactericidal activity.
Common surgical pathogens
The agent chosen should have activity against the most
common surgical site pathogens. The predominant organ-
isms causing SSIs after clean procedures are skin flora, in-
cluding S. aureus and coagulase-negative staphylococci (e.g.,
S. epidermidis) [61]. In clean-contaminated procedures, in-
cluding abdominal procedures and heart, kidney, and liver
transplantations, the predominant organisms include gram-
negative rods and enterococci in addition to skin flora. Ad-
ditional details on common organisms can be found in pro-
cedure-specific sections of these guidelines.
Recommendations for the selection of prophylactic anti-
microbials for various surgical procedures are provided in
Table 2. Adult and pediatric dosages are included in Table 1.
Agents that are FDA-approved for use in surgical antimicro-
bial prophylaxis include cefazolin, cefuroxime, cefoxitin, ce-
fotetan, ertapenem, and vancomycin [62–67].
Trends in microbiology
The causative pathogens associated with SSIs in U.S. hos-
pitals have changed over the past two decades. Analysis of
National Nosocomial Infections Surveillance (NNIS) System
data found that the percentage of SSIs caused by gram-
negative bacilli decreased from 56.5% in 1986 to 33.8% in 2003
[68]. Staphylococcus aureus was the most common pathogen,
causing 22.5% of SSIs during this time period. NHSN data
from 2006 to 2007 revealed that the proportion of SSIs caused
by S. aureus increased to 30%, with MRSA comprising 49.2%
of these isolates [61]. In a study of patients readmitted to U.S.
hospitals between 2003 and 2007 with a culture-confirmed
SSI, the proportion of infections caused by MRSA increased
significantly from 16.1% to 20.6% ( p< 0.0001) [69]. The MRSA
infections were associated with higher mortality rates, longer
hospital stays, and higher hospital costs compared with other
infections.
Spectrum of activity
Antimicrobial agents with the narrowest spectrum of ac-
tivity required for efficacy in preventing infection are re-
commended in these guidelines. Alternative antimicrobial
agents with documented efficacy are also listed herein. In-
dividual health systems must consider local resistance pat-
terns of organisms and overall SSI rates at their site when
adopting these recommendations. Resistance patterns from
organisms causing SSIs—in some cases procedure-specific
resistance patterns—should take precedence over hospital-
wide antibiograms.
Vancomycin
In 1999, HICPAC, an advisory committee to CDC and the
Secretary of the Department of Health and Human Services,
collaborated with other major organizations to develop rec-
ommendations for preventing and controlling vancomycin
resistance [70]. The recommendations are echoed by these and
other guidelines [6,7,41,71]. Routine use of vancomycin pro-
phylaxis is not recommended for any procedure [8]. Vanco-
mycin may be included in the regimen of choice when a
cluster of MRSA cases (e.g., mediastinitis after cardiac pro-
cedures) or methicillin-resistant coagulase-negative staphy-
lococci SSIs have been detected at an institution. Vancomycin
prophylaxis should be considered for patients with known
MRSA colonization or at high risk for MRSA colonization in
the absence of surveillance data (e.g., patients with re-
cent hospitalization, nursing-home residents, hemodialysis
patients) [5,41,72]. In institutions with SSIs attributable to
community-associated MRSA, antimicrobial agents with
known in vitro activity against this pathogen may be con-
sidered as an alternative to vancomycin.
Each institution is encouraged to develop guidelines for the
proper use of vancomycin. Although vancomycin is com-
monly used when the risk for MRSA is high, data suggest that
vancomycin is less effective than cefazolin for preventing SSIs
caused by methicillin-susceptible S. aureus (MSSA) [73,74].
For this reason, vancomycin is used in combination with ce-
fazolin at some institutions with both MSSA and MRSA SSIs.
For procedures in which pathogens other than staphylococci
and streptococci are likely, an additional agent with activity
against those pathogens should be considered. For example, if
there are surveillance data showing that gram-negative or-
ganisms are a cause of SSIs for the procedure, practitioners
may consider combining vancomycin with another agent
(cefazolin if the patient does not have a b-lactam allergy; an
aminoglycoside [gentamicin or tobramycin], aztreonam, or
single-dose fluoroquinolone if the patient has a b-lactam
allergy). The use of vancomycin for MRSA prophylaxis does
not supplant the need for routine surgical prophylaxis ap-
propriate for the type of procedure. When vancomycin is
used, it can almost always be used as a single dose due to its
long half-life.
Colonization and resistance
A national survey determined that S. aureus nasal coloni-
zation in the general population decreased from 32.4% in
2001–02 to 28.6% in 2003–04 (p < 0.01), whereas the prevalence
of colonization with MRSA increased from 0.8% to 1.5%
(p < 0.05) during the same time periods [75]. Colonization
with MRSA was independently associated with health care
exposure among men, having been born in the United States,
age of > 60 years, diabetes, and poverty among women. Si-
milarly, children are colonized with S. aureus and MRSA, but
colonization varies by age. Children under five years of age
have the highest rates, mirroring rates seen in patients over age
60 years [76]. The rates drop in children between five and 14
years of age and gradually increase to rates seen in the adult
population. Lo et al. [77]. reported that in a large cohort of
children, 28.1%were colonizedwith S. aureus between 2004 and
2006. Between 2007 and 2009, 23.3% of children were colonized
with S. aureus, but the proportion of children colonized with
MRSA had increased from 8.1% in 2004 to 15.1% in 2009.
Surgical antimicrobial prophylaxis can alter individual
and institutional bacterial flora, leading to changes in coloni-
zation rates and increased bacterial resistance [78–84]. Surgical
prophylaxis can also predispose patients to Clostridium
difficile-associated colitis [81]. Risk factors for development of
C. difficile-associated colitis include longer duration of prophy-
laxis or therapy and use of multiple antimicrobial agents [85].
Limiting the duration of antimicrobial prophylaxis to a single
preoperative dose can reduce the risk of C. difficile disease.
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The question of what antimicrobial surgical prophylaxis to
use for patients known to be colonized or recently infected
with multidrug-resistant pathogens cannot be answered eas-
ily or in a manner that can be applied uniformly to all patient
scenarios. Whether prophylaxis should be expanded to pro-
vide coverage for these pathogens depends on many factors,
including the pathogen, its antimicrobial susceptibility pro-
file, the host, the procedure to be performed, and the prox-
imity of the likely reservoir of the pathogen to the incision and
operative sites.While there is no evidence on themanagement
of surgical antimicrobial prophylaxis in a patient with past
infection or colonization with a resistant gram-negative path-
ogen, it is logical to provide prophylaxis with an agent active
against MRSA for any patient known to be colonized with this
gram-positive pathogen who will have a skin incision; specific
prophylaxis for a resistant gram-negative pathogen in a patient
with past infection or colonization with such a pathogen may
not be necessary for a purely cutaneous procedure. Similarly, a
patient colonized with vancomycin-resistant enterococci (VRE)
should receive prophylaxis effective against VRE when un-
dergoing liver transplantation but probably not when under-
going an umbilical hernia repair without mesh placement.
Thus, patients must be treated on a case-by-case basis, taking
into account multiple considerations.
Patients receiving therapeutic antimicrobials for a remote
infection before surgery should also be given antimicrobial
prophylaxis before surgery to ensure adequate serum and
tissue levels of antimicrobials with activity against likely
pathogens for the duration of the operation. If the agents used
therapeutically are appropriate for surgical prophylaxis, ad-
ministering an extra dose within 60 min before surgical inci-
sion is sufficient. Otherwise, the antimicrobial prophylaxis
recommended for the planned procedure should be used. For
patients with indwelling tubes or drains, consideration may be
given to using prophylactic agents active against pathogens
found in these devices before the procedure, even though
therapeutic treatment for pathogens in drains is not indicated at
other times. For patients with chronic renal failure receiving
vancomycin, a preoperative dose of cefazolin should be con-
sidered instead of an extra dose of vancomycin, particularly if
the probable pathogens associated with the procedure are
gram-negative. In most circumstances, elective surgery should
be postponedwhen the patient has an infection at a remote site.
Allergy to b-lactam antimicrobials
Allergy to b-lactam antimicrobials may be a consideration
in the selection of surgical prophylaxis. The b-lactam antimi-
crobials, including cephalosporins, are the mainstay of sur-
gical antimicrobial prophylaxis and are also the most
commonly implicated drugs when allergic reactions occur.
Because the predominant organisms in SSIs after clean pro-
cedures are gram-positive, the inclusion of vancomycin may
be appropriate for a patient with a life-threatening allergy to
b-lactam antimicrobials.
Although true Type 1 (immunoglobulin E [IgE]-mediated)
cross-allergic reactions between penicillins, cephalosporins,
and carbapenems are uncommon, cephalosporins and car-
bapenems should not be used for surgical prophylaxis in
patients with documented or presumed IgE-mediated peni-
cillin allergy. Confusion about the definition of true allergy
among patients and practitioners leads to recommendations
for alternative antimicrobial therapy with the potential for a
lack of efficacy, increased cost, and adverse events [86,87].
Type 1 anaphylactic reactions to antimicrobials usually occur
30–60 min after administration. In patients receiving penicil-
lins, this reaction is a life-threatening emergency that pre-
cludes subsequent use of penicillins [88]. Cephalosporins and
carbapenems can safely be used in patients with an allergic
reaction to penicillins that is not an IgE-mediated reaction
(e.g., anaphylaxis, urticaria, bronchospasm) or exfoliative
dermatitis (Stevens-Johnson syndrome, toxic epidermal ne-
crolysis), a life-threatening hypersensitivity reaction that can
be caused by b-lactam antimicrobials and other medications
[88,89]. Patients should be carefully questioned about their
history of antimicrobial allergies to determine whether a true
allergy exists before selection of agents for prophylaxis. Pa-
tients with allergies to cephalosporins, penicillins, or both
have been excluded from many clinical trials. Alternatives to
b-lactam antimicrobials are provided in Table 2 based mainly
on the antimicrobial activity profiles against predominant
procedure-specific organisms and available clinical data.
Drug administration
The preferred route of administration varies with the type
of procedure, but for a majority of procedures, i.v. adminis-
tration is ideal because it produces rapid, reliable, and pre-
dictable serum and tissue concentrations.
Timing of initial dose
Successful prophylaxis requires the delivery of the anti-
microbial to the operative site before contamination occurs.
Thus, the antimicrobial agent should be administered at such
a time to provide serum and tissue concentrations exceeding
the minimum inhibitory concentration (MIC) for the probable
organisms associated with the procedure, at the time of inci-
sion, and for the duration of the procedure [41,90]. In 1985,
DiPiro et al [91]. demonstrated that higher serum and tissue
cephalosporin concentrations at the time of surgical incision
and at the end of the procedurewere achievedwhen the drugs
were given intravenously at the time of anesthesia induction
compared with administration in the operating room. The
average interval between antimicrobial administration and
incision was 17–22 minutes [91] (Dellinger EP, personal
communication, May, 2011).
A prospective evaluation of 1,708 surgical patients receiv-
ing antimicrobial prophylaxis found that preoperative ad-
ministration of antimicrobials within 2 h before surgical
incision decreased the risk of SSI to 0.59%, compared with
3.8% for early administration (2–24 h before surgical incision)
and 3.3% for any postoperative administration (any time after
incision) [92]. In a study of 2,048 patients undergoing coro-
nary bypass graft or valve replacement surgery receiving
vancomycin prophylaxis, the rate of SSI was lowest in those
patients in whom an infusion was started 16–60 min before
surgical incision [93]. This time interval (16–60 min before
incision) was compared with four others, and the rates of SSIs
were significantly lowerwhen comparedwith infusions given
0–15 min before surgical incision (p < 0.01) and 121–180 min-
utes before incision (p = 0.037). The risk of infection was
higher in patients receiving infusions 61–120 min before
incision (odds ratio [OR], 2.3; 95% confidence interval [CI],
0.98–5.61) and for patients whose infusions were startedmore
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than 180 min before surgical incision (OR, 2.1; 95% CI,
0.82–5.62) [93].
In a large, prospective, multicenter study from the Trial to
Reduce Antimicrobial Prophylaxis Errors (TRAPE) study
group, the timing, duration, and intraoperative redosing of
antimicrobial prophylaxis and risk of SSI were evaluated in
4,472 patients undergoing cardiac surgery, hysterectomy, or
hip or knee arthroplasty [94]. The majority of patients (90%)
received antimicrobial prophylaxis per the SCIP guidelines
[41]. Patients were assigned to one of four groups for analysis.
Group 1 (n= 1,844) received a cephalosporin (or other anti-
microbial with a short infusion time) administered within 30
min before incision or vancomycin or a fluoroquinolone
within one hour before incision. Group 2 (n = 1796) received a
cephalosporin 31–60 min before incision or vancomycin 61–
120 min before incision. Group 3 (n = 644) was given antimi-
crobials earlier than recommended, and group 4 (n= 188) re-
ceived their initial antimicrobial doses after incision. The
infection risk was lowest in group 1 (2.1%), followed by group
2 (2.4%) and group 3 (2.8%). The risk of infectionwas highest in
group 4 (5.3%, p= 0.02 compared with group 1). When ceph-
alosporins and other antimicrobials with short infusion times
were analyzed separately (n= 3,656), the infection rate with
antimicrobials administered within 30 min before incision was
1.6% compared with 2.4% when antimicrobials were admin-
istered 31–60 min before incision (p= 0.13).
In a multicenter Dutch study of 1,922 patients undergoing
total hip arthroplasty, the lowest SSI rate was seen in patients
who received the antimicrobial during the 30 min before in-
cision [95]. The highest risk for infection was found in patients
who received prophylaxis after the incision.
It seems intuitive that the entire antimicrobial dose should
be infused before a tourniquet is inflated or before any other
procedure that restricts blood flow to the surgical site is ini-
tiated; however, a study of total knee arthroplasties compared
cefuroxime given 10–30 min before tourniquet inflation with
cefuroxime given 10 min before tourniquet deflation and
found no significant difference in SSI rates between the two
groups [96].
Overall, administration of the first dose of antimicrobial
beginning within 60 min before surgical incision is
recommended [41,94,97]. Administration of vancomycin and
fluoroquinolones should begin within 120 minutes before
surgical incision because of the prolonged infusion times re-
quired for these drugs. Because these drugs have long half-
lives, this early administration should not compromise serum
levels of these agents during most surgical procedures. Al-
though the recent data summarized above suggest lower in-
fection risk with antimicrobial administration beginning
within 30 min before surgical incision, these data are not
sufficiently robust to recommend narrowing the optimal
window to begin infusion to 1–30min before surgical incision.
However, these data do suggest that antimicrobials can be
administered too close to the time of incision. Although a few
articles have suggested increased infection risk with admin-
istration too close to the time of incision [93,96,97], the data
presented are not convincing. In fact, all of these articles
confirm the increased rate of SSI for antimicrobials given
earlier than 60 min before incision. In one article, the infection
rate for patients given an antimicrobial within 15 min of
incision was lower than when antimicrobials were given
15–30 min before incision [97]. In another article, small
numbers of patients were reported, and an assertion of high
infection rates for infusion within 15 min of incision was
made, but no numeric data or p values were provided [98]. In
a third article, only 15 of over 2,000 patients received antimi-
crobials within 15 minutes before incision [93]. Earlier studies
found that giving antimicrobials within 20 min of incision
and as close as 7 min before incision resulted in therapeutic
levels in tissue at the time of incision [41,90,91,94,97,98].
Dosing
To ensure that adequate serum and tissue concentrations of
antimicrobial agents for prophylaxis of SSIs are achieved,
antimicrobial-specific pharmacokinetic and pharmacody-
namic properties and patient factors must be considered
when selecting a dose. One of the earliest controlled studies of
antimicrobial prophylaxis in cardiac surgery found a lower
rate of infection in patients with detectable concentrations of
the drug in serum at the end of surgery compared with pa-
tients in whom the drug was undetectable [99]. In another
study, higher levels of antimicrobial in atrial tissue at the time
of starting the pump for open-heart surgery were associated
with fewer infections than were lower antimicrobial concen-
trations [100]. In patients undergoing colectomy, infection
levels were inversely related to the serum gentamicin con-
centration at the time of surgical closure [17]. In general, it
seems advisable to administer prophylactic agents in a man-
ner that will ensure adequate levels of drug in serum and
tissue for the interval during which the surgical site is open.
Weight-based dosing. The dosing of most antimicrobials
in pediatric patients is based on body weight, but the dosing
of many antimicrobials in adults is not based on body weight,
because it is safe, effective, and convenient to use standard-
ized doses for most of the adult patient population. Such
standardized doses avoid the need for calculations and reduce
the risk for medication errors. However, in obese patients,
especially those who are morbidly obese, serum and tissue
concentrations of some drugs may differ from those in nor-
mal-weight patients because of pharmacokinetic alterations
that depend on the lipophilicity of the drug and other factors
[101]. Limited data are available on the optimal approach to
dosing of antimicrobial agents for obese patients [102,103]. If
weight-based dosing is warranted for obese patients, it has
not been determined whether the patient’s ideal body weight
or total (i.e., actual) body weight should be used. In theory,
using the ideal bodyweight as the basis for dosing a lipophilic
drug (e.g., vancomycin) could result in subtherapeutic con-
centrations in serum and tissue, and the use of actual body
weight for dosing a hydrophilic drug (e.g., an aminoglyco-
side) could result in excessive concentrations in serum and
tissue. Pediatric patients weighing more than 40 kg should
receive weight-based doses unless the dose or daily dose ex-
ceeds the recommended adult dose [104].
Conclusive recommendations for weight-based dosing for
antimicrobial prophylaxis in obese patients cannot be made
because data demonstrating clinically relevant decreases in
SSI rates from the use of such dosing strategies instead of
standard doses in obese patients are not available in the
published literature.
In a small, nonrandomized, two-phase study of morbidly
obese adults undergoing gastroplasty and normal-weight
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adults undergoing upper abdominal surgery, blood and tis-
sue concentrations of cefazolin after the administration of a
1 g preoperative dose were consistently lower in morbidly
obese patients than in the normal-weight patients [101]. The
concentrations in morbidly obese patients also were lower
than the MICs needed for prophylaxis against gram-positive
cocci and gram-negative rods. In the second phase of the
study, adequate blood and tissue cefazolin concentra-
tions were achieved in morbidly obese patients receiving
preoperative doses of cefazolin 2 g, and the rate of SSIs was
significantly lower in these patients compared with morbidly
obese patients receiving 1 g doses during the first phase of
the study.
While the optimal cefazolin dose has not been established
in obese patients, a few pharmacokinetic studies have inves-
tigated the cefazolin concentrations in serum and tissue dur-
ing surgical procedures [13,105]. Two small pharmacokinetic
studies found that administering 1- or 2 g doses of cefazolin
may not be sufficient to produce serum and tissue concen-
trations exceeding the MIC for the most common pathogens.
In a small, single-center study, 38 adults undergoing Roux-
en-Y gastric bypass surgery were classified by body mass
index (BMI) in one of three groups [13]. All patients were
given cefazolin 2 g i.v. 30–60 min before the incision, followed
by a second 2-g i.v. dose 3 h later. The mean serum drug
concentration before the second dose of cefazolin was lower
than the resistance breakpoint in all three BMI groups. Serum
drug concentrations were lower in patients with a high BMI
than in patients with lower BMI values. Tissue drug concen-
trations were lower than a targeted concentration of 8mg/mL
at all measurement times, except the time of skin closure in the
patients with the lowest BMIs. These results suggest that a 1-g
dose of cefazolin may be inadequate for obese patients un-
dergoing gastric bypass surgery. A weakness of the literature
on drug dosing in morbidly obese patients is the practice of
reporting results by BMI rather than weight.
Doubling the normal dose of cephalosporins or making
fewer adjustments based on renal dysfunction may produce
concentrations in obese patients similar to those achieved
with standard doses in normal-weight patients [103]. Con-
sidering the low cost and favorable safety profile of cefazolin,
increasing the dose to 2 g for patients weighing more than 80
kg and to 3 g for those weighing over 120 kg can easily be
justified [41]. For simplification, some hospitals have stan-
dardized 2 g cefazolin doses for all adult patients.
Gentamicin doses have been compared for prophylaxis
only in colorectal surgery, where a single dose of gentamicin
4.5mg/kg in combination with metronidazole was more ef-
fective in SSI prevention than multiple doses of gentamicin
1.5mg/kg every eight hours [16,17]. In obese patients who
weigh 20% above their ideal body weight, the dose of genta-
micin should be calculated using the ideal body weight plus
40% of the difference between the actual and ideal weights
[106]. If gentamicin will be used in combination with a par-
enteral antimicrobial with activity against anaerobic agents
for prophylaxis, it is probably advisable to use 4.5–5mg/kg
as a single dose [16]. This dose of gentamicin has been
found safe and effective in a large body of literature exam-
ining the use of single daily doses of gentamicin for thera-
peutic indications [106–113]. When used as a single dose
for prophylaxis, the risk of toxicity from gentamicin is
very low.
Obese patients are often underrepresented in clinical trials
and are not currently considered a special population for
whomFDA requires separate pharmacokinetic studies during
antimicrobial research and development by the drug manu-
facturer. Obesity has been recognized as a risk factor for SSI;
therefore, optimal dosing of antimicrobial prophylaxis is
needed in these patients [114]. While a BMI of > 30 kg/m2 is
commonly used to define obesity, the body fat percentage
(> 25% in men and > 31% in women) may better predict SSI
risk, because the BMI may not reflect body composition. In a
recent prospective cohort study of 590 patients undergoing
elective surgery, there was no significant difference in SSI
rates in nonobese and obese patients when the BMI was used
to define obesity (12.3% versus 11.6%, respectively) [115].
However, when the body fat percentage (determined by
bioelectrical impedance analysis) was used as the basis for
identifying obesity (> 25% in men and > 31% in women),
obese patients had a five-fold-higher risk of SSI than did
nonobese patients (OR, 5.3; 95% CI, 1.2–23.1; p= 0.03). These
findings suggest that body fat percentage is a more sensitive
and precise measurement of SSI risk than is the BMI.
Redosing. Intraoperative redosing is needed to ensure
adequate serum and tissue concentrations of the antimi-
crobial if the duration of the procedure exceeds two half-
lives of the antimicrobial or there is excessive blood loss
(i.e., > 1,500mL) [17,41,94,116–121]. The redosing interval
should be measured from the time of administration of the
preoperative dose, not from the beginning of the procedure.
Redosing may also be warranted if there are factors that
shorten the half-life of the antimicrobial agent (e.g., extensive
burns). Redosing may not be warranted in patients in whom
the half-life of the antimicrobial agent is prolonged (e.g., pa-
tients with renal insufficiency or renal failure). See Table 1 for
antimicrobial-specific redosing recommendations.
Duration
The shortest effective duration of antimicrobial adminis-
tration for preventing SSI is not known; however, evidence is
mounting that postoperative antimicrobial administration is
not necessary for most procedures [6,7,41,122–124]. The du-
ration of antimicrobial prophylaxis should be less than 24
hours for most procedures. Cardiothoracic procedures for
which a prophylaxis duration of up to 48 hours has been
accepted without evidence to support the practice is an area
that remains controversial. The duration of cardiothoracic
prophylaxis in these guidelines is based on expert panel
consensus because the available data do not delineate the
optimal duration of prophylaxis. In these procedures, pro-
phylaxis for the duration of the procedure and certainly for
less than 24 hours is appropriate.
A 1992 meta-analysis of studies comparing first-generation
cephalosporins and antistaphylococcal antimicrobials (e.g.,
penicillins) with second-generation cephalosporins in patients
undergoing cardiothoracic surgery found a reduction in the
rate of SSI with second-generation cephalosporins but no
benefit from continuing surgical prophylaxis beyond 48 h
[125]. Reports published in 1980 [126], 1993 [127], 1997 [128],
and 2000 [129] involving seven studies that compared single-
dose prophylaxis or prophylaxis only during the operation
with durations of one to four days failed to show any reduction
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in SSIs with the longer durations of prophylaxis. In a more-
recent observational four-year cohort study of 2,641 patients
undergoing coronary artery bypass graft (CABG) surgery,
the extendeduseof antimicrobial prophylaxis (>48h) insteadof a
shorter durationofprophylaxis (<48h) failed to reduce the riskof
SSI (OR, 1.2; 95% CI, 0.8–1.6) [130]. Moreover, prolonged pro-
phylaxis was associated with an increased risk of acquired anti-
microbial resistance (cephalosporin-resistant Enterobacteriaceae
and VRE) compared with short-term prophylaxis (OR, 1.6; 95%
CI, 1.1–2.6). There are no data to support the continuation of
antimicrobial prophylaxis until all indwelling drains and intra-
vascular catheters are removed [19,31,32,41,131–134].
Topical administration of irrigations, pastes,
and washes
Intravenous and oral antimicrobial administration are the
main focus of these guidelines, and these routes of adminis-
tration are used for most surgical procedures addressed by
these guidelines, with the exception of ophthalmic procedures,
for which topical administration is the primary route of ad-
ministration. Limited high-quality data are available regarding
the use of antimicrobial irrigations, pastes, and washes that are
administered topically. Studies published in the early 1980s
demonstrated that prophylactic topical administration of an-
timicrobials in the surgical incision during various non-
ophthalmic procedures is superior to placebo but not superior
to parenteral administration, and topical administration does
not increase the efficacy of parenteral antimicrobialswhen used
in combination for prophylaxis [135–138]. Additional high-
quality data on the safety and efficacy of topical antimicrobial
administration as an adjunct to i.v. administration are needed
to determine the role of topical antimicrobial prophylaxis.
One area of interest for topical administration of antimicro-
bials, mainly gentamicin and vancomycin, is application to the
sternum during cardiac procedures in combination with i.v.
agents to prevent mediastinitis. This strategy has been evalu-
ated in cohort and randomized controlled studies [139–142].
While the studies found a significantly lower rate of SSI
with topical antimicrobials compared with standard prophy-
laxis [140], placebo [142], and a historical control [139], a
smaller, randomized, placebo-controlled study found no dif-
ference between groups [141].
More recently, implantable gentamicin collagen sponges
failed to show any efficacy in reducing SSIs in a large prospec-
tive study of patients undergoing cardiac surgery and resulted
in an increased infection rate in patients undergoing colectomy
[143,144]. The safety and efficacy of topical antimicrobials have
not been clearly established; therefore, routine use of this route
cannot be recommended in cardiac or other procedures [145].
Preoperative screening and decolonization
Staphylococcus aureus is the most common pathogen causing
SSIs, accounting for 30% of SSIs in the United States. Coloni-
zation with S. aureus, primarily in the nares, occurs in roughly
one in four persons and increases the risk of SSI by 2- to 14-fold
[146–152]. A national survey assessing nasal colonization with
S. aureus in the general population conducted from 2001
through 2004 found that while the rate of colonization with S.
aureus decreased from 32.4% in 2001–02 to 28.6% in 2003–04
( p< 0.01), the rate of colonization with MRSA increased from
0.8% to 1.5% ( p< 0.05) [75].
Preoperative screening for S. aureus carriage and decolo-
nization strategies have been explored as means to reduce the
rate of SSIs. Anterior nasal swab cultures are most commonly
used for preoperative surveillance, but screening additional
sites (pharynx, groin, wounds, rectum) can increase detection
rates [153]. Such preoperative surveillance swabs that can be
cultured on selective or nonselective media or sent for rapid
polymerase chain reaction (PCR)-based screening can be used
to identify colonized patients in the preoperative period.
When properly used, all of these techniques can identify
MSSA and MRSA. However, not all PCR-based systems will
identify both MRSA and MSSA so verification with the lab-
oratory is needed. While many studies have focused specifi-
cally on MRSA screening in high-risk hospitalized patients in
an effort to prevent MRSA SSI and hospital-acquired infec-
tions, the risk of developing an SSI remains elevated for any
S. aureus carrier. While some authors advocate screening for
MRSA carriage in the general population, the data supporting
universal screening in the surgical population are more
controversial [154,155]. Screening has been advocated to both
identify candidates for S. aureus decolonization and inform
the selection of optimal prophylactic antimicrobials, such as
the addition of vancomycin for those colonized with MRSA.
FDAhas approved intranasalmupirocin to eradicateMRSA
nasal colonization in adult patients and health care workers
[156]. It is noted in the prescribing information that there are
insufficient data to support use in prevention of autoinfection
of high-risk patients from their own nasal colonization with
S. aureus. However, additional data have demonstrated that
the use of intranasal mupirocin in nasal carriers of S. aureus
decreases the rate of S. aureus infections [157,158]. One meta-
analysis of seven studies focused on surgical patients only
[157]; the other meta-analysis of nine studies included high-
quality studies in dialysis patients [158].
Recent studies have confirmed that S. aureus decolonization
of the anterior nares decreases SSI rates in many surgical pa-
tients [159]. The data are most compelling in cardiac and or-
thopedic surgery patients. There are fewer data in general
surgery patients. A large, randomized controlled trial of gen-
eral, cardiac, and neurosurgical patients (n= 3,864) revealed
that prophylactic intranasal application of mupirocin did not
significantly reduce the overall rate of S. aureus SSIs (2.3% in
the mupirocin group versus 2.4% in the control group) but did
decrease the rate of S. aureus SSI among S. aureus carriers (3.7%
in themupirocin group versus 5.9% in the control group) [160].
Another randomized controlled trial found no significant
difference in the rate of postoperative S. aureus SSIs among
cardiac surgery patients receiving intranasal mupirocin and
those receiving placebo, but the studywas limited by the small
numbers of patients (n= 257) and reported SSIs (n= 5) [161].
Among elective orthopedic patients undergoing implantation
and other procedures, a randomized clinical trial demon-
strated a nonsignificant reduction in the rate of postoperative
S. aureus SSIs in patients receiving mupirocin (n= 315, 3.8%)
compared with those receiving placebo (n= 299, 4.7%) [150].
A recent randomized, double-blind, placebo-controlled,
multicenter study conducted in The Netherlands found that
the use of mupirocin nasal ointment and chlorhexidine baths
in identified S. aureus carriers reduced the risk of hospital-
associated S. aureus infections [162]. In the study, a real-time
PCR assay was used to rapidly identify S. aureus nasal carriers;
all of the S. aureus isolates were susceptible tomethicillin. Deep
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SSIs occurred in 0.9% of the mupirocin–chlorhexidine-treated
group (4 of 441 patients) versus 4.4% of the placebo group (16
of 367 patients) (relative risk, 0.21; 95% CI, 0.07–0.62). The
reduction in superficial SSIs was less marked (1.6% versus
3.5%; relative risk, 0.45; 95% CI, 0.18–1.11). It is plausible that
this approach would be beneficial in a setting of MRSA, but it
has not been proven.
Most studies conclude that the use of preoperative intra-
nasal mupirocin in colonized patients is safe and potentially
beneficial as an adjuvant to i.v. antimicrobial prophylaxis to
decrease the occurrence of SSIs. However, the optimal timing
and duration of administration are not standardized. In
most studies, mupirocin was used for five days before the
operation. While S. aureus resistance to mupirocin has been
detected [148,162], raising concerns about the potential for
widespread problems with resistance from routine use of this
agent, resistance has only rarely been seen in the preoperative
setting. Low-level resistance is associated with an increased
rate of failure of decolonization and has been seen in in-
stitutions that use standardized mupirocin decolonization
protocols [163]. Therefore, when decolonization therapy (e.g.,
mupirocin) is used as an adjunctive measure to prevent
S. aureus SSI, surveillance of susceptibility of S. aureus isolated
from SSIs to mupirocin is recommended [164]. While uni-
versal use of mupirocin is discouraged, specific recommen-
dations for the drug’s use can be found in the cardiac and
orthopedic sections of these guidelines.
Future research
Additional research is needed in several areas related to
surgical antimicrobial prophylaxis. The risks and benefits of
continuing antimicrobial prophylaxis after the conclusion of
the operative procedure, including dosing and duration, need
to be further evaluated. Insight is needed to make specific
recommendations for intraoperative repeat dosing, weight-
based dosing in obese patients, and timing of presurgical an-
timicrobials thatmust be administered over a prolongedperiod
(e.g., vancomycin, fluoroquinolones). Additional clarification
is needed regarding targeted antimicrobial concentrations and
intraoperative monitoring of antimicrobial serum and tissue
concentrations to optimize efficacy. The role of topical ad-
ministration of antimicrobial agents as a substitute for or an
adjunct to i.v. antimicrobial prophylaxis needs to be further
evaluated. Additional data are needed to guide the selection of
antimicrobial agents for prophylaxis, particularly combination
regimens, for patients with allergies to b-lactam antimicrobials.
Data are also needed to devise strategies to optimize antimi-
crobial prophylaxis in patients and facilities with a high risk or
high prevalence of resistant organisms implicated in SSIs (e.g.,
MRSA). Optimal strategies for screening for S. aureus and de-
colonization for certain procedures need to be identified. Fi-
nally, outcomes studies are needed to assess the impact of
using quality measures and pay-for-performance incentives
designed to reduce surgical morbidity and mortality.
Cardiac procedures
Background
Cardiac procedures include CABG procedures, valve re-
pairs, and placement of temporary or permanent implantable
cardiac devices, including ventricular assist devices (VADs).
SSIs, including mediastinitis and sternal SSI, are rare but
serious complications after cardiac procedures. In patients
undergoing CABG, the mean frequency of SSIs depending
on NHSN SSI risk index category ranges from 0.35 to 8.49
per 100 operations when donor sites are included [165].
The mean frequency of SSIs depending on NHSN SSI risk
index category for patients undergoing CABG with only
chest incisions ranges from 0.23 to 5.67 per 100 operations
[165]. Most of these infections are superficial in depth. Patient-
related and procedure-related risk factors for SSIs after
cardiac procedures have been identified from several single-
center cohort and case–control studies [117,128,166–176].
These include diabetes [166,169,171–175], hyperglycemia
[177–182], peripheral vascular disease [171,172,174], chronic
obstructive pulmonary disease [166,174,175], obesity (BMI of
> 30 kg/m2) [166–168,171,173–176], heart failure [171,172],
advanced age [117,128,166,172], involvement of internal
mammary artery [168–172], reoperation [169–171], increased
number of grafts [171], long duration of surgery [117,166,
167,176], and S. aureus nasal colonization [146,160].
Patients requiring extracorporeal membrane oxygena-
tion (ECMO) as a bridge to cardiac or lung transplanta-
tion should be treated with a similar approach. If there is no
history of colonization or previous infection, the general rec-
ommendations for SSI antimicrobial prophylaxis for the spe-
cific procedure should be followed. For ECMOpatients with a
history of colonization or previous infection, changing the
preoperative antimicrobial prophylaxis to cover these patho-
gens must be considered, weighing whether the pathogen is
relevant to SSIs in the planned procedure.
Organisms
Almost two thirds of organisms isolated in both adult and
pediatric patients undergoing cardiac procedures are gram-
positive, including S. aureus, coagulase-negative staphylo-
coccus, and, rarely, Propionibacterium acnes. Gram-negative
organisms are less commonly isolated in these patients and
include Enterobacter species, Pseudomonas aeruginosa, Escher-
ichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Acineto-
bacter species [93,139,146,183–192].
Efficacy
The SSI rate in cardiac procedures is low, but there are po-
tential consequences if infection occurs. Multiple studies have
found that antimicrobial prophylaxis in cardiac procedures
lowers the occurrence of postoperative SSI up to five-fold [125].
Choice of agent. Cephalosporins have been the most
studied antimicrobials for the prevention of SSIs in cardiac
procedures. Both first-generation (cefazolin) and second-
generation (cefamandole and cefuroxime) cephalosporins
have been shown to be effective in reducing SSI in cardiac
surgery; however, the superiority of one class over another
has not been proven [125,127,193–199].
A meta-analysis comparing cephalosporins with glyco-
peptides (e.g., vancomycin) as antimicrobial prophylaxis
regimens for cardiac procedures found a higher frequency of
postoperative chest and deep-chest SSIs and a trend toward
an increased risk of gram-positive SSI in the glycopeptide
group but a lower frequency of SSIs caused by resistant gram-
positive pathogens [72]. The routine use of vancomycin for the
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prevention of SSIs is not recommended, based on limited
evidence of efficacy and concerns of increased glycopeptide
resistance ofmicroorganisms [8,116]. There is no clear evidence
to support the use of vancomycin, alone or in combinationwith
other antimicrobials, for routine antimicrobial prophylaxis
in institutions that have a high prevalence of MRSA
[8,11,41,72,73,116,200]. Vancomycin should be considered in
patients who are colonized with MRSA [41,116,201]. The ac-
cepted alternative antimicrobial for b-lactam-allergic patients
undergoing cardiac procedures is vancomycin or clindamycin
for gram-positive coverage [41,116,201,202]. The addition of an
aminoglycoside, aztreonam, or a fluoroquinolone may be
prudent when gram-negative pathogens are a concern [8,116].
Mupirocin. The proportion of infections related to S. aureus
amongpatients undergoing cardiac surgery and the increase in
MRSA as a cause of SSIs at some institutions have led to in-
vestigations of methods for preoperative eradication, particu-
larly with intranasal mupirocin [203]. Readers are referred to
the Common Principles section of these guidelines for discus-
sion of the use of intranasal mupirocin. Of note, the data
demonstrated a 45% reduction in S. aureus SSIs with the use of
preoperativemupirocin among patients known to be colonized
with S. aureus who undergo cardiac procedures [157,193]. In-
stitutions shouldmonitor formupirocin resistance periodically.
Topical administration. Additional information on topical
administration of antimicrobials can be found in the Common
Principles section of these guidelines. Use of topical antimicro-
bials, mainly gentamicin or vancomycin, applied to the sternum
during cardiac procedures in combination with i.v. agents to
prevent mediastinitis has been evaluated in both cohort [139]
and randomized controlled studies [140–142].While the studies
found a significantly lower rate of SSIs with topical antimicro-
bials compared with standard prophylaxis [140], placebo [142],
and a historical control [139], a smaller randomized, placebo-
controlled study found no difference between groups [141].
More recent studies of gentamicin collagen sponges failed to
show any efficacy in a large prospective study of cardiac
surgery [143]. The safety and efficacy of topical antimicrobials
have not been clearly established and therefore cannot be re-
commended for routine use in cardiac procedures [139–142].
Cardiopulmonary bypass. Cardiopulmonary bypass
(CPB) is a common surgical technique in cardiac proce-
dures that alters the volume of distribution and bioavail-
ability of medications administered during the procedure
[116,204,205]. Several small cohort or comparative studies
[128,204–213] have evaluated the serum and tissue concen-
trations of several routinely used antimicrobial prophylactic
agents (i.e., cefazolin, cefuroxime, gentamicin, and vancomy-
cin) in patients undergoing CPB during cardiac procedures.
Until further clinical outcomes data and well-designed studies
become available to inform alternative dosing strategies, rou-
tinely used doses of common antimicrobial agents should be
used in patients undergoing CPB during cardiac procedures.
Duration. The optimal duration of antimicrobial prophy-
laxis for cardiac procedures continues to be evaluated. Data
support a duration ranging from a single dose up to 24 h
postoperatively [41,99,131,191,214–217]. No significant dif-
ferences were found in several small studies in patients un-
dergoing cardiac procedures between these dosing strategies
in patients primarily receiving first- or second-generation
cephalosporins. Although a recent meta-analysis suggested
the possibility of increased efficacy with cardiac surgical
prophylaxis extending beyond 24 h, the authors noted that the
findings were limited by the heterogeneity of antimicrobial
regimens used and the risk of bias in the published studies
[218]. The comparisons of varying durations were performed
with different antimicrobials with differing efficacy and do
not support longer durations. Consequently, this meta-anal-
ysis does not provide evidence to support changing the cur-
rently accepted prophylaxis duration of less than 24 hours,
particularly given the evidence from studies involving non-
cardiac operations. The currently accepted duration of pro-
phylaxis for cardiac procedures is less than 24 h, but
prophylaxis should be continued for the duration of the
procedure [41,59,126–129,131,201].
Two small studies did not support the continuation of an-
timicrobial prophylaxis until intravascular catheters or in-
traaortic balloon pumps were removed, due to a lack of
influence on infections or catheter colonization compared
with short-course (24 hours) cefazolin or cefuroxime
[219,220]. The practice of continuing antimicrobial prophy-
laxis until all invasive lines, drains, and indwelling catheters
are removed cannot be supported due to concerns regarding
the development of drug-resistant organisms, superinfec-
tions, and drug toxicity [41,131].
Pediatric efficacy
The rate of SSI in pediatric cardiac procedures is sometimes
higher than in adult patients [20,31,221]. Significant risk fac-
tors in pediatric patients with a mediastinal SSI included the
presence of other infections at the time of the procedure,
young age (newborns and infants), small body size, the du-
ration of the procedure (including CPB time), the need for an
intraoperative blood transfusion, an open sternum postoper-
atively, the need for a reexploration procedure, the length of
stay in the intensive care unit, an NNIS/NHSN risk score of 2,
and the performance of emergency procedures [20,31,221].
The organisms of concern in pediatric patients are the same
as those in adult patients [20,21,31,221]. However, MRSA is
rarely a concern in this population as a risk factor for SSI [221].
Pediatric patients considered at high risk for MRSA infection
are those with preoperativeMRSA colonization or a history of
MRSA infection, neonates younger than one month of age,
and neonates under three months of age who have been in the
hospital since birth or have a complex cardiac disorder [21].
Strategies such as intranasal mupirocin and changes in anti-
microbial prophylactic agent to vancomycin led to decreased
rates of MRSA carriage and the absence ofMRSA infections in
one time-series evaluation; however, the overall clinical im-
pact of these efforts is still unclear [21,221].
No well-controlled studies have evaluated the efficacy of
antimicrobial prophylaxis in pediatric patients undergoing
cardiac procedures. Therefore, the efficacy of antimicrobial
prophylaxis is extrapolated from adult studies and should be
considered the standard of care for pediatric cardiac surgery
patients [19].
No well-designed studies or consensus has established the
appropriate doses for common antimicrobial prophylactic
agents for use in pediatric cardiac patients. Antibiotic doses
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have been extrapolated from guidelines for the prevention of
bacterial endocarditis [11]. In recent evaluations, doses of
cefazolin have ranged from 25 to 50mg/kg [19–21,31], and
vancomycin doses have ranged from 10 to 20mg/kg [19–
21,31,222–226]. Gentamicin doses used in studies have in-
cluded 2.5 [20] and 5mg/kg [22]; however, the study authors
[22] felt that the higher dose was excessive. The expert panel
recognizes that the usual total daily dose for pediatric patients
older than six months can be 6.5–7.5mg/kg and that dosing
schedules for younger patients may be complicated.
Recommendations
For patients undergoing cardiac procedures, the re-
commended regimen is a single preincision dose of cefazolin or
cefuroxime with appropriate intraoperative redosing (Table 2).
Currently, there is no evidence to support continuing prophy-
laxis until all drains and indwelling catheters are removed.
Clindamycin or vancomycin is an acceptable alternative in pa-
tients with a documented b-lactam allergy. Vancomycin should
be used for prophylaxis in patients known to be colonized with
MRSA. If organizational SSI surveillance shows that gram-
negative organisms cause infections for patients undergoing
these operations, practitioners should combine clindamycin or
vancomycin with another agent (cefazolin if the patient is not
b-lactam-allergic; aztreonam, aminoglycoside, or single-dose
fluoroquinolone if the patient is b-lactam-allergic). Mupirocin
should be given intranasally to all patients with documented S.
aureus colonization. (Strength of evidence for prophylaxis=A.)
Cardiac device insertion procedures
Background
Antimicrobial prophylaxis is the standard of care for pa-
tients undergoing cardiac implantable device insertion (e.g.,
pacemaker implantation) [227]. Based on available data and
perceived infection risk, antimicrobial prophylaxis is not
routinely recommended for cardiac catheterization or trans-
esophageal echocardiogram [228].
The NHSN has reported a mean SSI rate after pacemaker
placement of 0.44 per 100 procedures [165]. This rate may
underestimate the risk of late SSI and complications [229].
Risk factors for device-related infection after implantation of
cardioverter–defibrillator systems or pacemakers identified in
two large, prospective, multicenter cohort studies [230,231]
and a large case–control study [232] included fever within 24 h
before implantation, temporary pacing before implantation,
and early reintervention for hematoma or lead replacement
[230]; corticosteroid use for more than one month during the
preceding year and more than two leads in place compared
with two leads [232]; and development of pocket hematoma
[231]. In all of the evaluations, antimicrobial prophylaxis was
found to be protective against device-related infection [230–
232]. Limited data are available on the efficacy and optimal
dose and duration of antimicrobial prophylaxis in patients
undergoing implantation of a new pacemaker, pacing system,
or other cardiac device.
A meta-analysis of 15 prospective, randomized, controlled,
mainly open-label studies evaluated the effectiveness of
systemic antimicrobial prophylaxis compared with controls
(no antimicrobials) on infection rates after pacemaker
implantation [227]. Antibiotics included penicillins or cepha-
losporins with a duration ranging from a single preoperative
dose to four days postoperatively. A consistent and signifi-
cant protective effect of antimicrobial prophylaxis was found
and encouraged the routine use of antimicrobial prophylaxis
in patients undergoing permanent pacemaker implantation.
A prospective, single-center cohort study found a low rate
(1.7%) of SSI complications with a single 2 g dose of cefazolin
in patients undergoing implantation of a new pacemaker,
pulse-generator replacement, or upgrading of a preexisting
pacing system [233]. A notable limitation of the study was the
exclusion of patients with temporary percutanous cardiac
stimulators who are at high risk of infection.
A large, randomized, double-blind, placebo-controlled
study found a significantly lower rate of SSI with a single 1 g
dose of cefazolin (0.64%) compared with placebo (3.28%)
(p = 0.016) given immediately before device implantation or
generator replacement in a permanent pacemaker, implant-
able cardioverter defibrillator, or cardiac resynchronization
device in a surgical operating room [231]. The expert panel
noted that the cefazolin dose was not adjusted for patient
weight. Recently, AHA produced evidence-based guidelines
that recommend the use of a single dose of a preoperative
antimicrobial [229].
Ventricular assist devices are increasingly used to bridge
patients to transplantation or to support individuals who do
not respond to medical therapy for congestive heart failure.
Very limited data exist on infection rates, and there are no
published studies that demonstrate the effectiveness of pre-
operative antimicrobial therapy. Using 2006–08 data from the
Interagency Registry for Mechanically Assisted Circulatory
Support, Holman and colleagues [234] reported that most
infections related to mechanical cardiac support devices were
bacterial (87%), with the remainder associated with fungal
(9%), viral (1%), protozoal (0.3%), or unknown (2%) causes.
Driveline infections are primarily caused by staphylococcal
species from the skin. Fungal organisms also play an impor-
tant role in VAD infections, most notably Candida species, and
carry a high risk of mortality. A recent survey of antimicrobial
surgical prophylaxis with VADs illustrates the variability and
lack of consensus with regimens, using anywhere from one to
four drugs for a duration of 24–72 h [235]. Immediate post-
operative infections are caused by gram-positive organisms.
Complications from long-term infections should not be con-
fused with immediate postprocedure SSIs [236]. Based on the
consensus of the expert panel, antimicrobial prophylaxis for
replacement of a VAD due to ongoing or recent infection
should incorporate coverage directed at the offending or-
ganism or organisms. While many centers use vancomycin
plus ciprofloxacin plus fluconazole, this practice is not based
on the published evidence.
Recommendation
A single dose of cefazolin or cefuroxime is recommended
for device implantation or generator replacement in a per-
manent pacemaker, implantable cardioverter defibrillator, or
cardiac resynchronization device. (Strength of evidence for
prophylaxis =A.) There is limited evidence to make specific
recommendations for VADs, and each practice should tailor
protocols based on pathogen prevalence and local suscepti-
bility profiles. Clindamycin or vancomycin is an acceptable
alternative in patients with a documented b-lactam allergy.
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Vancomycin should be considered for prophylaxis in patients
known to be colonized with MRSA.
Thoracic procedures
Background
Noncardiac thoracic procedures include lobectomy, pneu-
monectomy, thoracoscopy, lung resection, and thoracotomy.
In addition to SSIs, postoperative nosocomial pneumonia and
empyema are of concern after thoracic procedures [237].
NHSN has reported that the rate of infection associated
with thoracic surgery ranges from 0.76% to 2.04% [165]. Stu-
dies have found that the reported rate of SSIs after thoracic
procedures in patients receiving antimicrobial prophylaxis
ranged from 0.42% to 4% [238–241]. One study found an SSI
rate of 14% when prophylaxis was not used [239]. The re-
ported rates of pneumonia and empyema with antimicrobial
prophylaxis are 3–24% and 0–7%, respectively [237,239–244].
Video-assisted thoracoscopic surgery (VATS) is commonly
used for thoracic procedures. In some settings, VATS consti-
tutes one third or more of all thoracic surgical procedures
[245]. Since VATS uses small incisions, the rate of SSIs is lower
comparedwith the rate associatedwith open thoracic surgical
procedures [246]. A prospective cohort study (n= 346) con-
firmed a low rate of SSIs (1.7%) after minimally invasive VATS
procedures [240]. An additional prospective study of 988 lung
resection patients confirmed that the SSI rate was significantly
lower (5.5%) in VATS patients than in open thoracotomy pa-
tients (14.3%) [247]. Furthermore, SSI correlated with the du-
ration of surgery, serum albumin, concurrent comorbidity, age,
and forced expiratory volume in one second. Antimicrobial
prophylaxis recommendations in this section refer to both open
thoracotomy and VATS procedures. Based on available data
and perceived infection risk, antimicrobial prophylaxis is not
routinely recommended for chest tube insertion.
Results of a prospective cohort and case–control study re-
vealed the following independent risk factors for pneumonia
after thoracic procedures: extent of lung resection, intraoperative
bronchial colonization, chronic obstructive pulmonary disease,
BMI of >25kg/m2, induction therapy (chemotherapy, radio-
therapy, or chemoradiotherapy), advanced age (‡75 years old),
and stage III or IV cancer [243,244].
Organisms
The organisms reported from SSIs in patients undergoing
thoracic procedures were S. aureus and S. epidermidis [237].
Organisms isolated in patients with postoperative pneumonia
included gram-positive (Streptococcus and Staphylococcus species),
gram-negative (Haemophilus influenzae, Enterobacter cloacae, K.
pneumoniae, Acinetobacter species, P. aeruginosa, and Moraxella
catarrhalis), and fungal (Candida species) pathogens [237,239–243].
Efficacy
Antimicrobial prophylaxis is the standard of care for pa-
tients undergoing noncardiac thoracic surgery, including
pulmonary resection [11,201,237]. One randomized, double-
blind, placebo-controlled, single-center study of patients in
Spain undergoing pulmonary resection, persistent pneumo-
thorax without thoracotomy tube before surgery, and non-
pulmonary thoracic surgical procedures, excluding those
involving the esophagus and exploratory thoracotomies,
compared a single dose of cefazolin 1 g i.v. and placebo given
30minutes before the procedure [239]. The studywas stopped
early due to the significant difference in SSI rates between
groups (1.5% with cefazolin versus 14% with placebo,
p < 0.01). No differences in the rates of pneumonia and em-
pyema were seen between groups, but these were not end-
points of the study.
Choice of agent. There is no clear optimal choice for an-
timicrobial prophylaxis in thoracic procedures. The need to
consider pneumonia and empyema as well as SSIs after tho-
racic procedures has been raised in the literature [237,241–
244]. There are a limited number of small, single-center,
randomized controlled or cohort studies that evaluated sev-
eral antimicrobial agents. One small, randomized controlled
study and one cohort study found that ampicillin–sulbactam
was significantly better than cephalosporins (cefazolin and
cefamandole) for preventing pneumonia [242,243]. No sta-
tistically significant difference was found between cefuroxime
and cefepime in the rate of postoperative SSI, pneumonia, or
empyema in a small, randomized controlled study in patients
undergoing elective thoracotomy [241]. Lower rates of infec-
tions and susceptibility of all organisms were noted with ce-
furoxime compared with cefepime. Therefore, the study
authors concluded that cefuroxime was marginally more ef-
fective and was more cost-effective than cefepime.
Duration. No clear consensus on the duration of antimi-
crobial prophylaxis has been established. Studies have evalu-
ated different dosing strategies for cephalosporins or penicillins,
with most studies using single doses given preoperatively
within 60 min before surgical incision [237,239,240,242,244].
Studies found differing results when comparing agents given
for 24 h (cefepime, ampicillin–sulbactam) and 48 h (cefuroxime,
cefamandole); however, these findings may be attributable to
the different antimicrobials tested [241,243]. Additional discus-
sion on dosing is provided in the Common Principles section of
these guidelines.
Recommendations
In patients undergoing thoracic procedures, a single dose of
cefazolin or ampicillin– sulbactam is recommended (Appen-
dix B). Clindamycin or vancomycin is an acceptable alterna-
tive in patients with a documented b-lactam allergy.
Vancomycin should be used for prophylaxis in patients
known to be colonized with MRSA. If organizational SSI
surveillance shows that gram-negative organisms are associ-
ated with infections during these operations or if there is risk
of gram-negative contamination of the surgical site, practi-
tioners should combine clindamycin or vancomycin with
another agent (cefazolin if the patient is not b-lactam-allergic;
aztreonam, aminoglycoside, or single-dose fluoroquinolone if
the patient is b-lactam-allergic). (Strength of evidence for
prophylaxis for VATS =C; strength of evidence for prophy-
laxis for other thoracic procedures =A.)
Gastroduodenal procedures
Background
The gastroduodenal procedures considered in these
guidelines include resection with or without vagotomy for
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gastric or duodenal ulcers, resection for gastric carcinoma,
revision required to repair strictures of the gastric outlet,
percutaneous endoscopic gastrostomy (PEG) insertion, per-
forated ulcer procedures (i.e., Graham patch repair), pan-
creaticoduodenectomy (Whipple procedure), and bariatric
surgical procedures (gastric bypass, gastric banding, gastro-
plasty, other restrictive procedures, biliopancreatic diversion).
Studies specifically addressing antimicrobial prophylaxis for
gastroesophageal reflux disease procedures (Nissen fundopli-
cation) or highly selective vagotomy for ulcers (usually done
laparoscopically) could not be identified. Antireflux proce-
dures and highly selective vagotomy are clean procedures in
contrast to essentially all other gastroduodenal procedures that
are clean-contaminated. Other procedures that are generally
performed using laparoscopic or endoscopic techniques (e.g.,
endoscopic retrograde cholangiopancreatography) are not spe-
cifically discussed in this document.Natural orifice transluminal
endoscopic surgery (NOTES) is a developing operative tech-
nique using natural orifices (e.g., vagina, anus, mouth, stomach)
for entry into the abdomen that leaves no visible scar [248]. No
studies on antimicrobial prophylaxis using NOTES have been
published. SSI rates reported in patients not receiving antimi-
crobial prophylaxis were 6% after vagotomy and drainage, 13%
after gastric ulcer procedures, 6.8–17% after procedures for
gastric cancer [249–253], 8% for pancreaticoduodenectomy [254],
and 23.9–26% after PEG insertion [255,256].
The stomach is an effective barrier to bacterial colonization;
this is at least partially related to its acidity. The stomach and
the duodenum typically contain small numbers of organisms
( < 104] colony-forming units [CFU]/mL), the most common
of which are streptococci, lactobacilli, diphtheroids, and fungi
[257,258]. Treatment with agents that increase gastric pH
increases the concentration of gastric organisms [259–261].
Alterations in gastric and duodenal bacterial flora as a result
of increases in gastric pH have the potential to increase the
postoperative infection rate [262,263].
The risk of postoperative infection in gastroduodenal pro-
cedures depends on a number of factors, including the gas-
troduodenal procedure performed. Patients who are at
highest risk include those with achlorhydria, including those
receiving pharmacotherapy with histamine H2-receptor an-
tagonists or proton-pump inhibitors [264], gastroduodenal
perforation, decreased gastric motility, gastric outlet obstruc-
tion, morbid obesity, gastric bleeding, or cancer [265]. Similar
to other types of surgical procedures, risk factors for SSIs re-
lated to gastroduodenal procedures include long procedure
duration [252,266,267], performance of emergency procedures
[250,261], greater than normal blood loss [251,252], American
Society of Anesthesiologists (ASA) classification of ‡ 3, and
late administration of antimicrobials [268].
Organisms
The most common organisms cultured from SSIs after
gastroduodenal procedures are coliforms (E. coli, Proteus
species, Klebsiella species), staphylococci, streptococci, en-
terococci, and occasionally Bacteroides species [101,269–276].
Efficacy
Randomized controlled trials have shown that prophylac-
tic antimicrobials are effective in decreasing postoperative
infection rates in high-risk patients after gastroduodenal
procedures. The majority of available studies were conducted
in single centers outside of the United States. Relative to other
types of gastrointestinal tract procedures, the number of
clinical trials evaluating antimicrobial prophylaxis for gas-
troduodenal procedures is limited. In placebo-controlled tri-
als, infection rates ranged from 0% to 22% for patients
receiving cephalosporins or penicillins and from 1.7% to 66%
for patients receiving placebo [270,271,273–275,277–284]. The
difference was significant in most studies.
Data support antimicrobial prophylaxis for patients un-
dergoing PEG insertion [264,285–287]. A Cochrane review of
systemic antimicrobial prophylaxis for PEG procedures that
included 11 randomized controlled trials and 1,196 patients
found a statistically significant reduction in peristomal in-
fections with antimicrobial prophylaxis (OR, 0.35; 95% CI,
0.23–0.48) [288]. Two meta-analyses found statistically sig-
nificant decreases in SSIs with antimicrobial prophylaxis
compared with placebo or controls, from 23.9–26% to 6.4–8%,
respectively [255,256]. Most well-designed, randomized con-
trolled studies found a significant decrease in postoperative
SSIs or peristomal infections with single i.v. doses of a ceph-
alosporin or penicillin, ranging from 11% to 17%, compared
with from 18% to 66% with placebo or no antimicrobials [279–
282,288]. Conflicting results have been seen in studies evalu-
ating the use of preoperative patient MRSA screening, de-
contamination washes and shampoos, five-day preoperative
treatment with intranasal mupirocin, and single-dose teico-
planin preoperative prophylaxis to decrease postoperative
MRSA infections during PEG insertion [289,290].
While there have been no well-designed clinical trials of
antimicrobial prophylaxis for patients undergoing bariatric
surgical procedures, treatment guidelines support its use
based on morbid obesity and additional comorbidities as risk
factors for postoperative infections [264,291]. There is no
consensus on the appropriate antimicrobial regimen; how-
ever, higher doses of antimicrobials may be needed for ade-
quate serum and tissue concentrations in morbidly obese
patients [13,268,291].
A notable risk factor for SSIs after esophageal and gas-
troduodenal procedures is decreased gastric acidity and
motility resulting from malignancy or acid-suppression
therapy [264,276]. Therefore, antimicrobial prophylaxis is
indicated for patients undergoing gastric cancer procedures
(including gastrectomy) and gastroduodenal procedures re-
lated to gastric and duodenal ulcer disease or bariatric sur-
gery or pancreaticoduodenectomy. Evaluations of practice
for pancreaticoduodenectomy show that antimicrobials are
typically given due to concerns of bile contamination. Pro-
phylaxis for gastroduodenal procedures that do not enter the
gastrointestinal tract, such as antireflux procedures, should
be limited to high-risk patients due to lack of data supporting
general use in all patients. Furthermore, laparoscopic anti-
reflux procedures are associated with very low SSI rates
(0.3%) comparedwith open antireflux procedures (1.4%), just
as laparoscopic gastric bypass procedures are associatedwith
lower rates than in open procedures (0.4% versus 1.2%) [292].
Choice of agent. The most frequently used agents for
gastroduodenal procedures were first-generation [271,273,
277,278,284,293–297] and second-generation [269,270,274,275,
280,293,294,298] cephalosporins. No differences in efficacy
between first- and second-generation cephalosporins were
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found. Amoxicillin–clavulanate [279,282,283,299] and cipro-
floxacin [269,300] were also evaluated with similar results.
Relatively few studies have compared the efficacy of different
agents in reducing postoperative infection rates.
One meta-analysis recommended using a single dose of an
i.v. broad-spectrum antimicrobial for SSI prophylaxis in these
patients [256], while another found no differences between
penicillin- or cephalosporin-based regimens and three-dose or
single-dose regimens [255]. In a comparative study, oral or i.v.
ciprofloxacin and i.v. cefuroxime were similarly effective in
upper gastrointestinal procedures, including gastrectomy,
vagotomy, and fundoplication [300]. No differences in effi-
cacy were seen between ceftriaxone and combination cef-
triaxone and metronidazole for PEG insertion in pediatric
patients [301]. An open-label study found a significant decrease
in local peristomal and systemic infection (i.e., pneumonia)
after PEG insertion after a single 1 g i.v. dose of ceftriaxonewas
given 30 min before surgery when compared with placebo
(13.3% and 36.3%, respectively; p< 0.05) [281]. No differences
were noted between cefotaxime and piperacillin–tazobactam
for PEG SSIs [288]. Ampicillin–sulbactam and cefazolin had
equal efficacy in gastrectomy [253]. One study found that pi-
peracillin–tazobactam in combination with ciprofloxacin or
gentamicin was the most active regimen against bacteria re-
covered from bile in pancreatoduodenectomy patients [302].
Duration. The majority of studies evaluated a single dose
of cephalosporin or penicillin [256,279–284,288,290,297]. The
available data indicate that single-dose and multiple-dose
regimens are similarly effective. Three studies compared
single- and multiple-dose regimens of cefamandole [294],
amoxicillin–cluvulanate [299], and ampicillin–sulbactam and
cefazolin [253]. There were no significant differences in SSI
rates.Multiple-dose regimens of first-generation (cefazolin) or
second-generation (cefotiam) cephalosporins of four days,
operative day only, and three days in duration did not differ
in overall SSI rates [295].
Recommendations
Antimicrobial prophylaxis in gastroduodenal procedures
should be considered for patients at highest risk for postop-
erative infections, including risk factors such as increased
gastric pH (e.g., patients receiving acid-suppression therapy),
gastroduodenal perforation, decreased gastric motility, gas-
tric outlet obstruction, gastric bleeding, morbid obesity, ASA
classification of ‡ 3, and cancer.
A single dose of cefazolin is recommended in procedures
during which the lumen of the intestinal tract is entered
(Table 2). (Strength of evidence for prophylaxis =A.) A single
dose of cefazolin is recommended in clean procedures, such as
highly selective vagotomy, and antireflux procedures only in
patients at high risk of postoperative infection due to the
presence of the above risk factors. (Strength of evidence for
prophylaxis =C.) Alternative regimens for patients with
b-lactam allergy include clindamycin or vancomycin plus
gentamicin, aztreonam, or a fluoroquinolone. Higher doses of
antimicrobials are uniformly recommended in morbidly ob-
ese patients undergoing bariatric procedures. Higher doses of
antimicrobials should be considered in significantly over-
weight patients undergoing gastroduodenal and endoscopic
procedures.
Biliary tract procedures
Background
Biliary tract procedures include cholecystectomy, explora-
tion of the common bile duct, and choledochoenterostomy.
These guidelines pertain only to patients undergoing biliary
tract procedures with no evidence of acute biliary tract in-
fection and to patients with community-acquired acute cho-
lecystitis of mild-to-moderate severity. As noted in the
Common Principles section, patients receiving therapeutic
antimicrobials for an infection before surgery should be given
additional antimicrobial prophylaxis before surgery.
These guidelines do not address patients requiring bili-
ary tract procedures for more-severe infections, including
community-acquired acute cholecystitis with severe physio-
logical disturbance, advanced age, or immunocompromised
state; acute cholangitis; and health-care-associated or nosoco-
mial biliary infections. These biliary tract infections are treated
as complicated intraabdominal infections [303]. All patients
with a suspected biliary tract infection who undergo biliary
tract surgery should receive preoperative i.v. antimicrobials.
The majority of published literature regarding SSIs in bili-
ary tract procedures focuses on cholecystectomy. The overall
reported rate of postoperative infection in open biliary tract
procedures with antimicrobial prophylaxis is 1–19% [292,304–
311]. Infection rates after laparoscopic cholecystectomy range
from 0% to approximately 4% in patients without anti-
microbial prophylaxis [308,312–320] and from 0% to 7% with
prophylaxis [292,304–323]. Several studies found that laparo-
scopic cholecystectomy SSI rates were significantly lower than
those associated with open cholecystectomy [292,306–311].
Risk factors associated with postoperative SSIs after biliary
procedures include performance of emergency procedures
[305], diabetes [305,306,311,315,317], longer procedure dura-
tion (over 120 minutes) [305,317,324], intraoperative gall-
bladder rupture [305], age of > 70 years [6,311,315,317,325],
open cholecystectomy [7,311], conversion of laparoscopic to
open cholecystectomy [7], higher ASA classification (‡ 3)
[306,310,317], episode of biliary colic within 30 days before
the procedure [315,316], reintervention in less than a month
for noninfectious complications [310], acute cholecystitis
[6,7,306], bile spillage [7], jaundice [6,7,306], pregnancy [7],
nonfunctioning gallbladder [6], and immunosuppression [7].
The biliary tract is usually sterile. Patients with bacteria in
the bile at the time of surgery may be at higher risk of post-
operative infection [305,326,327]; however, some studies have
found no association between the presence of bacteria in the bile
and infection [305,315,316,319,321].Obesity (a BMI of >30kg/m2)
was found to be a risk factor in some studies [306] but not in
others [315,319]. Laparoscopic cholecystectomywas associated
with a significantly decreased risk for SSI [292,310,324,325].
Organisms
The organisms most commonly associated with infection af-
ter biliary tract procedures include E. coli, Klebsiella species, and
enterococci; less frequently, other gram-negative organisms,
streptococci, and staphylococci are isolated [305,306,312,315,
316,318,319,321,326,328–338]. Anaerobes are occasionally re-
ported, most commonly Clostridium species.
Recent studies have documented increasing antimicrobial
resistance in the causative pathogens in biliary tract infections
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and other intra-abdominal infections, with up to 40% of E. coli
isolates resistant to ampicillin–sulbactam and fluoroquinolones
[339–341]. Due to this increasing resistance of E. coli to fluor-
oquinolones and ampicillin–sulbactam, local population sus-
ceptibility profiles should be reviewed to determine the optimal
antimicrobials for SSI prevention in biliary tract procedures.
Efficacy
Numerous studies have evaluated the use of prophylactic
antimicrobials during biliary tract procedures, with a focus on
laparoscopic cholecystectomy. Laparoscopic cholecystectomy
has replaced open cholecystectomy as the standard of practice
because of the reduction in recovery time and shorter hospital
stay. The majority of studies of antimicrobial prophylaxis for
laparoscopic cholecystectomy were underpowered and var-
ied in control groups used (placebo, active, or no treatment),
follow-up (from 30 to 60 days, while some studies did not
clearly define length of time), and how SSIs were detected and
reported [308,312–316,318,319,321,322]. Some studies in-
cluded patients who were converted from laparoscopic to
open cholecystectomy and others did not.
A large, multicenter, quality assurance study in Germany
assessed the effectiveness of antimicrobial prophylaxis in
laparoscopic and open cholecystectomies [308]. This study
included 4,477 patients whose antimicrobial choice and dos-
age regimens were at the discretion of the medical center and
surgeon. Antimicrobials used included first-, second-, and
third-generation cephalosporins or penicillins alone or in
combination with metronidazole, gentamicin, or both met-
ronidazole and gentamicin. The most common cephalosporin
used was ceftriaxone, allowing its data to be separated from
data for other antimicrobials. Antimicrobial prophylaxis was
administered to 2,217 patients (ceftriaxone [n = 787 laparo-
scopic and n = 188 open] and other antimicrobials [n = 229
laparoscopic and n= 229 open]); none was given to 1,328
laparoscopic and 932 open cholecystectomy patients. Sig-
nificantly lower overall infectious complications occurred in
patients receiving antimicrobial prophylaxis (0.8% ceftriaxone
and 1.2% other antimicrobials), compared with 5% of those
who received no prophylaxis (p < 0.05). The overall rates of
infectious complications were 0.6%, 0.8%, and 3.3% in pa-
tients undergoing laparoscopic cholecystectomy receiving
ceftriaxone, other antimicrobials, and no prophylaxis, re-
spectively, and 1.6%, 3.9%, and 7.4%, respectively, for patients
undergoing open cholecystectomy. Significantly lower rates
of SSIs and postoperative pneumonia were noted in patients
receiving antimicrobials compared with those who did not
receive prophylaxis (p < 0.05). Rates of SSI were significantly
decreased in laparoscopic cholecystectomy patients who re-
ceived ceftriaxone (0.1%) or other antimicrobials (0.2%)
compared with those who received no antimicrobial pro-
phylaxis (1.6%). SSI rates were significantly decreased in open
cholecystectomy patients who received ceftriaxone (1.0%) or
other antimicrobials (2.6%) compared with those who re-
ceived no antimicrobial prophylaxis (4.4%). The study au-
thors concluded that antimicrobial prophylaxis should be
administered to all patients undergoing cholecystectomy, re-
gardless of approach. The study had several limitations, in-
cluding lack of randomization, lack of adequate controls, and
lack of clear definition of patient selection for the antimicro-
bial regimens. The statistical analysis was not clearly defined.
The study appears to have compared only the use and lack of
use of antimicrobials (with ceftriaxone and other antimicro-
bials combined for analysis) and did not specifically compare
the laparoscopic and open approaches.
The findings of this study contrast with those of several
other published studies. A meta-analysis of 15 randomized
controlled studies evaluated the need for antimicrobial pro-
phylaxis in elective laparoscopic cholecystectomy for patients
at low risk of infection [313]. Low risk was defined as not
having any of the following: Acute cholecystitis, a history of
acute cholecystitis, common bile duct calculi, jaundice, im-
mune suppression, and prosthetic implants. A total of 2,961
patients were enrolled in the studies, including 1,494 who
received antimicrobial prophylaxis, primarily with cephalo-
sporins, vancomycin, fluoroquinolones, metronidazole, and
amoxicillin–clavulanic acid, and 1,467 controls receiving
placebo or no treatment. No significant difference was found
in the rates of infectious complications (2.07% in patients re-
ceiving antimicrobial prophylaxis versus 2.45% in controls) or
SSIs (1.47% in patients receiving antimicrobial prophylaxis
versus 1.77% in controls). The authors of the meta-analysis
concluded that antimicrobial prophylaxis was not necessary
for low-risk patients undergoing elective laparoscopic chole-
cystectomy. An additional meta-analysis of nine randomized
controlled trials (n = 1,437) also concluded that prophylactic
antimicrobials do not prevent infections in low-risk patients
undergoing laparoscopic cholecystectomy [342].
A small, prospective, nonrandomized study compared the
use of cefotaxime 1 g i.v. during surgery with an additional
two i.v. doses given eight hours apart after surgery (n= 80)
with no antimicrobial prophylaxis (n = 86) in patients under-
going elective laparoscopic cholecystectomy with accidental
or incidental gallbladder rupture and spillage of bile [317].
Patients who had spillage of gallstone calculi or whose op-
erations were converted to open operations were excluded
from the study. The rate of SSIs did not significantly differ
between treatment groups (2.5% with antimicrobials versus
3.4% without antimicrobial prophylaxis). Based on results of
multivariable analysis, routine antimicrobial prophylaxis was
not recommended for these patients unless they were dia-
betic, were older than 60 years, or had anASA classification of
‡ 3 or the duration of the procedure exceeded 70 min.
Current data do not support antimicrobial prophylaxis for
low-risk patients undergoing elective laparoscopic cholecys-
tectomies or those with incidental or accidental gallbladder
rupture. Antimicrobial prophylaxis should be considered for
patients at high risk of infection, including those undergoing
open cholecystectomy, as described above, or who are con-
sidered to be at high risk for conversion to an open procedure.
Choice of agent. The data do not indicate a significant
difference among first-, second-, and third-generation ceph-
alosporins. First-generation [307,308,312,315,319,323,330,336,
338,343,344], second-generation [308,314,315,318,323,327–329,
331,332,335,344–352], and third-generation [308,309,315–317,
321,322,332,333,338,349,353,354] cephalosporins have been
studied more extensively than other antimicrobials. Limited
data are available for ampicillinwith gentamicin [355], piperacillin
[356], amoxicillin–clavulanate [305,338,351,354], ciprofloxacin
[320,333,352,357], and cephalosporins or penicillins alone or in
combination with metronidazole, gentamicin, or both metro-
nidazole and gentamicin [308].
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Several studies have compared first-generation cephalospo-
rins with second- or third-generation agents [315,336,338,344–
347,353,358]. With one exception [347], there was no significant
difference in efficacy among agents. Other studies found no
significant differences in efficacy between ampicillin and cefa-
mandole [335], ciprofloxacin and ceftriaxone [333], amoxicillin–
clavulanic acid and cefotaxime [354], amoxicillin–clavulanic
acid and cefamandole [351], ceftriaxone and ceftazidime [321],
and oral and i.v. ciprofloxacin and i.v. cefuroxime [352,357].
One study found that i.v. ampicillin– sulbactamwas associated
with significantly lower rates of infection compared with ce-
furoxime [306] and that patients treated with oral ceftibuten
had significantly lower infection rates than those who received
amoxicillin–clavulanate [338].
Duration. The effect of duration of prophylaxis on out-
come has been evaluated. A single dose of a cephalosporin
was compared with multiple doses in several studies; no sig-
nificant differences in efficacy were found [327,329,330,
348,349,353,359]. The largest study compared one dose of ce-
furoximewith three doses in 1,004 patients with risk factors for
infection who were undergoing biliary tract surgery [327].
There was no significant difference in the rates of minor or
major SSIs between the single- andmultiple-dose groups. In the
majority of studies, one dose of an antimicrobial was admin-
istered at induction of anesthesia [306,312,338,352,354], within
30 min before incision [338], or 1 [315,316,320,321] or 2 [338] h
before incision. Additional doses were given as follows: one
dose 12 h after administration of the initial dose [352], two
doses 12 and 24 h after administration of the initial dose [338],
two doses every 6 [338] or 8 [317,319] h after surgery, and one
dose 24 h after surgery [315] and five days after surgery [352].
In one study, a second dose of amoxicillin–clavulanic acid or
cefotaxime was administered for procedures lasting longer
than 4 h [354].
Recommendations
A single dose of cefazolin should be administered in pa-
tients undergoing open biliary tract procedures (Table 2).
(Strength of evidence for prophylaxis =A.) Alternatives in-
clude ampicillin–sulbactam and other cephalosporins (cefo-
tetan, cefoxitin, and ceftriaxone). Alternative regimens for
patients with b-lactam allergy include clindamycin or van-
comycin plus gentamicin, aztreonam, or a fluoroquinolone; or
metronidazole plus gentamicin or a fluoroquinolone.
Antimicrobial prophylaxis is not necessary in low-risk pa-
tients undergoing elective laparoscopic cholecystectomies.
(Strength of evidence against prophylaxis for low-risk
patients =A.) Antimicrobial prophylaxis is recommended in
patients undergoing laparoscopic cholecystectomy who have
an increased risk of infectious complications. Risk factors in-
clude performance of emergency procedures, diabetes, an-
ticipated procedure duration exceeding 120 min, risk of
intraoperative gallbladder rupture, age of > 70 years, open
cholecystectomy, risk of conversion of laparoscopic to open
cholecystectomy, ASA classification of ‡ 3, episode of biliary
colic within 30 days before the procedure, reintervention in
less than a month for noninfectious complications of prior
biliary operation, acute cholecystitis, anticipated bile spillage,
jaundice, pregnancy, nonfunctioning gallbladder, and im-
munosuppression. Because some of these risk factors cannot
be determined before the surgical intervention, it may be rea-
sonable to give a single dose of antimicrobial prophylaxis to all
patients undergoing laparoscopic cholecystectomy. (Strength
of evidence for prophylaxis for high-risk patients=A.)
Appendectomy procedures
Background
Cases of appendicitis can be described as complicated or
uncomplicated on the basis of the pathology. Patients with
uncomplicated appendicitis have an acutely inflamed ap-
pendix. Complicated appendicitis includes perforated or
gangrenous appendicitis, including peritonitis or abscess
formation. Because complicated appendicitis is treated as a
complicated intra-abdominal infection [303], it has not been
addressed separately in these guidelines. All patients with a
suspected clinical diagnosis of appendicitis, even those with
an uncomplicated case, should receive appropriate preoper-
ative i.v. antimicrobials for SSI prevention, which, due to the
common microbiology encountered, requires similar antimi-
crobial choices to those used to treat complicated appendicitis.
Approximately 80% of patients with appendicitis have
uncomplicated disease [59]. SSI has been reported in 9–30% of
patients with uncomplicated appendicitis who do not receive
prophylactic antimicrobials, though some reports suggest
lower complication rates in children with uncomplicated
appendicitis [165,360–365]. Mean SSI rates for appendectomy
reported in the most recent NHSN report (2006–08) were 1.15%
(60 of 5211) forNHSN risk index categories 0 and 1 versus 3.47%
(23 of 663) for NHSN risk index categories 2 and 3 [165]. La-
paroscopic appendectomy has been reported to produce lower
rates of incisional (superficial and deep) SSIs than open appen-
dectomy in adults and children in multiple meta-analyses and
several randomized clinical trials [292,310,366–371]. However,
the rate of organ/space SSIs (i.e., intra-abdominal abscesses)
was significantly increased with laparoscopic appendectomy.
Organisms
The most commonmicroorganisms isolated from SSIs after
appendectomy are anaerobic and aerobic gram-negative enteric
organisms. Bacteroides fragilis is the most commonly cultured
anaerobe, and E. coli is the most frequent aerobe, indicating that
the bowel flora constitute a major source for pathogens
[59,372,373]. Aerobic and anaerobic streptococci, Staphylococcus
species, and Enterococcus species also have been reported.
Pseudomonas aeruginosa has been reported infrequently.
Efficacy
Antibiotic prophylaxis is generally recognized as effective
in the prevention of postoperative SSIs in patients undergoing
appendectomy when compared with placebo [374].
Choice of agent. Randomized controlled trials have
failed to identify an agent that is clearly superior to other
agents in the prophylaxis of postappendectomy infectious
complications. An appropriate choice for SSI prophylaxis in
uncomplicated appendicitis would be any single agent or
combination of agents that provides adequate gram-negative
and anaerobic coverage. The second-generation cephalospo-
rins with anaerobic activity and a first-generation cephalo-
sporin plus metronidazole are the recommended agents on
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the basis of cost and tolerability. Given the relatively equiv-
alent efficacy between agents, a cost-minimization approach
is reasonable; the choice of agents should be based on local
drug acquisition costs and antimicrobial sensitivity patterns.
A wide range of antimicrobials have been evaluated for
prophylaxis in uncomplicated appendicitis. The most com-
monly used agents were cephalosporins. In general, a second-
generation cephalosporin with anaerobic activity (cefoxitin or
cefotetan) or third-generation cephalosporins with partial
anaerobic activity (cefotaxime) were effective, with postop-
erative SSI rates of < 5% in most studies [364,375–381].
Piperacillin 2 g was comparable to cefoxitin 2 g in a well-
controlled study [381]. Metronidazole used alone was less
effective than cefotaxime, with infection rates above 10%
[376]. However, when metronidazole was combined with
cefazolin, ampicillin [382], or gentamicin [378,383], the post-
operative SSI rates were 3–6%.
A double-blind, randomized, controlled trial was con-
ducted at two hospitals to evaluate the effect of metronida-
zole, which is effective against most anaerobes, and cefazolin,
which is effective against many aerobic organisms, singly and
in combination, on the rate of sepsis after appendectomy
[384]. Patients were randomized into one of four groups:
metronidazole and placebo, cefazolin and placebo, metroni-
dazole and cefazolin, or double placebo. Patients with gen-
eralized peritonitis were excluded for ethical reasons.
Treatment was started before the procedure and continued
every 8 h for 24 h. All patients in the trial were followed for
about two weeks after discharge from the hospital, and their
surgical sites were inspected. A total of 271 patients were as-
sessed. Sepsis rates at the two hospitals were similar. Patients
who received both cefazolin and metronidazole had a signifi-
cantly lower infection rate compared with the other groups
[384]. Consistent with the antibacterial spectrum of the agents,
a prospective study of antimicrobial prophylaxis for colorectal
procedures found that the combination of metronidazole with
aztreonam did not show adequate coverage of gram-positive
organisms [385]. The Common Principles section of these
guidelines provides additional considerations forweight-based
dosing.
Duration. In most of the studies of second- or third-
generation cephalosporins or metronidazole combinations, a
single dose [376–378,380,383] or two or three doses
[364,379,382] were given. Although direct comparisons were
not made, there was no discernible difference in postoperative
SSI rates between single-dose and multidose administration
in most studies. A randomized trial specifically comparing
different durations of regimens found no statistical difference
between a single preoperative dose, three doses (preoperative
dose plus two additional doses), or a five-day regimen [386].
A large cohort study found that single doses of metronidazole
and gentamicin in patients undergoing open appendectomy
were effective and sufficient in decreasing the SSI rate [387].
Pediatric efficacy
In pediatric patients, as with adults, preoperative deter-
mination of complicated versus uncomplicated appendicitis is
difficult. A comprehensive review is not provided here, but
this topic has been addressed by SIS [388].
Two pediatric studies demonstrated no difference in SSI
rates between placebo and several antimicrobials. The first
study compared metronidazole, penicillin plus tobramycin,
and piperacillin [389]. The second study compared single-
dose metronidazole and single-dose metronidazole plus
cefuroxime [390]. A meta-analysis including both adult and
pediatric studies found that for pediatric patients, antimicro-
bial prophylaxis trended toward being beneficial, but the re-
sults were not statistically significant [374]. A retrospective
chart review questioned the routine need for antimicrobial
prophylaxis in children with simple appendicitis, due to rel-
atively low infection rates in children not receiving prophy-
laxis [365]. However, these and other study authors have
suggested antimicrobial prophylaxis may be considered due
to the morbidity associated with infectious complications (e.g.,
prolonged hospitalization, readmission, reoperation) and due
to the inability to preoperatively identify appendicitis.
As a single agent, metronidazole was no more effective
than placebo in two double-blind studies that included chil-
dren 10 years of age or older [360] and 15 years of age or older
[363]. In a randomized study that included pediatric patients,
ceftizoxime and cefamandole were associated with signifi-
cantly lower infection rates and duration of hospitalization
than placebo [391]. Both cefoxitin and a combination of gen-
tamicin and metronidazole were associated with a lower rate
of postoperative infection in a randomized study that included
pediatric patients younger than 16 years [378]. Second-gener-
ation cephalosporins with anaerobic activity (cefoxitin or ce-
fotetan) and third-generation cephalosporins with anaerobic
activity (cefotaxime) were effective, with postoperative in-
fection rates of < 5% in two studies that included pediatric
patients younger than 12 years [364,378,379]. A single dose of
gentamicin with clindamycin was found to be safe and ef-
fective in children with simple appendicitis [392].
Recommendations
For uncomplicated appendicitis, the recommended regi-
men is a single dose of a cephalosporin with anaerobic activity
(cefoxitin or cefotetan) or a single dose of a first-generation
cephalosporin (cefazolin) plus metronidazole (Table 2). For
b-lactam-allergic patients, alternative regimens include (1)
clindamycin plus gentamicin, aztreonam, or a fluor-
oquinolone and (2) metronidazole plus gentamicin or a
fluoroquinolone (ciprofloxacin or levofloxacin). (Strength of
evidence for prophylaxis =A.)
Small intestine procedures
Background
Small intestine procedures, or small bowel surgery as de-
fined by NHSN, include incision or resection of the small in-
testine, including enterectomy with or without intestinal
anastomosis or enterostomy, intestinal bypass, and stricture-
oplasty; it does not include small-to-large bowel anastomosis.
The risk of SSI in small bowel surgery is variable. The
Surgical Site Infection Surveillance Service in England (data
collected by 168 hospitals in 13 categories of surgical proce-
dures between 1997 and 2002) reported an SSI rate of 8.9% (94
of 1,056) [393]. Mean SSI rates for small bowel procedures
reported in the most recent NHSN report (2006–08) were
3.44% forNHSN risk index category 0 versus 6.75% forNHSN
risk index categories 1, 2, and 3. A study of 1,472 patients
undergoing bowel surgery (small bowel and colon) at 31 U.S.
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academic medical centers between September and December
2002 found an SSI rate of 8.7% for all wound categories. For
patients with clean-contaminated wounds, the SSI rate was
7.9%; for those with contaminated or dirty-infected wounds,
the SSI rates were 12.0% and 20.4%, respectively [394].
In a study of 178 penetrating stomach and small bowel
injuries, 94% of which were operated on within six hours of
presentation, SSIs occurred in nearly 20% of cases. When as-
sociated colon injuries were excluded, SSIs occurred in 16% of
gastric injuries and 13% of small bowel injuries. Although 74%
of patients received antimicrobials, the specific timing of anti-
microbial administrationwas not provided [395]. Other studies
of small bowel injury confirm similar SSI rates [396–400].
Antimicrobial prophylaxis is recommended for small
bowel surgery, based on inferring effectiveness from other
clean-contaminated procedures. No specific prospective ran-
domized studies could be identified that addressed antimi-
crobial prophylaxis for small bowel surgery. Antimicrobial
prophylaxis for small bowel surgical procedures related to a
diagnosis of complicated intra-abdominal infection is not
addressed separately in these guidelines, as antimicrobial
therapy for established intraabdominal infection should be
initiated preoperatively.
Organisms
The most commonmicroorganisms isolated from SSIs after
small bowel surgery are aerobic gram-negative enteric or-
ganisms. Among the species isolated from patients with SSI
after small intestine surgery are gram-negative bacilli of gas-
trointestinal enteric origin (aerobic and anaerobic) and gram-
positive species, such as streptococci, staphylococci, and
enterococci, which is consistent with similar studies [401].
Escherichia coli is the most frequently identified aerobe, indi-
cating that the bowel flora constitute a major source of path-
ogens. Aerobic and anaerobic streptococci, Staphylococcus
species, and Enterococcus species also have been reported.
The microbiology of 2,280 SSIs after upper or lower ab-
dominal surgery conducted from 1999 to 2006 was described in
the Prevalence of Infections in SpanishHospitals (EPINE) study
[402]. The most frequent microorganisms isolated were E. coli
(28%), Enterococcus species (15%), Streptococcus species (8%),
P. aeruginosa (7%), and S. aureus (5%; resistant tomethicillin, 2%).
The microbiology of SSIs after upper abdominal tract surgery
did not show any significant differences compared with SSIs of
the lower tract, though there were relatively more staphylo-
cocci,K. pneumoniae,Enterobacter species,Acinetobacter species,
and Candida albicans isolates and fewer E. coli, B. fragilis, and
Clostridium species in the upper abdominal surgery group [402].
Efficacy
Antibiotic prophylaxis is generally recognized as effective
in the prevention of postoperative SSIs in patients undergoing
small bowel surgery when compared with placebo. However,
there are no prospective placebo-controlled trials to defini-
tively establish the efficacy of prophylactic antimicrobials in
this patient population.
Choice of agent. The antimicrobials selected for pro-
phylaxis must cover the expected pathogens for the small
intestine. The microbial ecology of the proximal small intes-
tine (i.e., jejunum) is similar to that of the duodenum, whereas
the microbial flora of the ileum are similar to those of the
colon. In patients with small intestine obstruction, the mi-
crobial flora are similar to those of the colon.
No randomized controlled trials have confirmed that one
antimicrobial agent is superior to other agents for SSI pro-
phylaxis in small bowel surgery. An appropriate antimicro-
bial choice for SSI prophylaxis in small bowel surgery is any
single agent or combination of agents that provides adequate
coverage for the small intestinal microbes. In patients with
small bowel obstruction, additional coverage of anaerobic
bacteria is also desirable.
For small intestine procedures with no evidence of ob-
struction, a first-generation cephalosporin (cefazolin) is re-
commended. For patients with small intestine obstruction, a
first-generation cephalosporin with metronidazole or a
second-generation cephalosporin with anaerobic activity
(cefoxitin or cefotetan) is the recommended agent. The choice
of agents should be based on local drug acquisition costs and
antimicrobial sensitivity patterns. The Common Principles
section of these guidelines provides additional considerations
for weight-based dosing.
Duration. Preoperative dosing of antimicrobials for SSI
prevention, with additional intraoperative antimicrobial
dosing dependent on the duration of the operation and no
postoperative dosing, is recommended for patients undergo-
ing small bowel surgery.
Pediatric efficacy
In pediatric patients, as with adults, antimicrobial pro-
phylaxis for SSI prevention in small bowel surgery is
recommended.
Recommendations
For small bowel surgery without obstruction, the re-
commended regimen is a first-generation cephalosporin (ce-
fazolin) (Table 2). For small bowel surgery with intestinal
obstruction, the recommended regimen is a cephalosporin
with anaerobic activity (cefoxitin or cefotetan) or the combi-
nation of a first-generation cephalosporin (cefazolin) plus
metronidazole. For b-lactam-allergic patients, alternative
regimens include (1) clindamycin plus gentamicin, az-
treonam, or a fluoroquinolone and (2) metronidazole plus
gentamicin or a fluoroquinolone (ciprofloxacin or levo-
floxacin). (Strength of evidence for prophylaxis =C.)
Hernia repair procedures (hernioplasty
and herniorrhaphy)
Background
All patients who undergo hernioplasty (prosthetic mesh
repair of hernia) or herniorrhaphy (suture repair of hernia)
should receive appropriate preoperative i.v. antimicrobials
for SSI prevention. The risk of SSIs is higher in hernioplasty
compared with herniorrhaphy [403]. There is a significant risk
of requiring prosthetic mesh removal in hernioplasty patients
who develop an SSI, and determination of whether mesh
placement will be required for hernia repair is not always
possible in the preoperative period.
Mean SSI rates for herniorrhaphy reported in the most re-
cent NHSN report (2006–08) were 0.74% (21 of 2,852) for
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NHSN risk index category 0, 2.42% (81 of 3,348) for NHSN
risk index category 1, and 5.25% (67 of 1,277) for NHSN risk
index categories 2 and 3 [165].
A Cochrane meta-analysis of 17 randomized trials
(n = 7,843; 11 hernioplasty trials, 6 herniorrhaphy trials) in
elective open inguinal hernia repair reported SSI rates of 3.1%
versus 4.5% in the antimicrobial prophylaxis and control
groups, respectively (OR, 0.64; 95% CI, 0.50–0.82) [404]. The
subgroup of patients with herniorrhaphy had SSI rates of
3.5% and 4.9% in the prophylaxis and control groups, re-
spectively (OR, 0.71; 95% CI, 0.51–1.00). The subgroup of
patients with hernioplasty had SSI rates of 2.4% and 4.2% in
the prophylaxis and control groups, respectively (OR, 0.56;
95% CI, 0.38–0.81).
A meta-analysis of nine randomized trials of open hernio-
plasty for inguinal hernia documented SSI rates of 2.4% (39 of
1,642) in the antimicrobial group and 4.2% (70 of 1,676) in the
control group. Antibiotics showed a protective effect in pre-
venting SSI after mesh inguinal hernia repair (OR, 0.61; 95%
CI, 0.40–0.92). Antibiotic prophylaxis did reduce the rate of
SSI in hernia patients undergoing mesh hernioplasty [405].
Based on the results of these two systematic reviews, pre-
operative antimicrobial prophylaxis for SSI prevention is re-
commended for both herniorrhaphy and hernioplasty.
Compared with open hernia repair, laparoscopic hernia re-
pair has been reported to produce lower rates of incisional
(superficial and deep) SSIs in randomized clinical trials [406–
408]. In a recent multicenter randomized trial of laparoscopic
versus open ventral incisional hernia repair (n = 162), SSI was
significantly less common in the laparoscopic group than in
the open repair group (2.8% versus 21.9%; OR, 10.5; 95% CI,
2.3–48.2; p= 0.003) [409]. Ameta-analysis of eight randomized
trials comparing laparoscopic and open incisional or ventral
hernia repair with mesh revealed that laparoscopic hernia
repair was associated with decreased SSI rates (relative risk,
0.22; 95% CI, 0.09–0.54) and a trend toward fewer infections
requiring mesh removal [410].
Organisms
The most commonmicroorganisms isolated from SSIs after
herniorrhaphy and hernioplasty are aerobic gram-positive
organisms. Aerobic streptococci, Staphylococcus species, and
Enterococcus species are common, and MRSA is commonly
found in prosthetic mesh infections [411].
Efficacy
Antibiotic prophylaxis is generally recognized as effective
when compared with placebo in the prevention of post-
operative SSIs in patients undergoing herniorrhaphy and
hernioplasty.
Choice of agent. Randomized controlled trials have failed
to identify an agent that is clearly superior to other agents for
SSI prophylaxis in hernia repair. A first-generation cephalo-
sporin is the recommended agent on the basis of cost and tol-
erability. The Common Principles section of these guidelines
provides additional considerations for weight-based dosing.
Duration. Based on the evidence to date, a single preop-
erative dose of antimicrobial is recommended in hernioplasty
and herniorrhaphy, with redosing as recommended in the
Common Principles section of these guidelines (if the proce-
dure duration exceeds the recommended redosing interval
from the time of initiation of the preoperative dose or if there
is prolonged or excessive bleeding).
Recommendations
For hernioplasty and herniorrhaphy, the recommended
regimen is a single dose of a first-generation cephalosporin
(cefazolin) (Table 2). For patients known to be colonized with
MRSA, it is reasonable to add a single preoperative dose of
vancomycin to the recommended agent. For b-lactam-allergic
patients, alternative regimens include clindamycin and van-
comycin. (Strength of evidence for prophylaxis =A.)
Colorectal procedures
Background
Surgical site infections have been reported to occur in ap-
proximately 4–10% of patients undergoing colon procedures,
3–7% in small bowel procedures, and 3–27% in patients after
rectal procedures, based on the risk index [165]. However,
when patients are followed carefully in clinical trials, rates
tend to be considerably higher (17–26%) [412]. Other septic
complications, such as fecal fistula, intra-abdominal ab-
scesses, peritonitis, and septicemia, are serious concerns but
are much less common [413]. Infectious complication rates
range from 30% to 60% without antimicrobial prophylaxis
[59,414] and are < 10% with appropriate antimicrobial pro-
phylaxis. A pooled analysis of clinical trials of antimicrobial
prophylaxis in colon procedures demonstrated that antimi-
crobial use significantly reduced mortality rates (11.2% for
control versus 4.5% for treatment) and SSI rates [415].
The type and duration of the procedure can affect the risk of
infection. Rectal resection is associated with a higher risk of
infection than is intraperitoneal colon resection [416–418].
Other risk factors include extended procedure duration (e.g.,
> 3.5 hours) [59,412,418,419], impaired host defenses [418],
age of > 60 years [418], hypoalbuminemia [419,420], bacterial
or fecal contamination of the surgical site [418,420], inadver-
tent perforation or spillage [412,421], corticosteroid therapy
[419], perioperative transfusion of packed red blood cells
[394,418], hypothermia [422], hyperglycemia [423,424], and
obesity [412,418].
Organisms
The infecting organisms in colorectal procedures are de-
rived from the bowel lumen, where there are high concen-
trations of organisms. Bacteroides fragilis and other obligate
anaerobes are the most frequently isolated organisms from
the bowel, with concentrations 1,000–10,000 times higher than
those of aerobes [425]. Escherichia coli is the most common
aerobe. Bacteriodes fragilis and Escherichia coli comprise ap-
proximately 20–30% of the fecal mass. They are the most
frequently isolated pathogens from infected surgical sites af-
ter colon procedures.
Efficacy
Results from randomized controlled trials and a Cochrane
review of 182 studies of over 30,000 patients support the
routine use of prophylactic antimicrobials in all patients un-
dergoing colorectal procedures [426].
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Choice of agent. The agent chosen for antimicrobial pro-
phylaxis in colorectal procedures should have activity against
the anaerobic and aerobic floras of the bowel. The most ap-
propriate regimen for antimicrobial prophylaxis for colorectal
procedure (e.g., oral, i.v, oral–i.v. combination) and the optimal
choice of antimicrobial agent have not been fully resolved.
Oral regimens. The efficacy of oral prophylactic antimi-
crobial agents has been established in studies only when used
with mechanical bowel preparation (MBP). A variety of oral
agents administered after MBP have been evaluated for pro-
phylaxis for colorectal procedures. The most common com-
binations include an aminoglycoside (neomycin and, less
often, kanamycin, which is only available in injectable form
in the United States) plus a medication with anaerobic ac-
tivity, usually erythromycin [427–434] or metronidazole
[432,433,435–439]. In placebo-controlled studies, the oral
combination was significantly more effective than placebo in
reducing SSIs [427,433,434,439,440]. Postoperative SSI rates
were 0–11% with neomycin plus erythromycin [427–432] and
2–13% with neomycin and metronidazole [436–438]. Combi-
nations of neomycin and tetracycline [440], neomycin and
clindamycin [436], and neomycin and tinidazole [441] have
also been used successfully, with postoperative SSI rates of
< 10%. The use of metronidazole as a single agent appears to
be less effective, with reported SSI rates of 12–15% [442–444].
Oral antimicrobials have been compared with i.v. agents in
a few studies. Oral neomycin plus oral erythromycin was
similarly effective as i.v. cefoxitin in one study [429] but in-
ferior in another [445] and was similarly effective as i.v. cef-
triaxone plus i.v. metronidazole in patients undergoing
elective colorectal procedures [431]. The addition of i.v. cefa-
mandole to oral neomycin plus oral erythromycin did not
improve efficacy [430]. In one of these studies, oral neomycin
and erythromycin were more effective than i.v. cefoxitin for
procedures lasting longer than 4 h [445]. A randomized con-
trolled studywas stopped early due to the significantly higher
rate of infection in the oral neomycin and erythromycin group
(41%) compared with the single-dose i.v. metronidazole and
ceftriaxone group (9.6%) (p < 0.01) [446]. Similarly, a study of
oral metronidazole and kanamycin compared with the same
medications given intravenously found an increased rate of
postoperative sepsis (36%versus 6.5%, respectively) (p< 0.001),
greater numbers of E. coli resistant to kanamycin, more bacte-
rial overgrowth, and antimicrobial-associated pseudomem-
branous colitis in the oral group [447]. However, the oral
antimicrobials were not given on a schedule expected to be
effective, as they were discontinued 36 h before the procedure.
The fact that oral antibiotics were given for three days rather
than less than one day, as is the current practice, was suggested
as a possible reason for the resistance and colitis observed.
I.V. regimens. Awide rangeof i.v. antimicrobials havebeen
evaluated for prophylaxis in colorectal procedures. Cephalos-
porins are the most common agents, usually administered as a
single agent. Themajority of studies found that single-agent first-
generation cephalosporins (cefazolin and cephalothin) [445,448–
451] were ineffective, with postoperative SSI rates ranging from
12%to39%[448,449]. The lackof efficacy is likelydue to their lack
of B. fragilis activity. The combination of cefazolin and metroni-
dazole provides adequate coverage of pathogens and may be a
cost-effective prophylaxis strategy [6,41].
Second-generation cephalosporins with anaerobic activity,
such as cefoxitin and cefotetan, have been widely evaluated.
In single-agent therapy, SSI rates ranged from 0% to 17%
[91,417,445,452–459]; however, more than half of the studies
found SSI rates of > 10%.
Third-generation agents, cefotaxime and ceftriaxone, have
been evaluated in a few trials; postoperative SSI rates were
8–19% with single-agent use [456,460,461]. In some studies,
second- or third-generation cephalosporins were combined
with other i.v. agents,most commonlymetronidazole [452,459–
462]. However, in all but one of these studies, a combination of
a second- or third-generation cephalosporin plus metronida-
zole was no more effective than the cephalosporin alone. The
use of third- or fourth-generation cephalosporins for routine
antimicrobial prophylaxis is not recommended as usemay lead
todevelopment of resistant organisms [6,41,444,463].However,
in institutions where there is increasing gram-negative resis-
tance from isolates to first- and second-generation cephalo-
sporins, a single dose of ceftriaxone plusmetronidazolemay be
preferred over routine use of a carbapenem.
Three small studies, with under 200 patients each, found i.v.
ampicillin–sulbactam or amoxicillin–clavulanic acid to be as ef-
fective as i.v. combinations of gentamicin andmetronidazole [464],
gentamicin and clindamycin [465], and cefotaxime and metroni-
dazole for preventing SSIs in elective colorectal procedures.
A randomized controlled study of adult patients under-
going elective colon or rectal procedures evaluated the use of
a single high dose of gentamicin 4.5mg/kg i.v. plus metroni-
dazole 500mg i.v. in sequential order over 30 min compared
with multiple standard doses of gentamicin 1.5mg/kg plus
metronidazole given preoperatively and every 8 h for 24 h
postoperatively [16]. All patients underwent MBP before sur-
gery. Patients with a serum creatinine concentration exceeding
1.7mg/dL were excluded from the study. No statistically sig-
nificant differenceswere seen in deep and superficial incisional
SSI rates between groups. Significantly fewer superficial SSIs
were seen in the single-dose group compared with the multi-
dose group in procedures lasting longer than 3.5 h (22.2%
versus 55%, p= 0.021). A pharmacodynamic study of these
patients found the gentamicin concentration at the time of
surgical site closure as the strongest independent factor for
infection [17]. Of note, the infection rate was 80% in 10 patients
with gentamicin concentrations of < 0.5mg/L.
Other i.v. agents that have been evaluated either alone or in
combination include aminoglycosides [464,466–469], clin-
damycin [466], ampicillin [467,469–471], penicillins plus
b-lactamase inhibitors [464,465,468,472,473], doxycycline
[470,474–476], piperacillin [91,473], imipenem-cilastatin [462],
and ciprofloxacin [300].
Ertapenem, a broad-spectrum carbapenem, is approved
by FDA for the prophylaxis of SSIs after elective colorectal
procedures [67]. Cefotetan is also FDA-approved for surgical
prophylaxis in clean-contaminated procedures (e.g., gastroin-
testinal procedures) in adult patients undergoing elective colon
or rectal procedures [62]. A large, multicenter, randomized
controlled study compared a single 1 g i.v. dose of ertapenem
with cefotetan 2g i.v. infused within 60 min before surgical
incision [412]. All patients received MBP preoperatively. Rates
of SSI were significantly lower in the ertapenem group versus
cefotetan in the per-protocol (18.1% and 31.1%, respectively)
and the modified intent-to-treat (17.1% and 50.9%) popula-
tions. Ertapenem was found to be superior to cefotetan for SSI
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prevention. Although not statistically significant, higher rates
of skin-related events (i.e., pruritis and rash), gastrointestinal
events, and C. difficile infection were seen in the ertapenem
group. The study authors concluded that ertapenem is an ac-
ceptable alternative to cefotetan and cefoxitin. Routine use of
ertapenem for surgical prophylaxis remains controversial due
to theoretical concerns regarding increases in resistant organ-
isms and a potential increase in adverse events [477].
Alternative agents for patients with a high likelihood of
past serious adverse event or allergy to b-lactams include (1)
clindamycin plus an aminoglycoside, aztreonam, or a fluor-
oquinolone and (2) metronidazole plus an aminoglycoside or
a fluoroquinolone [41].
Combination oral and i.v. regimens. Combinations of oral
and i.v. antimicrobials have been used in an attempt to further
reduce postoperative infection rates. Regimens include oral
neomycin and erythromycin plus i.v. administration of a
cephalosporin [416,417,429,445,449,478,479], metronidazole
[480,481], and gentamicin plus clindamycin [466]. Post-
operative SSI rates in these studies ranged from 0% to 7%.With
one exception [416], therewas no significant difference between
oral neomycin–erythromycin plus an i.v. antimicrobial and oral
neomycin–erythromycin alone [429,449,466,478]. When com-
bination oral and i.v. agents were compared with i.v. agents
alone, combination therapy was favored in five of six studies
[417,429,445,449,480,482]; the differencewas significant in three
[417,449,482]. The most recent Cochrane review found that the
infection rate was significantly lower with the combination of
oral plus i.v. prophylaxis when compared with i.v. alone (rel-
ative risk, 0.55; p= 0.000084) or with oral prophylaxis alone
(relative risk, 0.34; p= 0.024) [426]. A recent report of over 2,000
patients recorded prospectively in the Michigan Surgical
Quality Collaborative—Colectomy Best Practices Project and
analyzed retrospectively revealed a significantly lower rate of
postoperative infections when 370 colectomy patients received
MBP and oral antimicrobial prophylaxis compared with pro-
pensity-matched patients receiving i.v. prophylaxis alone [483].
A multicenter, randomized, controlled study of 491 pa-
tients who received MBP plus oral antimicrobials (kanamycin
and erythromycin) with i.v. cefmetazole (not available in the
United States but noted by the expert panel to have a simi-
lar spectrum of activity as cefotetan) or i.v. cefmetazole alone
found nodifference in SSI between groups for colon procedures
[484]. However, the combination of oral and i.v. antimicrobials
was significantly better than i.v. alone for rectal procedures,
particularly abdominoperineal excision. Another study found
the postoperative SSI rates after rectal resection were 23% and
11%, respectively, for patients receiving i.v. cefoxitin and ce-
foxitin plus oral neomycin and erythromycin [417].
The safety and tolerability of oral antimicrobials have been
investigated in two studies. One case–control study found an
increased incidence of C. difficile colitis among patients with
oral plus i.v. antimicrobials and MBP compared with i.v. an-
timicrobials and MBP alone [485]. However, another case–
control study found a lower rate (not statistically significant)
of C. difficile infection in patients who had received oral anti-
microbials compared with those who had not (1.6% versus
2.9%, p = 0.09) [486]. A randomized controlled study of 300
patients undergoing elective colorectal procedures found
significantly higher rates of nausea and vomiting among pa-
tients receiving three doses of oral antimicrobials (neomycin
andmetronidazole, 44% and 31%, respectively) in combination
with i.v. cefoxitin andMBP comparedwith regimens including
one dose of oral antimicrobials (18% and 11%, respectively) and
no oral antimicrobials (13% and 9%, respectively) [487]. No
difference was noted between groups for rates of abdominal
pain, SSIs, or intraabdominal abscesses. An increased number
of gastrointestinal adverse events was also reported in another
comparative study in the combination oral and i.v. group
(2.9%) compared with the i.v.-only group (2.1%), although the
results were not statistically significant [484]. Overall, the evi-
dence suggests that the combination of oral antimicrobialswith
MBP in addition to i.v. prophylactic antimicrobials reduces the
rate of postoperative infections compared with i.v. antimicro-
bials alone without MBP, although the addition of oral anti-
microbials increases gastrointestinal symptoms.
Duration. Single and multiple doses were compared in
several studies [454–456,461,471,475]. However, only two of
these studies compared single doses with multiple doses of
the same antimicrobial [471,475]. There was no significant
difference in infection rates between single-dose and multi-
dose administration. One study found a single dose of cefo-
taxime plus metronidazole was significantly more effective
than three doses of cefotaxime alone [461]. The most recent
Cochrane review found no benefit to extending the duration
of prophylaxis (p = 0.58) [426]. Generally, antimicrobial pro-
phylaxis should be continued for no more than 24 h and can
typically be stoppedwhen the procedure is completed and the
surgical site is closed [6,41,444]. No evidence supports greater
efficacy for doses given after the completion of the procedure.
Additional discussion on this topic is found in the Common
Principles section of these guidelines.
Consideration should be given to an additional dose of the
i.v. antimicrobial if an agent with a short half-life is used and
the procedure duration exceeds the recommended redosing
interval (starting from the time of initiation of the preoperative
dose) and if intraoperative blood loss occurs [6,41,120,418,
444,445]. No significant difference was seen in SSI rates with
single-dose cefazolin, single-dose cefotetan, and cefazolin gi-
ven as one preoperative dose and a second dose three hours
later for procedures with a duration of less than three hours
[118]. Rates of SSI were significantly higher with a single dose
of cefazolin for procedureswith a duration of greater than three
hours. Using an agent with a longer half-life can decrease the
necessity to redose the antimicrobial during long procedures.
Pediatric efficacy
No well-controlled studies have evaluated the efficacy of
antimicrobial prophylaxis in pediatric patients undergoing
colorectal procedures. However, there is no reason to suspect
that prophylaxis efficacy would be different. The safety, effi-
cacy, tolerability, and cost-effectiveness of intestinal lavage
have been demonstrated in two studies of 20 and 21 pediatric
patients [488,489].
Recommendations
A single dose of second-generation cephalosporin with
both aerobic and anaerobic activities (cefoxitin or cefotetan) or
cefazolin plus metronidazole is recommended for colon pro-
cedures (Table 2). In institutions where there is increasing
resistance to first- and second-generation cephalosporins
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among gram-negative isolates from SSIs, the expert panel
recommends a single dose of ceftriaxone plus metronidazole
over routine use of a carbapenem. An alternative regimen is
ampicillin–sulbactam. Inmost patients,MBP combinedwith a
combination of oral neomycin sulfate plus oral erythromycin
base or oral neomycin sulfate plus oral metronidazole should
be given in addition to i.v. prophylaxis. The oral antimicrobial
should be given as three doses over approximately 10 hours
the afternoon and evening before the operation and after the
MBP. Alternative regimens for patients with b-lactam aller-
gies include (1) clindamycin plus an aminoglycoside, az-
treonam, or a fluoroquinolone and (2) metronidazole plus an
aminoglycoside or a fluoroquinolone. Metronidazole plus
aztreonam is not recommended as an alternative because this
combination has no aerobic gram-positive activity [385].
(Strength of evidence for prophylaxis =A.)
Head and neck procedures
Background
Elective procedures of the head and neck are predomi-
nantly clean or clean-contaminated [490]. Clean procedures
include thyroidectomy and lymph node excisions. Clean-
contaminated procedures include all procedures involving an
incision through the oral or pharyngeal mucosa, ranging from
parotidectomy, submandibular gland excision, tonsillectomy,
adenoidectomy, and rhinoplasty to complicated tumor-
debulking and mandibular fracture repair procedures requir-
ing reconstruction. The frequency of SSIs reported for
clean procedures without antimicrobial prophylaxis is < 1%
[491,492]. In contrast, infection rates in patients undergoing
complicated head and neck cancer surgery are quite high,with
infection occurring in 24–87% of patients without antimicro-
bial prophylaxis [493–497].Whilemany of these head andneck
cancer procedures are clean-contaminated, these procedures
can fall into different wound classifications. Head and neck
cancer patients often havemany of the risk factors for infection
mentioned below [498].
Postoperative SSI rates are affected by age, nutritional
status, and the presence of concomitant medical conditions
such as diabetes mellitus, anemia, and peripheral vascular
disease [496,499–504]. Use of tobacco [498,505], alcohol
[505,506], or drugs of abuse [507] has also been associated with
a higher risk of postoperative infection, particularly in patients
with mandibular fracture. The hospital course, including
length of hospitalization before operation, duration of antimi-
crobial use before operation, length of operation, presence of
implants, and previous tracheotomy can also affect postoper-
ative SSI rates [496,497,501–504,508]. In patients with cancer,
preoperative radiation and chemotherapy as well as the stage
of the malignancy may also affect infection risk [497,498,502–
504]. Procedure-related risk factors for infection include radical
or bilateral neck dissections [501,508] and reconstruction with
myocutaneous flaps or microvascular-free flaps [497–499,508].
Organisms
The normal floras of the mouth and the oropharynx are
responsible for most infections that follow clean-contaminated
head and neck procedures [6,8,496,498,499,506,509–519].
Anaerobic and aerobic bacteria are abundant in the orophar-
ynx. As a result, postoperative SSIs are usually polymicrobial
and involve both aerobic and anaerobic bacteria. The pre-
dominant oropharyngeal organisms include various strepto-
cocci (aerobic and anaerobic species), other oral anaerobes
including Bacteroides species (but not B. fragilis), Peptos-
treptococcus species, Prevotella species, Fusobacterium species,
Veillonella species, Enterobacteriaceae, and staphylococci. Nasal
flora includes Staphylococcus species and Streptococcus species.
Efficacy
Clean procedures. Systemic administration of prophy-
lactic antimicrobials has not been proven effective in reducing
SSI rates in patients undergoing clean procedures of the head
and neck and are not recommended for routine use [6–8,
497,520]. One randomized, double-blind, multicenter study of
500 patients undergoing thyroid procedures for goiter or
carcinoma found no difference in postoperative SSI rates in
those who received antimicrobial prophylaxis (0.8%) and
those who did not (0.4%) [491].
Clean-contaminated procedures. Based on the best
available evidence, current guidelines and review articles
recommend the use of antimicrobial prophylaxis for the ma-
jority of clean-contaminated procedures [6–8,497,520,521].
However, antimicrobial prophylaxis did not lower infection
risk in randomized controlled trials of patients undergoing
adenoidectomy, tonsillectomy [522,523], and septoplasty
[524], and systematic reviews have not recommended pro-
phylaxis for these procedures [7,525,526].
The efficacy of antimicrobial prophylaxis is best established
for head and neck cancer surgery. Several small randomized,
controlled trials found high infection rates in placebo groups
(24–78%) and markedly lower infection rates in the prophy-
laxis groups (5.8–38%) using a variety of regimens, including
cefazolin, third-generation cephalosporins, and ampicillin
plus cloxacillin. Although these studies were small, the results
are concordant, and the high infection rates allowed the
studies to reach statistical significance despite the small
sample sizes. Similar results were reported in several addi-
tional small, uncontrolled studies [500,527–529].
Choice of agent. Several randomized, single-center
studies have compared antimicrobial regimens for clean-
contaminated procedures. In one study, 189 patients under-
going head and neck cancer procedures were randomized to
receive cefazolin 1 g (n = 92) or amoxicillin–clavulanic acid
(n= 97), both givenwithin one hour of incision and every eight
hours postoperatively for three doses [511]. The postoperative
SSI rates were 24% with cefazolin and 21% with amoxicillin–
clavulanic acid; therewas no statistically significant difference
in infection rates in this underpowered study. Two studies have
compared ampicillin–sulbactam to clindamycin and yielded
discordant results. One study of 242 patients (169 evaluable)
undergoing head and neck cancer procedures compared
ampicillin–sulbactam 1.5 g (n = 119) and clindamycin 600mg
(n = 123) given within one to two hours of incision and every
six hours postoperatively for a total of four doses [510]. No
difference in SSIs was found, with 15 infections reported in
each group (13% for the ampicillin–sulbactam group and 12%
for the clindamycin group). There was no significant differ-
ence in adverse events between groups. There was a higher
rate of C. difficile-positive patients in the clindamycin group
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(n= 7) than in the ampicillin–sulbactam group (n= 1), with no
reported statistical analysis. Another study of 212 patients un-
dergoing clean-contaminated head and neck oncology surgery
found significantly fewer infections in the ampicillin–sulbactam
group (13.3%) compared with the clindamycin group (27.1%)
( p= 0.02) [530]. A greater number of gram-negative pathogens
were recovered from patients randomized to the clindamycin
group. The combination of gentamicin and clindamycin was
superior to cefazolin in one older clinical trial [531].
Duration. Studies of clean-contaminated head and neck
procedures found no difference in efficacy between regimens
of 24 hours and longer regimens of three, five, or seven days
[499–501,505,507,512,524,531–534]. Limited data exist on
single-dose prophylaxis in these procedures.
One study of patients undergoing free-flap reconstruction
after head and neck procedures found a significantly lower
rate of acquisition and infection with MRSA in patients re-
ceiving short-term cefuroxime and metronidazole (one dose
during induction of anesthesia and one dose eight hours
postoperatively) compared with long-term therapy (same
antimicrobials with additional doses every eight hours for up
to five days) (p = 0.005 and p = 0.01, respectively, for acquisi-
tion and infection) [535].
Recommendations
Clean procedures. Antimicrobial prophylaxis is not re-
quired in patients undergoing clean surgical procedures of the
head and neck. If there is placement of prosthetic material, a
preoperative dose of cefazolin or cefuroxime is reasonable,
though there are few data supporting the efficacy of pro-
phylaxis in this setting (Table 2). A reasonable alternative for
patients with b-lactam allergies is clindamycin. (Strength of
evidence against prophylaxis without prosthesis place-
ment =B; strength of evidence for prophylaxis with prosthesis
placement =C.)
Clean-contaminated procedures. Antimicrobial prophy-
laxis has not been shown to benefit patients undergoing ton-
sillectomy or functional endoscopic sinus procedures. The
preferred regimens for patients undergoing other clean-
contaminated head and neck procedures are (1) cefazolin or
cefuroxime plus metronidazole and (2) ampicillin–sulbactam.
Clindamycin is a reasonable alternative in patients with a
documented b-lactam allergy. The addition of an aminogly-
coside to clindamycin may be appropriate when there is an
increased likelihood of gram-negative contamination of the
surgical site. (Strength of evidence for prophylaxis in cancer
surgery patients =A; strength of evidence for prophylaxis for
other clean-contaminated procedures except tonsillectomy
and functional endoscopic sinus procedures =B.)
Neurosurgery procedures
Background
Nosocomial central nervous system (CNS) infections do
not often occur but have potentially serious consequences and
poor outcomes, including death [536]. One of the greatest
risks for these infections in children and adults is undergoing
a neurosurgical procedure. A classification system for neu-
rosurgery, validated by Narotam et al. [537], divides proce-
dures into five categories: clean, clean with foreign body,
clean-contaminated, contaminated, and dirty. Risk factors for
postoperative infections after neurological procedures in-
clude an ASA classification of ‡ 2 [538], postoperative moni-
toring of intracranial pressure [538,539] or ventricular drains
[536,538] for five or more days, cerebrospinal fluid (CSF) leak
[539–541], procedure duration of more than two to four hours
[540,542–544], diabetes [544], placement of foreign body [536],
repeat or additional neurosurgical procedures [538,541–543],
concurrent (remote, incision, or shunt) or previous shunt in-
fection [536,539,545,546], and emergency procedures [542,545].
Organisms
Data from most published clinical trials indicate that SSIs
are primarily associated with gram-positive bacteria, S. aureus,
and coagulase-negative staphylococci [6,8,537–545,547–554].
Several cohort studies revealed high rates (up to 75–80% of iso-
lates) of MRSA [540–543,548–552] and coagulase-negative
staphylococci among patients undergoing a variety of neuro-
surgical procedures [539,540,543,549]. Other skin organisms such
as P. acnes may be seen after CSF shunt placement, craniotomy,
and other procedures [536,555,556]. Gram-negative bacteria have
also been isolated as the sole cause of postoperative neurosur-
gical SSIs in approximately 5–8% of cases and have been isolated
in polymicrobial infections [537–539,541–545,547–550,552,553].
Efficacy
Clean procedures. Antimicrobial prophylaxis is re-
commended for adult and pediatric patients undergoing
craniotomy and spinal procedures [7,520]. One meta-analysis
of six studies found decreased odds of meningitis in patients
undergoing craniotomy who received antimicrobial prophy-
laxis (1.1%) versus no prophylaxis (2.7%) (p = 0.03) [557]. Two
cohort studies [540,543] in patients undergoing craniotomy at
the same institution found that antimicrobial prophylaxis
with cloxacillin or amoxicillin–clavulanic acid, clindamycin for
b-lactam-allergic patients, and other antimicrobials (not de-
tailed) had a significantly lower infection rate (5.8%) than no
prophylaxis (9.7%) (p < 0.0001) [543]. A significantly lower
infection rate of 4.6% was seen in low-risk patients (clean
craniotomy, no implant) with antimicrobial prophylaxis
compared with those without prophylaxis (4.6% versus 10%,
p < 0.0001). A significantly lower rate of scalp infections, bone
flap osteitis, and abscess or empyema was seen with antimi-
crobial prophylaxis compared with no prophylaxis. Anti-
microbial prophylaxis demonstrated no difference in
postoperative meningitis [540,543] and infection rates in high-
risk patients (those undergoing emergency, clean-contami-
nated, and dirty procedures or reoperation or with operative
times exceeding four hours) [543].
Prospective studies involving large numbers of patients
have also demonstrated lower neurosurgical postoperative
infection rates when antimicrobial prophylaxis is used [558–
561]. One such study of patients undergoing craniotomy,
spinal, or shunting procedures was stopped early because of
an excessive number of SSIs in the placebo group [562].
Choice of agent. Studies of clean neurosurgical proce-
dures reported antimicrobial regimens including clin-
damycin [540,543,557], vancomycin [542,557], cefotiam (not
marketed in the United States) [557], piperacillin [557], clox-
acillin [540,543,557], oxacillin [542,557], cefuroxime [547],
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cefotaxime [548], sulfamethoxazole–trimethoprim [548], ce-
fazolin [542,544], penicillin G [542], and amoxicillin–clavulanic
acid [540,542,543]. A meta-analysis found no significant
difference in the rates of postcraniotomy meningitis with
various antimicrobial regimens (single-dose regimens of
clindamycin, vancomycin, or cefotiam; three doses of piper-
acillin; four doses of cloxacillin; and six doses of oxacillin) [557].
A randomized, open-label, multicenter study of 613 adult
patients undergoing elective craniotomy, shunt, or stereo-
tactic procedures found no difference in single doses of cefo-
taxime and trimethoprim–sulfamethoxazole in postoperative
abscess formation, SSIs, and shunt infections [548].
Duration. The majority of studies included single doses
of antimicrobials; therefore, the use of single-dose antimicro-
bial prophylaxis given within 60 min before surgical inci-
sion in patients undergoing neurosurgery is generally
recommened [6,7,520,540,543,547,548,557,563].
Efficacy for CSF shunting procedures
Antimicrobial prophylaxis is recommended for adults
undergoing placement of a CSF shunt [7]. Prophylaxis in
patients undergoing ventriculostomy or intraventricular
prophylaxis at the time of ventriculoperitoneal shunt inser-
tion has shown some benefit in reducing infection but remains
controversial due to limited evidence [6,7].
Because CNS infections after shunting procedures are re-
sponsible for substantial mortality and morbidity, especially
in children, the possible role of prophylactic antimicrobials in
such procedures has been studied in numerous small, well-
conducted, randomized controlled trials [564–571]. Meticu-
lous surgical and aseptic techniques and short procedure
times were determined to be important factors in lowering
infection rates after shunt placement. Although the number of
patients studied in each trial was small, two meta-analyses of
these data demonstrated that antimicrobial prophylaxis use in
CSF-shunting procedures reduced the risk of infection by
approximately 50% [572,573].
Intrathecal pump placement involves the implantation of a
permanent intrathecal catheter to allow instillation of medi-
cation. Central nervous system infections may occur after
these procedures, which are performed in both pediatric and
adult populations. Several retrospective series have reported
infection rates of 4.5–9% after intrathecal baclofen pump
placement [574–576]. There are minimal published trial data
regarding appropriate prophylaxis for intrathecal pump
procedures. It has been suggested that prophylaxis for intra-
thecal pump procedures be managed similarly to prophylaxis
for CSF shunting procedures [577].
There is no consensus on the use of antimicrobial prophy-
laxis in patients with extraventricular drains (EVDs) or in-
tracranial pressure monitors [134]. An international survey of
neurosurgeons and critical care medicine and infectious dis-
eases specialists illustrates the difference in practices. The
majority of neurosurgeons used or recommended the use of
antimicrobial prophylaxis with EVDs (73.5%) and other
monitoring devices (59%), compared with rates of 46–59% for
critical care medicine specialists and 35% for infectious dis-
eases specialists. The majority of specialists did not recom-
mend or use antimicrobial-coated EVD catheters.
Two randomized controlled studies comparing antimicrobial-
impregnated shunts to standard, non-antimicrobial-
impregnated shunts along with antimicrobial prophylaxis
with i.v. cephalosporin found a decrease in rates of shunt
infections [549] and a significant decrease in CSF infection
with antimicrobial-impregnated shunts [545]. At this time,
routine use of antimicrobial-impregnated devices is not re-
commended; additional well-designed studies are needed to
establish their place in therapy [7,578].
Choice of agent. In CSF-shunting procedures, no single
antimicrobial agent has been demonstrated to have greater
efficacy than others [546,548,551–554,579]. There is a lack of
data on the necessity of antimicrobials with CNS penetration
relating to prevention of infection in CNS shunting procedures.
Duration. The majority of studies support the use of
single-dose prophylaxis regimens or regimens with a dura-
tion of 24–48 hours postoperatively [6–8,520,539,546,549–
552,579]. There is a lack of data evaluating the continuation of
EVDs with and without antimicrobial prophylaxis. The in-
ternational survey mentioned above asked respondents to
indicate their recommended duration for antimicrobial pro-
phylaxis with EVDs as either periprocedural, for 24 hours, for
the first three days, for the entire time the device is in place, or
other [135]. The respondents from the specialties of neuro-
surgery, neurocritical care, and critical care had similar re-
sults, with 28–31% using or recommending periprocedural
antimicrobials, 4–10% for 24 hours, 2–4% for the first three
days, 43–64% for the entire time the device is in place, and 0–
14% for other. The infectious diseases specialists reported
rates of 62%, 19%, 4%, 12%, and 4%, respectively.
One retrospective single-center cohort study of 308 patients
with EVDs placed for three days or more received antimicro-
bial prophylaxis for the duration of EVD use (n= 209) com-
pared with patients receiving cefuroxime 1.5g i.v. every eight
hours for three doses or less frequently periprocedurally
(timing not clearly defined in article) (n= 99) [580]. The overall
rate of bacterial ventriculitiswas 3.9%,with 8 patients (3.8%) in
the extended-use group and 4 patients (4%) in the short-term
prophylaxis group, the difference ofwhichwas not significant.
The study authors concluded that there was no benefit to the
use of a prolonged duration of antimicrobial prophylaxis.
Pediatric efficacy for CSF shunting procedures
Antimicrobial prophylaxis is recommended for children
undergoing a CSF-shunting procedure [7]. The efficacy of
antimicrobial prophylaxis is extrapolated from adult studies.
A retrospective pediatric study of 384 CSF shunting proce-
dures found a lower infection rate in patients who received
antimicrobials (2.1%) comparedwith thosewho did not (5.6%),
but this difference failed to reach statistical significance [581].
Two randomized, prospective studies that included pediatric
patients did not demonstrate a significant difference in infec-
tion rates between the control group and the groups that re-
ceived cefotiam [571] (not available in the United States) or
methicillin [568]. A randomized, double-blind, placebo-con-
trolled study that included pediatric patients undergoing
ventriculoperitoneal shunt surgeries failed to demonstrate that
the use of perioperative sulfamethoxazole–trimethoprim re-
duced the frequency of shunt infection [564].
Other studies have demonstrated efficacy for prophylactic
antimicrobials [566,582]. A single-center, randomized, double-
102 SURGICAL PROPHYLAXIS GUIDELINES
blind, placebo-controlled trial of perioperative rifampin plus
trimethoprim was performed in pediatric patients [582].
Among patients receiving rifampin plus trimethoprim, the in-
fection rate was 12%, compared with 19% in patients receiving
placebo. The study was ended because of the high infection
rates before significance could be achieved. Infection rates at
the study institution had been 7.5% in the years before the
study. An open-label randomized study, including pediatric
patients, demonstrated a lower infection rate in a group re-
ceiving oxacillin (3.3%) than in a control group (20%) [566].
Recommendations
A single dose of cefazolin is recommended for patients
undergoing clean neurosurgical procedures, CSF-shunting
procedures, or intrathecal pump placement (Table 2). Clin-
damycin or vancomycin should be reserved as an alternative
agent for patients with a documented b-lactam allergy (van-
comycin for MRSA-colonized patients). (Strength of evidence
for prophylaxis =A.)
Cesarean delivery procedures
Background
Approximately 1.2 million infants are born by cesarean
delivery in the United States annually [583]. The infection rate
after cesarean delivery has been reported to be 4–15% [583],
though recentNHSNdata showedan infection rate of 2–4% [165].
Postpartum infectious complications are common after
cesarean delivery. Endometritis (infection of the uterine lin-
ing) is usually identified by fever, malaise, tachycardia, ab-
dominal pain, uterine tenderness, and sometimes abnormal or
foul-smelling lochia [584]. Fever may also be the only symp-
tom of endometritis.
Endometritis has been reported to occur in up to 24% of
patients in elective cesarean delivery and up to approximately
60% of patients undergoing nonelective or emergency section
[584,585]. Risk factors for endometritis include cesarean de-
livery, prolonged rupture of membranes, prolonged labor
with multiple vaginal examinations, intrapartum fever, and
low socioeconomic status [585,586]. Patients with low socio-
economic status may have received inadequate prenatal care.
The factor most frequently associated with infectious mor-
bidity in postcesarean delivery is prolonged labor in the
presence of ruptured membranes. Intact chorioamniotic
membranes serve as a protective barrier against bacterial
infection. Rupture of the membrane exposes the uterine sur-
face to bacteria from the birth canal. The vaginal fluid with
bacterial flora is drawn into the uteruswhen it relaxes between
contractions during labor. Women undergoing labor for more
than six to eight hours in the presence of ruptured membranes
should be considered at high risk for developing endometritis
[587]. Other risk factors for SSIs after cesarean delivery include
systemic illness, poor hygiene, obesity, and anemia [587,588].
Organisms
The normal flora of the vagina include staphylococci,
streptococci, enterococci, lactobacilli, diphtheroids, E. coli,
anaerobic streptococci (Peptococcus species and Peptos-
treptococcus species), Bacteroides species (e.g., Bacteroides bivius,
B. fragilis), and Fusobacterium species [584,587,589–592]. En-
dometritis infections are often polymicrobial and include
aerobic streptococcus (particularly group B b-hemolytic
streptococcus and enterococci), gram-negative aerobes (par-
ticularly E. coli), gram-negative anaerobic rods (particularly
B. bivius), and anaerobic cocci (Peptococcus species and
Peptostreptococcus species). Ureaplasma urealyticum has been
commonly isolated from endometrial and surgical-site cul-
tures. Additional commonly isolated organisms from SSIs
include Staphylococcus species and enterococci.
Efficacy
While the use of antimicrobial prophylaxis in low-risk
procedures (i.e., those with no active labor and no rupture of
membranes) has been brought into question by the results of
several randomized, placebo-controlled studies that found no
reduction in infectious complications (fever, SSI, urinary tract
infection, or endometritis) with the use of prophylaxis, the
majority of these evaluations were underpowered and in-
cluded administration of antimicrobial prophylaxis at cord
clamping [593–599]. However, the efficacy of antimicrobial
prophylaxis in cesarean delivery has been shown in several
studies and two meta-analyses for both elective and non-
elective procedures. Therefore, prophylaxis is recommended
for all patients undergoing cesarean delivery [584,592].
One meta-analysis that reviewed seven placebo-controlled
randomized trials in low-risk elective cesarean delivery found
that prophylaxis was associated with a significant decrease in
endometritis and fever [592]. A larger meta-analysis of 81
randomized trials with 11,937 women undergoing both elec-
tive and nonelective cesarean delivery found that antimicro-
bial prophylaxis was associatedwith a significant reduction in
risk of fever, endometritis, SSI, urinary tract infection, and
serious infection [585]. The relative risk for endometritis in
elective cesarean section was 0.38 (95% CI, 0.22–0.64) in those
receiving antimicrobial prophylaxis compared to those re-
ceiving no prophylaxis.
Choice of agent. Although several different antimicrobi-
als used alone or in combination for antimicrobial prophylaxis
during cesarean delivery have been evaluated, the use of first-
generation cephalosporins (specifically cefazolin) has been
advocated by the American College of Obstetrics and Gyne-
cology (ACOG) and the American Academy of Pediatrics
(AAP), based on their efficacy, narrow spectrum of activity,
and low cost [584]. This recommendation is supported by a
meta-analysis of 51 randomized controlled trials comparing at
least two antimicrobial regimens that concluded that ampicillin
and first-generation cephalosporins have similar efficacy [600].
Newer prospective randomized controlled and cohort studies
have evaluated the addition of metronidazole, azithromycin
[601–603], or doxycycline [601] to a first- or second-generation
cephalosporin to extend the spectrum of activity against com-
mon organisms isolated from endometrial and surgical-site cul-
tures, specifically U. urealyticum and Mycoplasma species. These
studies found significantly lower rates of postoperative infec-
tions (including endometritis and SSI) and a shorter duration of
hospital stay comparedwith prophylaxis with a first- or second-
generation cephalosporin alone [601–604]. Antibiotic adminis-
tration occurred either postoperatively or after cord clamping in
these studies. Further study, particularly with preoperative an-
timicrobial administration, is needed to confirm these prelimi-
nary findings and establish a place in therapy for this practice.
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Timing. Historically, administration of antimicrobials in
cesarean delivery was delayed until after cord clamping
[600,605,606]. The principal reasons were to avoid suppres-
sion of the neonate’s normal bacterial flora that could promote
the selection of resistant organisms and concern that the
antimicrobials could potentially mask neonatal infection,
complicating evaluation of neonatal sepsis. However, more
contemporary data support the administration of antimicrobial
prophylaxis before surgical incision to protect against bacterial
contamination of the surgical site and decrease the risk of in-
fection. The practice of antimicrobial prophylaxis administra-
tion before surgical incision is endorsed by ACOG and AAP
[584,607]. See the Common Principles section of these guide-
lines for additional discussion on antimicrobial timing.
A meta-analysis of three randomized controlled trials and
two nonrandomized controlled studies provided evidence
that preoperative antimicrobial administration significantly
decreased the rate of endometritis compared with adminis-
tration after cord clamping (3.9% and 8.9%, respectively;
p = 0.012) [605]. A lower SSI rate was also seen with preop-
erative antimicrobial administration (3.2% versus 5.4%),
though this difference was not significant. The overall rate of
infection-related morbidity was also significantly lower. No
differences between the groups were seen in neonatal out-
comes, including sepsis, sepsis workups, and neonatal in-
tensive care unit admissions. The largest study included in
this meta-analysis was a prospective, randomized, controlled,
double-blind, single-center, double-dummy study of 357 pa-
tients comparing cefazolin 1 g i.v. given preoperatively and
after cord clamping, which had results consistent with the
overall meta-analysis [606].
In a recent randomized trial of more than 1,100 women
undergoing cesarean section between 2004 and 2010,Witt and
colleagues [608] found no difference in SSI rates for patients
having antimicrobial administration before surgical incision
compared with those who received antimicrobial prophylaxis
at the time of cord clamping. All patients received a single
dose of cefazolin 2 g.
Duration. A meta-analysis of 51 studies found that mul-
tidose regimens provided no apparent benefit over single-
dose regimens [600]. The use of single-dose prophylaxis is
supported by ACOG and AAP for procedures lasting less
than two hours [584]. Additional intraoperative doses may be
warranted for patients with excessive blood loss or for whom
the duration of the procedure is extended. For additional
discussion of dosing, see the Common Principles section of
these guidelines.
Recommendation
The recommended regimen for all women undergoing
cesarean delivery is a single dose of cefazolin administered
before surgical incision (Table 2). (Strength of evidence for
prophylaxis =A.) For patients with b-lactam allergies, an al-
ternative regimen is clindamycin plus gentamicin.
Hysterectomy procedures
Background
Hysterectomy is second only to cesarean delivery as the
most frequently performed major gynecologic procedure in
the United States, with over 600,000 hysterectomies performed
annually [609]. Uterine fibroid tumors account for 40% of all
presurgical diagnoses leading to hysterectomy [609]. Other
common diagnoses are dysfunctional uterine bleeding, genital
prolapse, endometriosis, chronic pelvic pain, pelvic inflam-
matory disease, endometrial hyperplasia, and cancer.
Hysterectomy involves the removal of the uterus and,
occasionally, one or two fallopian tubes, the ovaries, or a
combination of ovaries and fallopian tubes [610]. Radical
hysterectomy entails removal of the uterus, fallopian tubes,
and ovaries and extensive stripping of the pelvic lymph nodes
in patients with extension of their cancer. Hysterectomies
are performed by a vaginal or abdominal approach using a
laparoscopic- or robot-assisted method. During a vaginal
hysterectomy, the procedure is completed through the vagina
with no abdominal incision. Abdominal hysterectomy in-
volves an abdominal incision. Laparoscopic and robotic
methods involve small incisions and require additional
equipment, increased operator experience, and increased
length of procedures [611,612]. In the United States, between
2000 and 2004, the abdominal approach for hysterectomywas
used in 67.9% of surgical procedures and the vaginal ap-
proach in 32.1%. Of hysterectomies performed via the vaginal
approach, 32.4% also used laparoscopy [609]. The ACOG
Committee on Gynecologic Practice recommends vaginal
hysterectomy as the approach of choice for benign disease,
based on evidence of better outcomes and fewer complications
[613]. Laparoscopic abdominal hysterectomy is an alternative
when the vaginal route is not indicated or feasible [613,614]. Of
note, ACOG has stated that the supracervical approach—
removal of the uterus with preservation of the cervix—should
not be recommended as a superior technique for hysterectomy
due to the lack of advantage in postoperative complications,
urinary symptoms, or sexual function and the increased risk of
future trachelectomy to remove the cervical stump [615].
Infections after hysterectomy include superficial and or-
gan/space (vaginal cuff infection, pelvic cellulitis, and pelvic
abscess) SSIs [589]. The reported SSI rates between January
2006 and December 2008 in the United States, based on NNIS
risk index category, were 0.73–1.16 per 100 procedures for
vaginal hysterectomy and 1.10–4.05 per 100 procedures for
abdominal hysterectomy [165]. A multicenter surveillance
study found amean infection rate of 2.53% associated with all
types of hysterectomy and a significantly lower mean rate of
infection with laparoscopic versus abdominal hysterectomies
(1.15% versus 3.44%, respectively) [325].
Risk factors for infection after vaginal or abdominal hyster-
ectomy include longer duration of surgery, young age, diabe-
tes, obesity, peripheral vascular disease, collagen disease,
anemia, transfusion, poor nutritional status, and previous
history of postsurgical infection [590,616–622]. The depth of
subcutaneous tissue is also a significant risk factor for infection
after abdominal hysterectomy [623]. Additional risk factors for
infection after radical hysterectomy for cervical cancer include
the presence of malignancy, prior radiation therapy, and the
presence of indwelling drainage catheters [619,620].
Organisms
The vagina is normally colonized with a wide variety of
bacteria, including gram-positive and gram-negative aerobes
and anaerobes. The normal flora of the vagina includes
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staphylococci, streptococci, enterococci, lactobacilli, diphthe-
roids, E. coli, anaerobic streptococci, Bacteroides species, and
Fusobacterium species [589,624]. Postoperative vaginal flora
differs from preoperative flora; the amount of enterococci,
gram-negative bacilli, and Bacteroides species increases post-
operatively. Postoperative changes in flora may occur inde-
pendently of prophylactic antimicrobial administration and are
not by themselves predictive of postoperative infection
[589,625,626]. Postoperative infections associated with vaginal
hysterectomy are frequently polymicrobial, with enterococci,
aerobic gram-negative bacilli, and Bacteroides species isolated
most frequently. Postoperative SSIs after abdominal and radi-
cal hysterectomies are also polymicrobial; gram-positive cocci
and enteric gram-negative bacilli predominate, and anaerobes
are frequently isolated [626,627].
Efficacy
A meta-analysis of 25 randomized controlled trials dem-
onstrated the efficacy of antimicrobial prophylaxis, including
first- and second-generation cephalosporins and metronida-
zole, in the prevention of infections after abdominal hyster-
ectomy [628]. The infection rates were 21.1% with placebo or
no prophylaxis and 9.0% with any antimicrobial. Another
meta-analysis found that the rate of postoperative infection
(surgical and pelvic sites) in women undergoing vaginal
hysterectomy who received placebo or no prophylactic anti-
microbial ranged from 14% to 57%, which was significantly
higher than the 10% rate reported with antimicrobials [629].
Malignant disease as the reason for hysterectomy is a
common exclusion from studies of antimicrobial prophylaxis.
Older, prospective, placebo-controlled studies found a lower
rate of SSIs with antimicrobial prophylaxis after radical
hysterectomy [619,630–633]. The applicability of these results
is limited by small sample size and the inclusion of antimi-
crobials not available in the United States. Radical hysterec-
tomy is primarily completed through an abdominal approach
but can also be performed by a vaginal approach and using
laparoscopic or robotic methods [634]. Therefore, antimicro-
bial prophylaxis would be warranted, regardless of approach.
No placebo-controlled studies have been conducted to eval-
uate the efficacy of antimicrobial prophylaxis when used for
laparoscopic hysterectomy.
Choice of agent. Cephalosporins are the most frequently
used and studied antimicrobials for prophylaxis in vaginal
and abdominal hysterectomies. Studies directly comparing
different cephalosporins have found no significant differences
in rates of infection in vaginal hysterectomy and have indi-
cated that first-generation cephalosporins (primarily cefazolin)
are equivalent to second- and third-generation agents [635–
644]. In abdominal hysterectomy, no significant differences in
the rates of serious infectionswere noted between second- and
third-generation cephalosporin regimens [641,645–649]. Few
comparisons have been made between second-generation
cephalosporins and cefazolin. Cefazolin has been at least as
effective in preventing infectious complications as second-
and third-generation cephalosporins [636,650–652]. However,
one double-blind controlled study of 511 women undergoing
abdominal hysterectomy found that the risk of major SSIs
requiring antimicrobial therapy was significantly higher in
the group receiving preoperative cefazolin 1 g (11.6%; relative
risk, 1.84; 95% CI, 1.03–3.29) than in those treated with cefo-
tetan 1 g (6.3%) [617]. A multicenter, randomized, double-
blind, active- and placebo-controlled study compared single
doses of ampicillin, cefazolin, and placebo administered to wo-
men undergoing elective total abdominal hysterectomy at two
centers in Thailand [653]. The study found a significantly lower
rate of infection, including superficial and deep SSIs, urinary
tract infections, vaginal cuff infection, and pneumonia, with
cefazolin (10.3%) comparedwith placebo (26.9%) and ampicillin
(22.6%).Nodifferencewas seen between ampicillin andplacebo.
The study authors concluded that cefazolin was more effective
than ampicillin for elective total abdominal hysterectomy.
A randomized controlled study of 511 patients undergo-
ing laparoscopic gynecological procedures at one center in
Italy compared single doses of amoxicillin–clavulanate 2.2 g
and cefazolin 2 g i.v. administered 20–30 min before the
procedure [654]. A second dose was given if the surgery
lasted over three hours or there was extensive blood loss
(> 1,500mL). No significant differences in the rates of any
postoperative infection, including SSIs, were found between
groups. The statistical power of the study was not stated.
In light of the organisms encountered in the vaginal canal
and comparative studies conducted among different classes
of cephalosporins, cefazolin, cefotetan, cefoxitin, cefuroxime,
and ampicillin–sulbactam have been supported as appropri-
ate first-line choices for prophylaxis during vaginal or ab-
dominal hysterectomy [6,9,41]. Alternative agents for patients
with a history of immediate hypersensitivity to penicillin in-
clude either clindamycin or metronidazole plus an ami-
noglycoside or a fluoroquinolone (ciprofloxacin, levofloxacin,
or moxifloxacin) or aztreonam (with clindamycin only).
Duration. Studies comparing single doses of one antimi-
crobial with multidose regimens of a different antimicrobial
have shown the two regimens to be equally effective in re-
ducing the postoperative infection rate in women undergoing
vaginal and abdominal hysterectomies [635–643,645–650,
655–663]. The limited comparative trials involving single-
dose cefazolin [637,654,655,664] or ampicillin–sulbactam
[654,663] indicate that a single dose of antimicrobial is sufficient
prophylaxis for SSIs for vaginal hysterectomy. Single doses of
cefotetan, ceftizoxime, or cefotaxime appear to be as effective as
multiple doses of cefoxitin [644–649,665]. A second dose of
antimicrobial is warranted when the procedure lasts three
hours or longer or if blood loss exceeds 1,500mL [9,654].
Recommendation
The recommended regimen forwomen undergoing vaginal
or abdominal hysterectomy, using an open or laparoscopic
approach, is a single dose of cefazolin (Table 2). Cefoxitin,
cefotetan, or ampicillin–sulbactam may also be used. Alter-
native agents for patients with a b-lactam allergy include (1)
either clindamycin or vancomycin plus an aminoglycoside,
aztreonam, or a fluoroquinolone and (2) metronidazole plus
an aminoglycoside or a fluoroquinolone. (Strength of evi-
dence for prophylaxis =A.)
Ophthalmic procedures
Background
Ophthalmic procedures include cataract extractions, vit-
rectomies, keratoplasties, intraocular lens implantation,
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glaucoma procedures, strabotomies, retinal detachment re-
pair, laser in situ keratomileusis, and laser-assisted sub-
epithelial keratectomy. Most of the available data regarding
antimicrobial prophylaxis involve cataract procedures. The
goal of prophylaxis is primarily to reduce acute postoperative
endophthalmitis, defined as severe intraocular inflamma-
tion due to infection, which can lead to loss of vision if
untreated [666]. Since 2000, the reported frequency of en-
dophthalmitis after ophthalmic procedures is lowworldwide,
ranging from zero to 0.63% [667–680]. The reported time from
procedure to diagnosis of endophthalmitis ranges from one
day to six weeks, with the majority of infections identified
within one week [666,669,671,673,674,681–683].
Potential risk factors for postoperative ophthalmic infec-
tions include preoperative factors such as diabetes [666],
active ocular infection or colonization [666,684], lacrimal
drainage system infection or obstruction, age of > 85 years
[685], and immunodeficiency [684]. Procedure-related risk
factors include clear corneal incisions (as opposed to scleral
tunnel incisions) [680,686], any surgical complication, vitre-
ous loss [684], posterior capsule tear [681,684,685], silicone
intraocular lens implantation [677,680], and the nonuse of
facemasks in the operating theater [681].
Organisms
Among organisms isolated from patients developing
postoperative endophthalmitis after cataract procedure, ap-
proximately 25–60% were coagulase-negative Staphylococcus
species, primarily S. epidermidis [668,670,671,673,674,678,683,
684,686]. Other gram-positive organisms identified included
S. aureus, Streptococcus species, Enterococcus species, P. acnes,
and Corynebacterium species. Gram-negative organisms iso-
lated included Serratia species, Klebsiella species, P. mirabilis,
and P. aeruginosa. These organisms represent the normal flora
isolated preoperatively in a number of studies [675,687–693].
Efficacy
Data on antimicrobial prophylaxis efficacy in ophthalmic
procedures to prevent endophthalmitis are limited; however,
prophylaxis is common [684]. The low rate of postoperative
endophthalmitis makes it difficult to complete an adequately
powered study to show efficacy of antimicrobial prophylaxis in
ophthalmic procedures; therefore, surrogate markers of eradi-
cation of normal flora bacteria and reduction of bacterial count
on the conjunctiva, lower and upper eyelids, eyelashes, and
inner canthus (corner of the eye) preoperatively and postoper-
atively are used. Many of the available studies are flawed with
retrospective or uncontrolled design, inadequate follow-up,
variations in surgical techniques (including disinfection, anti-
microbial prophylaxis strategies, and methods for performing
procedures), and limited reporting of clinical outcomes.
The large, randomized, partially-masked, placebo-
controlled, multinational, multicenter study conducted by the
European Society of Cataract and Refractive Surgeons
(ESCRS) compared the rate of postoperative endophthalmitis
in over 16,600 patients undergoing routine cataract proce-
dures at 24 centers in Europe randomized to one of four
perioperative prophylaxis groups [679,680,694]. Patients re-
ceived no antimicrobial prophylaxis, intracameral cefuroxime
at the end of the procedure alone, perioperative levofloxacin
0.5% ophthalmic solution given within the hour before the
procedure, or both intracameral cefuroxime and perioperative
levofloxacin. All patients had the eye area disinfected with
povidone–iodine 5% preoperatively and received topical le-
vofloxacin postoperatively. The study was stopped after an
interim analysis due to results of a multivariable analysis in-
dicating that patients not receiving intracameral cefuroxime
were approximately five times more likely to develop en-
dophthalmitis. The study has been questioned for its high rate
of endophthalmitis, selection of cefuroxime due to gaps in
gram-negative coverage, unknown drug concentrations in the
aqueous humor, risks of hypersensitivity, the lack of a com-
mercially available preparation, the lack of a subconjunctival
cefuroxime treatment group, selection of topical levofloxacin,
and methods for statistical analysis [695–697].
Two single-center, historical-controlled studies in hospitals
in Spain reported decreases in acute postoperative en-
dophthalmitis among patients undergoing a cataract proce-
dure with intracameral cefazolin added to the previous
routine prophylaxis of preoperative eyelid cleansing with
soap for three days [670] and povidone–iodine eye area
preparation [670,674], topical antimicrobial, and corticoste-
roid preparations given at the end of the procedure and
postoperatively. One study found a significant decrease and
a relative risk reduction of 88.7% in postoperative en-
dophthalmitis with intracameral cefazolin [670]. The other
found a decrease from 0.63% to 0.055% in postoperative
endophthalmitis with intracameral cefazolin [674]. No statis-
tical analysis was performed in this study.
A retrospective cohort study of patients undergoing cata-
ract procedure at one center in Canada between 1994 and 1998
found no significant difference in the rate of postopera-
tive endophthalmitis with preoperative topical antimicrobi-
als compared with none [668]. A significant decrease in
endophthalmitis was seen with subconjunctival administra-
tion of antimicrobials at the end of the procedure compared
with no antimicrobials.
Several prospective studies have shown decreases in ocular
flora, measured by bacterial isolate and CFU counts, with
preoperative antimicrobial irrigation [675], topical antimi-
crobials [687,688,691,692,698–700], and intracameral antimi-
crobials [682]. These studies did not report rates of
endophthalmitis, limiting the application of the results.
Choice of agent. Along with careful site preparation and
disinfection, the ideal antimicrobial prophylaxis agent should
be bactericidal against common pathogens of postoperative
endophthalmitis and be used safely in the eye [6,8,684]. There
is no consensus on the agent of choice for antimicrobial pro-
phylaxis in ophthalmic procedures, and no agent is FDA-
approved for this indication. There are limited studies
evaluating the efficacy of a particular choice of antimicrobial
prophylaxis for ophthalmic surgeries. The most efficacious an-
timicrobial cannot be determined from the available data due
to study flaws and a lack of direct comparisons. Local ocular
flora resistance patterns should be monitored to aid in the se-
lection of appropriate agents for prophylaxis [683,689,701].
Based on the available literature, use of povidone–iodine as
a preoperative antiseptic agent is recommended to decrease
ocular microbes and thereby prevent endophthalmitis [6,684,
702]. Povidone–iodine 5% or 10% is instilled in the conjunc-
tival sac and applied topically to the ocular skin surface
[703]. The most effective protocol has not been established, as
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povidone–iodine is frequently used in combinationwith other
antimicrobials [670,674,675,678,687,704]. Chlorhexidine has
been used as an effective alternative to povidone–iodine,
particularly in patients who are iodine-allergic [682,703].
Ophthalmic surgeons surveyed in the United Kingdom
reported that commonly used antimicrobial prophylactic
agents included cephalosporins, aminoglycosides, vancomy-
cin, chloramphenicol, neomycin alone or in combination with
polymyxin, and fluoroquinolones [695,703]. A similar survey
of members of the American Society of Cataract and Re-
fractive Surgery found that over 90% of respondents used
fluoroquinolones (mainly fourth-generation agents), vanco-
mycin, and cephalosporins [697]. These antimicrobials have
been recommended in practice guidelines [6].
Cephalosporins, specifically cefazolin, cefuroxime, and
ceftazidime, have been shown to be safe and effective in
decreasing postoperative endophthalmitis when added to
regimens of povidone–iodine and topical antimicrobials
[670,674,677,679,680,699]. Vancomycin has been shown to
decrease cultures and reach adequate concentrations to pre-
vent and treat most corneal pathogens [675,705]. Aminogly-
cosides alone [687] or in combination with an antiseptic agent
(chlorhexidine) [682] showed no significant difference in the
reduction of culture results compared with an antiseptic alone
(povidone–iodine or chlorhexidine) [682,690] and no antimi-
crobial prophylaxis.
A randomized controlled study compared the antimicro-
bial activity and safety of trimethoprim 0.1%–polymyxin B
sulfate 10,000 units/mL ophthalmic solution and tobramycin
0.3% ophthalmic solution in patients undergoing cataract
procedures [692]. All patients received one drop and a sub-
conjunctival injection of corticosteroids and gentamicin
postoperatively followed by one drop of study medication
four times daily for five to seven days. No significant differ-
ences were seen between groups for positive culture results
from conjunctiva at baseline, at procedure, or at postoperative
days 5–7 or in lidmargin culture at baseline and postoperative
days 5–7. A higher rate of positive cultures at procedure was
seen in the trimethoprim–polymyxin group (37 of 59 cultures,
63%) compared with 13 (41%) of 32 cultures in the tobramycin
group (p = 0.043). Both medications eradicated the majority of
bacteria on the day of procedure and postoperative days 5–7.
Aqueous humor concentrations did not achieve the minimum
inhibitory concentrations (MICs) of S. aureus or S. epidermidis
and were undetectable for polymyxin B sulfate. The adverse
events of irritation and allergic reaction were experienced by
three patients in the trimethoprim–polymyxin group. The
study authors concluded that there was no difference between
trimethoprim and tobramycin in ocular flora reduction.
A randomized controlled study compared conjunctiva and
contact lens culture results after treatment with tobramycin
0.3% versus ofloxacin 0.3% ophthalmic solutions in patients
undergoing photorefractive keratectomy [693]. No differences
were seen among preoperative, postoperative, or contact lens
cultures between treatment groups. Although not statistically
significant, logistic regression found that cultures from pa-
tients treated with tobramycin were two times more likely to
be positive than those treated with ofloxacin. The study had
low power and did not compare baseline and posttreatment
culture results for any treatment group.
Fluoroquinolones have been found in studies to sig-
nificantly decrease the ocular culture results from baseline
[667,673,691,698,700,706]; achieve aqueous humor, vitreal,
and corneal tissue concentrations adequate to prevent and
treat common ocular pathogens [705,707–710]; and result in
improved ocular measurements (i.e., visual acuity, epithelial
cell counts, and epithelial healing) [711–716]. A retrospective
multicenter case series of 20,013 patients who underwent
uncomplicated cataract surgeries and received fourth-gener-
ation fluoroquinolones preoperatively and postoperatively
reported the rates of postoperative endophthalmitis [673].
Endophthalmitis occurred in 9 (0.06%) of 16,209 surgeries in
patients treated with gatifloxacin 0.3% ophthalmic solution
(95% CI, 0.03–0.1%) and in 5 (0.1%) of 3,804 surgeries in pa-
tients treated with moxifloxacin 0.5% ophthalmic solution
(95% CI, 0.05–0.3%). There were no significant differences in
efficacy between agents. In a retrospective cross-sectional
study conducted over a 10-year period with third- and fourth-
generation fluoroquinolones, significantly lower rates of
endophthalmitis were reported for the fourth-generation
agents moxifloxacin and gatifloxacin (0.56 per 1000 cataract
surgeries) than for the third-generation agents cipro-
floxacin and ofloxacin (1.97 per 1000 surgeries) (p = 0.0011)
[671].
Route. There is no consensus on the most effective route
of antimicrobial administration for the prevention of en-
dophthalmitis. The routes of antimicrobial administration
used in ophthalmic procedures include preoperative topical
antimicrobial ophthalmic drops, addition of antimicrobials to
the irrigation solution, instillation of antimicrobials in-
tracamerally at the end of surgery, subconjunctival injection
of antimicrobials, and postoperative topical application of
antimicrobials [6,684,702,717].
The ESCRS randomized controlled studymentioned above
found that patients not receiving intracameral cefuroxime
were approximately six times more likely to develop post-
operative endophthalmitis [679,680,694]. Surveys of the im-
pact of the ESCRS study findings found that there was an
increase in the use of intracameral over subconjunctival ce-
furoxime based on preliminary study results [703]. For re-
spondents who had not adopted this practice, the reported
reasons for not using intracameral cefuroxime included the
need for further study, concerns about risk and cost of ther-
apy, the lack of a subconjunctival comparator group, the high
rate of endophthalmitis in the control groups, concerns about
statistical analysis, and questions regarding the selection of
cefuroxime due to gaps in ophthalmic pathogen coverage
[695,697]. There is no commercially available cefuroxime
formulation for intracameral administration, which was re-
ported as one of the main barriers to use of this route. Con-
cerns regarding compounded intracameral antimicrobials
expressed by survey respondents included inflammation,
dilution errors, corneal endothelial injury, and the risk for
bacterial contamination and infection.
A retrospective cohort study compared the efficacy of in-
tracameral cefuroxime versus subconjunctival cefuroxime in
reducing the rate of endophthalmitis after cataract procedures
at one center in northeast England [718]. A total of 19,425
patients received antimicrobial prophylaxis with preopera-
tive povidone–iodine 5% in the conjunctival sac and sub-
conjunctival injection of cefuroxime 50mg at the end of the
procedure, and 17,318 patients received intracameral cefur-
oxime 1mg at the end of the procedure. There were two
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groups of patients excluded from the analysis: Protocol vio-
lators who received no prophylaxis and patients who were
enrolled in the ESCRS study. The overall rate of en-
dophthalmitis in analyzed patients was 35 cases in 36,743
procedures (0.95 per 1,000 cases). Of these, 27 occurred in the
subconjunctival cefuroxime group (1.39 per 1,000 cases), and 8
occurred in the intracameral group (0.46 per 1,000 cases) (OR,
3.01; 95% CI, 1.37–6.63; p = 0.0068).
Several studies found a lower rate of endophthalmitis with
the addition of intracameral cephalosporins (cefazolin and
cefuroxime) at the end of the surgical procedure after routine
perioperative and postoperative topical antimicrobial pro-
phylaxis regimens [670,674]. A case–control study revealed a
5.7-times increased likelihood of developing postoperative
endophthalmitis with topical antimicrobial prophylaxis only
(including gentamicin 0.3% and chlorhexidine 0.05%) com-
pared with the addition of intracameral cefuroxime 1mg to
the regimen in cataract procedure [677]. Both intracameral
cephalosporins and moxifloxacin have been shown as safe,
with no adverse events and no effects on visual acuity and
endothelial cell counts [670,674,699,715,716].
One study involving healthy adult volunteers found that
orally administered levofloxacin and moxifloxacin achieved
adequate aqueous humor concentrations to provide activity
against gram-positive and most gram-negative ocular path-
ogens without adverse events [707]. The addition of sub-
conjunctival antimicrobials to existing topical antimicrobial
prophylaxis regimens has also been shown to reduce the rate
and risk of endophthalmitis in intraocular procedures com-
pared with topical antimicrobials alone [668,681,686]. Topical
antimicrobials have been shown to be safe and effective in
lowering rates of endophthalmitis [671,673], decreasing bac-
terial organisms and CFUs in conjunctiva [667,675,691,
692,698,700], and achieving adequate concentrations to be
effective against most ocular pathogens [705,706,708–710,719],
with no notable adverse events [711–714].
Duration and timing. There are a lack of clear evidence
and no consensus on the appropriate duration and timing of
antimicrobial prophylaxis in ophthalmic procedures [6,684].
Commonly reported times of antimicrobial prophylaxis in-
clude preoperatively, intraoperatively, at the end of the
procedure, and postoperatively [684]. Few studies have in-
vestigated the differences between the timing and duration of
antimicrobial prophylaxis regimens. Many of the regimens
are used in combination, making it difficult to determine the
optimal timing and duration. Preoperative antimicrobial
timing reported in the literature has ranged from one to
multiple drops within an hour preoperatively on the day of
the procedure [671,673,679,680,692–694,698,703,709,710,716]
or one to three days before the procedure [667,698,700,
703,708,710,712,714].
Two topical moxifloxacin regimens were compared for
conjunctival bacterial flora and aqueous humor concentra-
tions in a randomized controlled study of patients undergoing
cataract procedures [691,719]. In one regimen, patients were
administered moxifloxacin 0.5% four times a day beginning
one day before the procedure plus one drop two hours before
the procedure (total of five drops before the procedure); the
other group received moxifloxacin 0.5% two hours before
surgery and every 15 minutes for the first hour of the proce-
dure (total of five drops). Therewere no cases of postoperative
endophthalmitis up to six months after the procedure in any
patient. Administration of moxifloxacin on the day of the
procedure was found to result in a significant decrease in
median CFU compared with baseline and was found (based
on change in log CFU) to be more effective than antimicrobial
administration on the day before the procedure. Mean aque-
ous humor concentrations of moxifloxacin at the beginning of
the procedure were significantly higher in the group who
received the drug on the day of the procedure.
A small, randomized controlled study compared aqueous
humor concentrations of levofloxacin and ciprofloxacin in
patients undergoing a cataract procedure with routine
phacoemulsification given as (1) one or two drops four
times daily for two days before the procedure, with the last
dose given immediately before bedtime on the night before
the procedure, (2) five doses (one or two drops) delivered
every 10 min in the hour before the procedure, or (3) a
combination of both dosing strategies [706]. Aqueous humor
concentrations of levofloxacin were significantly higher than
those of ciprofloxacin. Significantly higher doses of drug were
delivered to the aqueous humor in the group receiving
same-day prophylaxis than in patients receiving levofloxacin
or ciprofloxacin two days before surgery. No cases of endo-
phthalmitis or ocular or systemic toxicities were reported.
A randomized controlled study compared the effectiveness
of topical ofloxacin in the reduction or elimination of con-
junctival bacterial flora when given as one drop every five
minutes for three applications one hour before the procedure
alone (control group) or combined with ofloxacin one drop
four times daily for three days (study group) before cataract
procedures [688]. No differences in positive conjunctival cul-
tures were seen between groups five days before topical anti-
microbials or before the administration of ofloxacin on the day
of the procedure. Significantly higher positive culture rates
were seen in the control group than in the study group one hour
after the administration of the preoperative antimicrobial and
before povidone–iodine, immediately before the procedure,
and at the conclusion of the procedure. Mean CFU counts did
not significantly differ five days preoperatively and immedi-
ately before the procedure but were significantly higher in the
control group at all other time points. Neither outcomes of en-
dophthalmitis nor patient compliance with antimicrobial use
was reported. The study’s authors concluded that three days of
topical ofloxacin was more effective than administration just
one hour before the procedure in reducing the number of pos-
itive bacterial cultures at several time points perioperatively.
Numerous studies have evaluated the efficacy of in-
tracameral and subconjunctival injections of antimicrobials
given at the end of surgery [6,674,677,679–682,697,699,703,
716,718]. The most commonly reported dose of intracameral
cefuroxime was 1mg [677,679,680,682,699,718], and the most
commonly reported subconjunctival dose was 50mg [718].
Doses of 2.5 or 1mg of intracameral cefazolin were studied
[670,674], as were 250- and 500 mg doses of intracameral
moxifloxacin [715,716]. Postoperative dosing strategies re-
ported in the literature include four times daily for 3–7 days
[667,670,671,673–675,679,680,692,711,712,715] and for up to
15 days [713,714] or until the bottle was empty [716].
Despite the lack of well-controlled trials, the consequences
of bacterial endophthalmitis support the use of prophylactic
antimicrobials. No definitive studies have clearly delineated
superiority of antimicrobial route, timing, or duration.
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Recommendation
Due to the lack of robust data from trials, specific recom-
mendations cannot be made regarding choice, route, or du-
ration of prophylaxis. As a general principle, the antimicrobial
prophylaxis regimens used in ophthalmic procedures should
provide coverage against common ocular pathogens, includ-
ing Staphylococcus species and gram-negative organisms,
particularly Pseudomonas species.
Preoperative antisepsis with povidone–iodine is re-
commended, based on available evidence. Appropriate
topical antimicrobials include commercially available
neomycin–polymyxin B–gramicidin solution or fluor-
oquinolones (particularly fourth-generation agents) given as
one drop every 5–15 min for five doses within the hour
before the start of the procedure (Table 2). The addition of
subconjunctival cefazolin 100mg or intracameral cefazolin
1–2.5mg or cefuroxime 1mg at the end of the procedure is
optional. While some data have shown that intracameral
antimicrobials may be more effective than subconjunctival
antimicrobials, there are no commercially available antimi-
crobials approved for these routes of administration.
(Strength of evidence for prophylaxis = B.)
Orthopedic procedures
Background
Orthopedic procedures considered in these guidelines in-
clude clean orthopedic procedures (not involving replace-
ment or implantations), spinal procedures with or without
instrumentation, repair of hip fractures, implantation of in-
ternal fixation devices (screws, nails, plates, and pins), and
total-joint-replacement procedures. Grade III open fractures
(extensive soft tissue damage and crushing) are often asso-
ciated with extensive surgical site contamination and are
routinely managed with empirical antimicrobial treatment
and surgical debridement, for which guidelines have been
published separately [720]. Available guidelines recommend
that antimicrobial prophylaxis in grade I (clean wound with
£ 1 cm laceration) and grade II (clean wound with > 1 cm
laceration without extensive soft tissue damage) open
fractures be handled similarly to other clean orthopedic
procedures [721–724].
Between 2006 and 2008, SSIs were reported nationally,
based on risk category, in approximately 0.70–4.15 per 100
procedures for patients undergoing spinal fusion, 0.72–2.30
per 100 procedures in patients undergoing laminectomy,
0.67–2.40 per 100 procedures in patients undergoing hip
prosthesis, and 0.58–1.60 per 100 procedures in patients un-
dergoing knee prosthesis [165]. Postoperative SSI is one of the
most costly complications of orthopedic procedures due to
hospital readmissions, extended hospital length of stay, the
need for additional procedures (often removal and re-
implantation of implanted hardware), convalescent or nursing
home care between procedures, and significant increases in
direct hospital costs (e.g., prolonged antimicrobial therapy)
[725,726]. Studies have found that the estimated economic
impact of one deep SSI was $100,000 in hospital cost alone after
hip arthroplasty and $60,000 after knee arthroplasty [727–731].
In light of the serious consequences, antimicrobial pro-
phylaxis is well accepted in procedures involving the im-
plantation of foreign materials [8,732]. Prophylaxis is also
indicated in spinal procedures without instrumentation,
where an SSI would pose catastrophic risks [726,733–738].
Organisms
Skin flora are the most frequent organisms involved in SSIs
after orthopedic procedures. The most common pathogens in
orthopedic procedures are S. aureus, gram-negative bacilli,
coagulase-negative staphylococci (including S. epidermidis),
and b-hemolytic streptococci [739–743]. Spinal procedures
may be complicated by polymicrobial infection that includes
gram-negative bacteria [740].
A contributing factor to SSIs in arthroplasty is the forma-
tion of bacterial biofilm, particularly with S. aureus and
S. epidermidis, on inert surfaces of orthopedic devices. Bac-
terial biofilm confers antimicrobial resistance and makes
antimicrobial penetration difficult [744–748].
There is increasing concern regarding the emergence of SSIs
due to resistant microorganisms, specifically VRE and MRSA
in surgical patients. Several studies have investigated MRSA
colonization and SSIs and evaluated the effect of decoloni-
zation, including the use of topical mupirocin, in orthopedic
procedures [150,157,741,749–753]. Mupirocin decolonization
protocols as an adjunct to i.v. cephalosporin prophylaxis in
orthopedic patients resulted in significant decreases in nasal
MRSA carriage [150,751] and overall SSIs [157,750–752]. Pre-
operative decolonizationwith intranasal mupirocinmay have
utility in patients undergoing elective orthopedic procedures
who are known to be colonized or infected with either MRSA
or MSSA [150,151,157,741,749–755]. Readers are referred to
additional discussion in the Common Principles section of
these guidelines.
Clean orthopedic procedures not involving
implantation of foreign materials
Background
In clean orthopedic procedures, such as knee, hand, and foot
procedures, and those not involving the implantation of foreign
materials, the need for antimicrobial prophylaxis is not well es-
tablished [738,749,756]. Antimicrobial prophylaxis in patients
undergoing diagnostic and operative arthroscopic procedures
is controversial [6,757–760]. The risks of SSI and long-term
sequelae are low for procedures not involving implantation.
Efficacy
The efficacy of antimicrobial prophylaxis in clean ortho-
pedic procedures was first investigated in the middle part of
the 20th century. A number of these studies and reviews have
since been found to be flawed, as patients were not random-
ized to treatment groups and the timing and duration of an-
timicrobial prophylaxis were not studied [761,762]. Further,
patients were administered prophylactic antimicrobials after
the surgical procedure, which may have led to invalid results.
The low rate of infection and absence of serious morbidity
failed to justify the expense or potential for toxicity and re-
sistance associated with routine use of antimicrobial pro-
phylaxis in the setting of clean orthopedic procedures.
Recommendations
Antimicrobial prophylaxis is not recommended for patients
undergoing clean orthopedic procedures, including knee,
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hand, and foot procedures, arthroscopy, and other proce-
dures without instrumentation or implantation of foreign
materials. (Strength of evidence against prophylaxis =C.) If
the potential for implantation of foreign materials is un-
known, the procedure should be treated as with implantation.
Spinal procedures with and without instrumentation
Background
Data support the use of antimicrobial prophylaxis for or-
thopedic spinal procedures with and without instrumenta-
tion, including fusions, laminectomies, and minimally
invasive disk procedures, to decrease the rate of postoperative
spinal infection [8,543,563,732,733,739,763–766]. Surgical site
infections after orthopedic spinal procedures, including min-
imally invasive disk procedures, are associated with high
morbidity. Invasion of the epidural space in organ/space SSIs
is of particular concern after spinal procedures [8,145,767].
Surgical site infection rates vary with the complexity of the
procedure. One retrospective, multicenter study of 1274 adult
patients found an overall SSI rate of 0.22% with antimicrobial
prophylaxis after minimally invasive spinal procedures (i.e.,
any spinal procedures performed through a tubular retractor-
type system) [768]. Procedures included simple decom-
pressive procedures (such as microscopic or endoscopic dis-
cectomy or foraminotomy or decompression of stenosis),
minimally invasive arthrodeses with percutaneous instru-
mentation, and minimally invasive intradural procedures.
The SSI rate in patients receiving antimicrobial prophylaxis
undergoing spinal procedures with instrumentation has ran-
ged from 2.8% to 9.7% [165,764,765,769,770]. Monosegmental
instrumentation has a reported SSI rate of < 2%, compared
with 6.7% for instrumentation at multiple levels [771].
Several case–control studies of adults undergoing spinal
procedures with and without instrumentation have found the
following notable patient-related risk factors for SSI: pro-
longed preoperative hospitalization [771], diabetes [767,772–
775], elevated serum glucose concentration (> 125mg/dL
preoperatively [within 30 days] or > 200mg/dL postopera-
tively) [773], older age [767,776], smoking and alcohol abuse
[776], previous procedure complicated by infection [774–776],
and obesity [770–775,777]. Procedure-related risk factors in-
clude extended duration of procedure (defined in studies as
two to five hours or greater than five hours [775], greater than
three hours [771], and greater than five hours [776]), excessive
blood loss ( > 1 L) [771,775], staged procedure [776], multilevel
fusions [777], foreign-body placement (e.g., screw, rod, plate)
[767], combined anterior and posterior fusion [776], and
suboptimal antimicrobial timing (> 60 min before or after
incision) [773]. A significant decrease in SSIs was seen with
procedures at the cervical spine level [772,773] or with an
anterior surgical approach [775].
Efficacy
Despite the lack of comparative studies evaluating
prophylaxis for spinal procedures with and without instru-
mentation (implantation of internal fixation devices), antimi-
crobial prophylaxis is recommended due to the associated
morbidity and assumed costs of SSIs [771]. Ameta-analysis of
six studies with 843 patients undergoing spinal procedures
(types of procedures were not differentiated in the analysis)
demonstrated an overall effectiveness of antimicrobial
prophylaxis [732]. Antimicrobials studied included single-
dose or multidose regimens of < 24 h duration of cephalori-
dine (a first-generation cephalosporin no longer available in
the United States), vancomycin and gentamicin, cefazolin
with and without gentamicin, piperacillin, and oxacillin. The
pooled SSI rate with antimicrobial prophylaxis was 2.2%,
compared with 5.9% in controls (OR, 0.37; 95% CI, 0.17–0.78;
p < 0.01). One randomized controlled study of 1237 adult
patients undergoing spinal procedures to repair a herniated
disk (hemilaminectomy, laminectomy, flavectomy, spondy-
losyndesis) found no significant difference in the rate of SSIs
between single-dose cefuroxime 1.5 g i.v. (1.3%) and placebo
(2.9%) given within 60 min before surgical incision. No sig-
nificant difference was seen between treatment groups for
incisional SSIs (0.98% and 1.12%, respectively) or deep SSIs
(0.33% and 0.32%, respectively), but the difference in organ/
space infections was significant between groups (0% and
1.44%, respectively; p < 0.01) [778].
Choice of agent. There is no clearly superior antimicrobial
agent or regimen for spinal procedures [563,769]. The antimi-
crobials most often studied for prophylaxis in orthopedic
procedures are first-generation cephalosporins, particularly
cefazolin. Cefazolin has been noted as a suitable agent for
spinal procedures with its spectrum of activity (e.g., against
Staphylococcus species and gram-negative bacilli such as E. coli)
and adequate tissue [121] and disk concentrations [779,780].
Second- and third-generation cephalosporins offer no
major advantages over first-generation agents. Their routine
use is not recommended due to their higher cost and poten-
tial to promote resistance, particularly among health-care-
associated gram-negative bacilli [8]. Broader coverage may be
considered for instrumented fusion due to the risk of poly-
microbial infections, including those caused by gram-negative
bacteria [563,769].
Clindamycin and vancomycin have adequate activity
against the most common pathogens involved in orthopedic
procedures and would be acceptable alternatives under cer-
tain circumstances, such as prophylaxis for patients with a
b-lactam allergy. Vancomycin should be included with cefa-
zolin or used as an alternative agent for routine antimicrobial
prophylaxis for patients who are known to be colonized with
MRSA [6,8,41,733,781].
Duration. The majority of available studies of antimicro-
bial prophylaxis in spinal procedures have used single doses
or regimens of < 24 h duration [732]. There is no high-quality
evidence supporting a duration of > 24 h [782], and some
sources recommend only a single preoperative dose [8,
769,778].
Pediatric efficacy
While no studies have evaluated the efficacy of antimicro-
bial prophylaxis in pediatric patients undergoing spinal pro-
cedures with or without instrumentation, the incidence and
risk factors for SSIs in this population have been reported. The
frequencies of SSIs in pediatric patients undergoing spinal
fusion were 3.5% (<18 years old) [783], 3.8% (<19 years old)
[784], 4.4% (ages 1–22 years old), and 5.2% (<17 years old) [764]
for varying conditions, including Scheuermann kyphosis [784],
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myelodysplasia [764], idiopathic scoliosis [783,785], neuro-
muscular scoliosis [785], kyphosis [783], and spondylolisth-
esis [783]. The majority of patients in studies reporting
antimicrobial prophylaxis received cefazolin, vancomycin, or
clindamycin [764,783,785].
Risk factors for SSIs after spinal procedures with instru-
mentation in a pediatric population include myelodysplasia
[764], procedure at the sacral spine, obesity [785], ASA classifica-
tion of >2, a complex medical condition (including spinal bifida,
cerebral palsy, Marfan syndrome, achondroplasia, osteogenesis
imperfecta, other unspecified genetic disease, muscular dystro-
phy, spinal muscular atrophy, or other debilitating myopathies)
[783], and previous spinal procedures. One study found a de-
creased risk of infection with hypothermia (core body temper-
ature of <35.5 C for the duration of the procedure) [785].
Two studies found suboptimal antimicrobial prophylaxis
as a risk factor for SSIs in spinal procedures [764,783]. Optimal
antimicrobial prophylaxis was defined as cefazolin 20mg/kg
(up to 2 g) given within 30 min [764] or 60 min [783] before
surgical incision, vancomycin 10mg/kg (up to 1 g) given
within 60 min [783] or 150 min [764] before surgical incision,
or clindamycin 10mg/kg (up to 600mg) given within 60 min
before surgical incision [783]. Intraoperative redosing was
defined as appropriate for cefazolin if administered for pro-
cedures lasting more than four hours and for vancomycin or
clindamycin for procedures lastingmore than six hours in one
study [783] and for cefazolin administered every eight hours
in the other study [764]. A third study found that use of
clindamycin as the perioperative antimicrobial increased the
risk of SSI [785].
Recommendations
Antimicrobial prophylaxis is recommended for orthopedic
spinal procedures with and without instrumentation. The
recommended regimen is cefazolin (Table 2). (Strength of
evidence for prophylaxis in orthopedic spinal proce-
dures =A.) Clindamycin and vancomycin should be reserved
as alternative agents as described in the Common Principles
section. If there are surveillance data showing that gram-negative
organisms are a cause of SSIs for the procedure, practitioners
may consider combining clindamycin or vancomycin with
another agent (cefazolin if the patient is not b-lactam allergic;
aztreonam, gentamicin, or single-dose fluoroquinolone if the
patient is b-lactam allergic). Mupirocin should be given intra-
nasally to all patients known to be colonized with S. aureus.
Hip fracture repair
Background
Data support the use of antimicrobial prophylaxis for hip
fracture repair to reduce the rate of SSIs, particularly in pro-
cedures that involve internal fixation (e.g., nails, screws,
plates, wires). Surgical site infections after hip fracture repair
can result in extensive morbidity, including prolonged and
repeated hospitalization, sepsis, persistent pain, device re-
placement, and possible death [726,739,786–790].
Efficacy
The efficacy of antimicrobial prophylaxis in hip fracture
repair has been illustrated in two meta-analyses [787,788].
One meta-analysis of 15 hip fracture procedure trials (the
majority of procedures involved closed, proximal femoral, or
trochanteric fractures with internal fixation) demonstrated
that any dose and duration of prophylaxis are superior to no
prophylaxis with respect to preventing SSIs (deep and su-
perficial SSIs were analyzed together) [787]. The rate of SSIs
was 10.4% in controls versus 5.39% in treatment groups. A
second meta-analysis of 22 studies reiterated the efficacy of
antimicrobial prophylaxis in fracture procedures [788]. The
analysis included the same hip fracture studies examined in
the first meta-analysis, with additional studies of long-bone
fracture repair (i.e., closed ankle fracture and other closed
fractures, some noted with internal fixation). This second
meta-analysis reviewed 10 studies of 1,896 patients receiving
a preoperative and two or more postoperative doses of a
parenteral antimicrobial compared with a placebo or with no
treatment. The authors found a relative risk of deep SSIs of
0.36 (95%CI, 0.21–0.65) and a relative risk of superficial SSIs of
0.48 (95% CI, 0.28–0.81) associated with antimicrobial use.
Choice of agent. The antimicrobials most often studied
for prophylaxis in orthopedic procedures are first-generation
cephalosporins due to their ease of administration, low cost,
and safety profile [787,788,791]. Second- and third-generation
cephalosporins have not been shown to offer clear advantages
over first-generation agents. These agents are not re-
commended for routine use due to their higher cost, potential
to promote resistance, and association with adverse events
(e.g., C. difficile-associated diarrhea) [8,790,792].
Alternative regimens may be needed for institutions with
highly resistant organisms, such as MRSA or C. difficile. Suc-
cess in decreasing rates of C. difficile-associated disease and
mortality was seen in a single-center study with the antimi-
crobial prophylaxis regimen change from three doses of ce-
furoxime [790,792] to a single preoperative dose of cefuroxime
plus gentamicin [792]. In another study, C. difficile-associated
disease decreased after the prophylaxis regimen was changed
from cefuroxime to amoxicillin–clavulanate [790].
Clindamycin and vancomycin have adequate activity
against the most common pathogens involved in orthopedic
procedures and would be acceptable alternatives under
certain circumstances, such as prophylaxis for patients with a
b-lactam allergy. Vancomycin should be included with cefa-
zolin or used as an alternative agent for routine antimicrobial
prophylaxis for patients who are known to be colonized with
MRSA [6,8,41,733,781].
Duration. For effective prophylaxis, the MIC of the anti-
microbial needs to be exceeded at the target site from the
moment of incision until surgical-site closure [788]. Twometa-
analyses demonstrating the efficacy of antimicrobial pro-
phylaxis in long-bone and hip fracture procedures also
showed that multiple perioperative doses did not offer an
advantage over a single preoperative dose [787,788]. These
studies support a duration of antimicrobial prophylaxis of
£ 24 h.
Recommendations
The recommended regimen in hip fracture repair or other
orthopedic procedures involving internal fixation is cefazolin.
Clindamycin and vancomycin should be reserved as alter-
native agents, as described in the Common Principles section.
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If there are surveillance data showing that gram-negative
organisms are a cause of SSIs for the procedure, practitioners
may consider combining clindamycin or vancomycin with
another agent (cefazolin if the patient is not b-lactam-allergic;
aztreonam, gentamicin, or single-dose fluoroquinolone if the
patient is b-lactam-allergic). Mupirocin should be given in-
tranasally to all patients with documented colonization with
S. aureus. (Strength of evidence for prophylaxis =A.)
Total joint replacement
Background
In 2005, more than 750,000 hip or knee replacements were
performed in the United States [793]. The reported frequency
of SSIs complicating hip, knee, elbow, ankle, or shoulder re-
placement ranges from 0.6% to 12% [743,786,794–797]. Rates
of SSI as high as 11% after hip replacement and 12% after
elbow replacement have been reported [786,797]. However,
for hip and knee replacements, the most common joint ar-
throplasties, infection rates are typically less than 2% [165].
The introduction of antimicrobial prophylaxis, stringent
infection-control protocols, and the use of ultraclean operat-
ing rooms has led to a substantial reduction in SSI rates (to
£ 1%) [734,786,796,798,799]. Postoperative prosthetic joint in-
fection is an organ/space SSI that occurs early (within 3 mos
postoperatively), is delayed (3–12 mos postoperatively), or
occurs late (> 12 mos after surgery) [748]. These infections
frequently require removal of the prosthesis, a prolonged
course of antimicrobials, and one- or two-stage reimplanta-
tion of the prosthesis and may result in permanent disability
[796,800]. Studies have shown an estimated economic im-
pact of one deep SSI of $100,000 in hospital cost alone af-
ter hip arthroplasty and $60,000 after knee arthroplasty
[727–731].
Common risk factors for prosthetic joint infection [748]
include advanced age; obesity; diabetes mellitus; corticoste-
roid use; malignancy; rheumatoid arthritis; previous ar-
throplasty on the same joint; arthroplasty undertaken to treat
a fracture; type of joint replaced (e.g., risk is greater for the
knee than the hip); perioperative surgical-site complications,
including superficial SSI; hematoma; and persistent surgical-
site drainage. Operative risk factors include ASA classifica-
tion of ‡ 3, duration of procedure exceeding the 75th per-
centile for the procedure or exceeding three hours, surgical
site classified as contaminated or dirty, and no systemic an-
timicrobial prophylaxis. Excluding the presence of a systemic
antimicrobial, patients with these operative risk factors are at
the greatest risk of developing an SSI. A contributing factor to
SSIs in arthroplasty is the formation of bacterial biofilm,
particularly with S. aureus and S. epidermidis, on inert surfaces
of orthopedic devices to confer antimicrobial resistance and
difficulty in antimicrobial penetration [744–748].
Efficacy
The majority of studies that have evaluated antimicrobial
prophylaxis in joint replacements have been conducted in
patients undergoing total hip or total knee arthroplasty [801].
There is a lack of efficacy data involving elbow, shoulder, and
ankle arthroplasty; however, the same antimicrobial pro-
phylaxis principles can be applied. In light of the serious
potential consequences, antimicrobial prophylaxis is well
accepted in procedures involving the implantation of foreign
materials [8,543,732,733].
A meta-analysis supports the use of antimicrobial pro-
phylaxis for SSI reduction in patients undergoing total joint
replacement [801]. Of the 26 randomized controlled studies
examined, 24 included patients undergoing total hip or total
knee arthroplasty. The meta-analysis noted that the studies
did not clearly state if the arthroplasties were primary or re-
vision. The SSIs were defined as visible purulent exudates at
the surgical site (deep or superficial) in the included studies.
Seven studies (n= 3,065 patients) pooled to compare antimi-
crobial prophylaxis with placebo found a relative risk re-
duction of SSIs of 81%.
Choice of agent. There are no data supporting superior-
ity of one class of antimicrobials over another for antimicro-
bial prophylaxis in total joint replacement. A meta-analysis of
studies, mainly in total hip or total knee replacement, found
no difference in SSIs between cephalosporins with teicoplanin
(not available in the United States) in five studies with 2,625
patients, cephalosporins and penicillin derivatives in three
studies of 386 patients, and first- and second-generation
cephalosporins in eight studies of 2,879 patients [801]. Selec-
tion should be based on cost, availability, and local resistance
patterns. First-generation cephalosporins are the agents most
commonly studied and used for antimicrobial prophylaxis in
joint replacement procedures.
Clindamycin and vancomycin have adequate activity
against the most common pathogens involved in orthopedic
procedures and would be acceptable alternatives under
certain circumstances, such as prophylaxis for patients with a
b-lactam allergy. Vancomycin should be included with
cefazolin or used as an alternative agent for routine antimi-
crobial prophylaxis in institutions that have a high prevalence
of MRSA SSIs and for patients who are known to be colonized
with MRSA [6,8,41,733,781]. Readers are referred to the sec-
tion on implantation of internal fixation devices for further
discussion of antimicrobial prophylaxis choice.
Antimicrobial-laden bone cement. The use of antimicro-
bial-laden bone cement in conjunction with i.v. antimicrobial
prophylaxis is common worldwide, particularly for the
prevention of infection in primary hip and knee arthroplasties
[802–806]. The FDA has approved premixed aminoglycoside
(i.e., gentamicin and tobramycin) in bone cement products for
use in hip, knee, or other joints in second-stage revision of total
joint arthroplasty [807]. The products are not approved for
prophylaxis in primary joint replacement procedures. While
antimicrobial bone cement has not been shown to be superior
to i.v. antimicrobials [808,809], there is evidence that supports
the combination of using antimicrobial-laden bone cement
together with systemic antimicrobial prophylaxis.
Although the evidence for the prophylactic use of
antimicrobial-laden bone cement in primary joint arthroplasty
looks favorable, a recent multicenter evaluation of risk factors
for SSI in patients undergoing total hip arthroplasty did not
find that use of antimicrobial-laden bone cement reduced the
risk for infection [95]. In addition, questions remain regarding
the risk for antimicrobial resistance and allergy, as well as the
increased cost [41,802–807,810–813]. Readers are referred to
reviews of this topic for additional information about tissue
penetration, clinical application, and safety [805,810–815].
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Duration. The duration of prophylaxis in joint replace-
ment procedures has been controversial. More recent data and
clinical practice guidelines do not support prophylaxis beyond
24 h [6,41,133,723]. Studies involving total hip replacement
have used antimicrobials for 12 h to 14 days postoperatively
[726,734–737,816]. A duration of 24 h was supported in a
randomized trial of 358 patients undergoing total hip ar-
throplasty, total knee arthroplasty, or hip fracture repair that
compared prophylaxis that lasted 24 h versus 7 d of either
nafcillin or cefazolin started 20min before the procedure [816].
The difference in SSI rates between groups was not significant.
There is no evidence of benefit of antimicrobial administration
until all drains or catheters are removed [32,41,133].
Recommendations
The recommended regimen for patients undergoing total
hip, elbow, knee, ankle, or shoulder replacement is cefazolin.
Clindamycin and vancomycin should be reserved as alternative
agents, as described in the Common Principles section. If there
are any surveillance data showing that gram-negative organ-
isms are a cause of SSIs for the procedure, practitioners may
consider combining clindamycin or vancomycin with another
agent (cefazolin if the patient is not b-lactam allergic; az-
treonam, gentamicin, or a single-dose fluoroquinolone if the
patient is b-lactam allergic). Mupirocin should be given intra-
nasally to all patients with documented colonization with
S. aureus. (Strength of evidence for prophylaxis=A.)
Urologic procedures
Background
The goals of antimicrobial prophylaxis in urologic proce-
dures are the prevention of bacteremia and SSIs and the
prevention of postoperative bacteriuria [59]. Postoperative
urinary tract infections (UTIs) are the main concern for mor-
bidity in patients after urologic procedures [817,818]. Bacter-
iuria, defined as > 103 or > 104 CFU/mL in symptomatic UTI
and > 105 CFU/mL in asymptomatic bacteriuria, within 30 d
postoperatively is a frequent primary outcome in urologic
procedure studies [819–825]. The benefits of preventing
postoperative bacteriuria are not clearly known [825].
In addition to general risk factors discussed in the Common
Principles section of these guidelines, urologic-specific risk
factors include anatomic anomalies of the urinary tract, [818]
urinary obstruction, [826] urinary stone, [817,825,826] and
indwelling or externalized catheters [817,818,822,826]. Pre-
operative UTI, particularly if recurrent, is recognized as a high-
risk factor for postoperative infection, which is typically treated
before procedures and is a common exclusion criterion from
studies of efficacy of antimicrobial prophylaxis in urologic
procedures [817,826–828]. Additional urologic operation-
specific risk factors include length of postoperative catheteri-
zation, [829] mode of irrigation (closed versus open), and
postoperative pyuria [821].
Organisms
Escherichia coli is the organism most commonly isolated in
patients with postoperative bacteriuria; however, other gram-
negative bacilli and enterococci may also cause infection
[818,821,827,830–839]. Organisms such as S. aureus, coagulase-
negative Staphylococcus species, and group A Streptococcus
species are also a concern in procedures entering the skin with
or without entering the urinary tract [818,827,830–832,838,
840,841]. There is also some concern with biofilm-forming
bacteria (S. epidermidis and P. aeruginosa) in patients with
prosthesis implantation [842].
Efficacy
The efficacy of antimicrobial prophylaxis in select urologic
procedures has been investigated in several clinical trials. Of
note, many of these placebo-controlled studies have excluded
patients with risk factors for infection, those requiring anti-
microbial prophylaxis for another indication (e.g., infective
endocarditis), and those with preoperative UTI or bacteriuria.
The efficacy of antimicrobial prophylaxis in clean proce-
dures among patients at low risk of complications has been
variable. One randomized, placebo-controlled study of oral
antimicrobials in 2,083 patients undergoing flexible cystos-
copy found a positive urine culture (bacteriuria with > 105
CFU/mL) in 9.1% of patients receiving placebo, 4.6% of pa-
tients receiving trimethoprim, and 2.8% of patients receiving
ciprofloxacin [839]. The rates of bacteriuria compared with
baseline were significantly higher with placebo and signifi-
cantly lower with use of antimicrobials compared with pla-
cebo. A randomized, placebo-controlled study of 517 patients
undergoing prostate brachytherapy found no significant dif-
ference in postimplantation epididymitis with or without
antimicrobial prophylaxis (0.4% and 1.5%, respectively) [843].
A meta-analysis of eight randomized, placebo-controlled or
no-treatment-controlled studies with 995 patients undergoing
urodynamic studies found a decrease in bacteriuria with an-
timicrobial prophylaxis (OR, 0.39; 95% CI, 0.24–0.61) [820].
The number needed to treat was 13 to prevent one episode of
asymptomatic bacteriuria using a pooled rate of 13.7% for
bacteriuria. One study found that not using antimicrobial
prophylaxis was a significant risk factor for bacteriuria caused
by urinary dynamic studies [821].
Antimicrobial prophylaxis has been studied in urologic
procedures involving entry into the gastrointestinal tract,
with themajority of the literature on transurethral resection of
the prostate (TURP) and prostate biopsy. Two large meta-
analyses have suggested prophylactic antimicrobials may be
effective in all patients undergoing TURP, including low-risk
patients and those with preoperatively sterile urine [844,845].
One meta-analysis of 32 trials with 4,260 patients found that
prophylactic antimicrobials decreased the combined bacteri-
uria (> 105 CFU/mL) event rate from 26% to 9.1%, for a relative
risk reduction of 65% (95% CI, - 55 to - 72), and the combined
clinical septicemia episode rate from 4.4% to 0.7% in TURP
patients, including low-risk patients [846]. Another meta-
analysis of 28 trials that included a total of 4,694 patients
found prophylactic antimicrobials decreased the post-TURP
rate of bacteriuria, fever, and bacteremia, as well as the need
for additional postoperative antimicrobials [847]. An addi-
tional multicenter, open-label, randomized, active- and pla-
cebo-controlled trial in patients with sterile urine undergoing
TURP found a decreased rate of bacteriuria ( ‡ 5CFU/mL)
with antimicrobial prophylaxis (21% with levofloxacin and
20% with sulfamethoxazole– trimethoprim) compared with
placebo (30%) (p = 0.009) [822].
Three randomized, placebo-controlled studies of patients
undergoing transrectal needle biopsy of the prostate found
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significant differences in infectious complications (including
bacteriuria, positive urine cultures, and UTI) in patients
treated with single doses of oral antimicrobial prophylaxis
compared with placebo [819,837,838]. These three studies
support the routine use of antimicrobial prophylaxis in all
patients undergoing transrectal needle biopsy of the prostate.
Of note, all patients undergoing transrectal needle biopsy of
the prostate received a cleansing enema before the procedure
[819,837,838]. Use of MBP has been reported in urologic
procedures that involve entering the gastrointestinal tract
(e.g., urinary diversion) [844,846].
The use of antimicrobial prophylaxis in patients undergo-
ing extracorporeal shock wave lithotripsy (ESWL) and ur-
eterorenoscopy is supported by the results of a meta-analysis
[847] and a small randomized controlled trial [848]. The meta-
analysis included eight randomized controlled trials with 885
patients and six clinical case series involving 597 patients
undergoing ESWL [845]. The overall rate of UTI in the ran-
domized controlled trials ranged from 0% to 7.7% with anti-
microbial prophylaxis and from 0% to 28% in the control
groups (relative risk, 0.45; 95% CI, 0.22–0.93). A randomized,
placebo-controlled study of 113 patients undergoing ureter-
orenoscopy found a rate of postoperative bacteriuria of
1.8% with antimicrobial prophylaxis and 12.5% without
( p= 0.0026) [848]. No patients had symptomatic UTI or in-
flammation complications of the urogenital tract postopera-
tively. There are no studies of antimicrobial prophylaxis in
major open or laparoscopic procedures (cystectomy, radical
prostatectomy, and nephrectomy); therefore, data have been
extrapolated from other major intraabdominal procedures.
Choice of agent. No single antimicrobial regimen appears
superior for urologic procedures. A wide range of antimicro-
bial regimens, including cephalosporins [658,835,836,843,849–
855], aminoglycosides [856,857], piperacillin–tazobactam
[849,858,859], trimethoprim–sulfamethoxazole [822,838,860],
trimethoprim [839], nitrofurantoin [861], and fluoroquinolones
[819,821,822,824,831,835–837,839,840,843,848,851,853–855,862,
863], have been evaluated in urologic procedures. The efficacy
of fluoroquinolones for antimicrobial prophylaxis in urologic
surgical procedures has been well established. One study
found better reduction of bacteriuria with either ciprofloxacin
or trimethoprim compared with placebo [839], while other
studies found no difference in efficacy between a fluor-
oquinolone and sulfamethoxazole–trimethoprim, both of
which were better than placebo [822,838]. No differences were
found in studies between oral or i.v. fluoroquinolones (cipro-
floxacin or ofloxacin) compared with i.v. or intramuscular
cephalosporins (ceftriaxone, cefotaxime, or cefazolin) and in-
tramuscular penicillin (piperacillin–tazobactam) in various
urologic procedures [835,836,851,854,855,858]. In several
studies, fluoroquinolones were administered orally, which
appears to be feasible in patients undergoing procedures not
involving opening the urinary or gastrointestinal tract, when
the i.v. route would be preferred [822,836,838,851,855,858].
Recently, resistance to fluoroquinolones has been emerging;
the fact that most of the literature was published before resis-
tance became prevalent should be considered, since resistance
may decrease the relevance of these studies [836,846,847,
858,864]. Local resistance patterns to fluoroquinolones, partic-
ularly with E. coli, should be evaluated to help guide antimi-
crobial selection.
Broad-spectrum antimicrobials, such as third-generation
cephalosporins and carbapenems, are no more effective than
first- or second-generation cephalosporins, aminoglycosides,
or oral agents (trimethoprim–sulfamethoxazole, nitrofur-
antoin, or fluoroquinolones) and should be reserved for pa-
tients with active infection orwho require additional coverage
for intestinal organisms. [6,826,827] Their routine use is not
recommended due to their higher cost and potential to pro-
mote resistance, particularly among health-care-associated
gram-negative bacilli [8].
Duration. While longer durations of postoperative pro-
phylaxis (up to three weeks) have been studied [856,858,
860,861], more-recent data support the use of shorter dura-
tions (i.e., a single dose or less than 24 h duration) in urologic
procedures [658,817,818,823,824,826,831,832,834,836,846,853,
857,859,862,865,866]. Based on bioavailability, oral antimicro-
bial prophylaxis should be administered 1–2 h before surgical
incision or start of the procedure [817,819–822,824,826,
836,838,840,848,851,855].
Pediatric efficacy
Limited data on antimicrobial prophylaxis are available for
pediatric patients undergoing urologic procedures. One pro-
spective, open-label, nonrandomized study of boys under-
going hypospadias repair with tabularized incision plate
urethroplasty allocated patients to receive cefonicid (no lon-
ger available in the United States) with one i.v. dose before the
procedure only or the addition of oral cephalexin three times
daily starting on postoperative day 1 until two days after
catheter removal (median, 8.3 days) [833].More patients in the
single-dose group had bacteriuria and complications (ure-
throcutaneous fistula and meatal stenosis); however, the rate
of infection and infection-related complications did not sig-
nificantly differ between groups.
Recommendations
No antimicrobial prophylaxis is recommended for clean
urologic procedures in patients without risk factors for post-
operative infections. Patients with preoperative bacteriuria or
UTI should be treated before the procedure, when possible, to
reduce the risk of postoperative infection. For patients un-
dergoing lower urinary tract instrumentationwith risk factors
for infection, the use of a fluoroquinolone or trimethoprim–
sulfamethoxazole (oral or i.v.) or cefazolin (i.v. or intramus-
cular) is recommended (Table 2). For patients undergoing
clean urologic procedures without entry into the urinary
tract, cefazolin is recommended, with vancomycin or clin-
damycin as an alternative for those patients allergic to
b-lactam antimicrobials. For patients undergoing clean uro-
logic procedures with entry into the urinary tract, cefazolin is
recommended, with alternative antimicrobials to include a
fluoroquinolone, the combination of an aminoglycoside plus
metronidazole, or an aminoglycoside plus clindamycin. For
clean-contaminated procedures of the urinary tract (often
entering the gastrointestinal tract), antimicrobials as re-
commended for elective colorectal surgery are recommended.
This would generally include the combination of cefazolin
with or without metronidazole, cefoxitin, or, for patients with
b-lactam allergy, a combination of either a fluoroquinolone
or aminoglycoside given with either metronidazole or
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clindamycin. Themedical literature does not support continuing
antimicrobial prophylaxis until urinary catheters have been re-
moved. See the colorectal procedures section of these guidelines
for recommendations pertaining to procedures entering the
gastrointestinal tract. (Strength of evidence for prophylaxis=A.)
Vascular procedures
Background
Infection after vascular procedures occurs with low fre-
quency but can be associated with extensive morbidity and
mortality [867,868]. Postoperative infections involving vas-
cular graft material can result in limb loss and life-threatening
conditions [868]. As a result, antimicrobial prophylaxis is
widely used in procedures that involve implantation of
prosthetic material and procedures for which there is greater
risk of infection, such as aneurysm repair, thromboendarter-
ectomy, and vein bypass [6,41,867,869]. Patients undergoing
brachiocephalic procedures (e.g., carotid endarterectomy,
brachial artery repair) without implantation of prosthetic
graft material do not appear to benefit from routine antimi-
crobial prophylaxis [6,41,867,870].
Risk factors for postoperative SSI in patients undergoing
vascular procedures include lower-extremity sites, delayed
procedures after hospitalization, diabetes mellitus, and a
history of vascular or aortocoronary bypass procedures
[871,872]. Currently, prospective data from well-designed
studies on prophylaxis for endovascular stenting do not exist.
However, if prophylaxis is desired, the same antimicrobials
and short duration of therapy used for open vascular proce-
dures should be given. Risk factors that warrant consideration
of prophylaxis in patients undergoing endovascular stenting
include prolonged procedures (more than two hours), re-
intervention at the surgical site within seven days, vascular
stent placement in the groin through a hematoma or sheath,
procedures in immunosuppressed patients, and the presence
of another intravascular prosthesis [873–877].
Organisms
The predominant organisms involved include S. aureus,
S. epidermidis, and enteric gram-negative bacilli. MRSA is an
emerging organism of concern. Several studies evaluated the
rate of colonization, carriage, and infection with MRSA in
patients undergoing various vascular procedures [878–884].
Independent risk factors for MRSA infection included MRSA
colonization, open abdominal aortic aneurysm, tissue loss,
and lower-limb bypass [878]. Patients who have or develop
MRSA infections before vascular procedures have increased
risk of inhospital death, intensive care unit admission, repeat
surgeries, increased length of stay, and delayed wound
healing, comparedwith patients without infections [880–883].
Efficacy
Prophylactic antimicrobials decrease the rate of infection
after procedures involving the lower abdominal vasculature
and procedures required to establish dialysis access. The fol-
low-up time for patients with late surgical site complications
was at least once after hospital discharge (not further defined)
for most studies [829,865,871,885–887], at one month
[869,871,888,889], at six months [872], and at three years [138].
A meta-analysis of 10 randomized controlled trials in pa-
tients undergoing peripheral arterial reconstruction with bi-
ological or prosthetic graft procedures found an overall
consistent reduction in SSIs with systemic antimicrobial pro-
phylaxis compared with placebo (relative risk, 0.25; 95% CI,
0.17–0.38; p < 0.00001) [890]. An overall reduction was found
among 5 studies evaluating early graft infection (relative risk,
0.31; 95% CI, 0.11–0.85; p = 0.02), though no individual study
found a significant reduction in SSIs.
The largest study included in the meta-analysis above was
a randomized, prospective, double-blind, placebo-controlled
study of patients undergoing peripheral vascular procedures
(n= 462). The infection rate was significantly lower with ce-
fazolin than with placebo (0.9% and 6.8%, respectively) [885].
Four deep graft infections were observed in the placebo
group; none occurred in the patients who received cefazolin.
No infections were observed in patients who underwent
brachiocephalic (n = 103), femoral artery (n = 56), or popliteal
(n= 14) procedures.
Patients undergoing vascular access procedures for hemodi-
alysis may benefit from the administration of antistaphylococcal
antimicrobials. A placebo-controlled study of 408 patients
undergoing permanent vascular access placement demonstrated
an upper-extremity prosthetic polytetrafluoroethylene graft in-
fection rate of 6% with placebo compared with 1% with vanco-
mycin (p=0.006). [869]
Choice of agent. Cefazolin remains the preferred and
most cost-effective prophylactic agent for use in vascular
procedures [6,8,41,872,886,887]. There was no significant dif-
ference in infection rates between cefazolin and cefuroxime in
patients undergoing abdominal aortic and lower-extremity
peripheral vascular procedures, [886] between cefazolin and
cefamandole (no longer available in the United States) in pa-
tients undergoing aortic or infrainguinal arterial procedures,
[887] or between cefazolin and ceftriaxone in patients un-
dergoing arterial reconstruction involving infraclavicular
sites [872].
A multicenter, randomized, double-blind, prospective trial
of 580 patients undergoing arterial procedures involving the
groin who received either two doses of ciprofloxacin 750mg
orally or three doses of cefuroxime 1.5 g i.v. on the day of the
procedure found an SSI rate of 9.2% (27 patients) and 9.1% (26
patients), respectively, within 30 d of the procedure [889]
Although oral ciprofloxacin was shown to be as effective as
i.v. cefuroxime, this study did not address concerns about
resistance with routine use of fluoroquinolones [891]. There-
fore, i.v. cefazolin remains the first-line agent for this indica-
tion. The efficacy of oral agents for prophylaxis needs to be
further evaluated.
There are limited data regarding the choice of an antimi-
crobial for b-lactam-allergic patients undergoing vascular
procedures. The main alternative agents are vancomycin and
clindamycin, since prophylaxis is largely directed against
gram-positive cocci. Vancomycin can also be used for pro-
phylaxis in institutions with MRSA or methicillin-resistant
S. epidermidis (MRSE) clusters or in patients with b-lactam
allergy [6,8,41]. Clindamycinmay be an acceptable alternative
to vancomycin, though local antimicrobial resistance patterns
should be taken into account.
An aminoglycoside may be added to vancomycin for the
addition of aerobic gram-negative bacilli coverage if the
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procedure involves the abdominal aorta or a groin incision,
due to the potential for gastrointestinal flora. See the Common
Principles section of these guidelines for further discussion
of the use of vancomycin. Alternative antimicrobials for
b-lactam-allergic patients receiving vancomycin may include
a fluoroquinolone or aztreonam [6].
Duration. A meta-analysis of three randomized con-
trolled studies involving vascular procedures, including
lower-limb reconstruction and open arterial procedures,
found no additional benefit of continuing prophylactic
antimicrobials for over 24 h postoperatively compared
with no more than 24 h (relative risk, 1.28; 95% CI, 0.82–1.98)
[890].
A randomized, double-blind study compared infection
rates of a one-day and a three-day course of cefuroxime with
placebo in 187 patients undergoing peripheral vascular
procedures [888]. The infection rates were 16.7%, 3.8%, and
4.3% in the placebo, one-day, and three-day groups, respec-
tively. The difference in the infection rates between the one-
and three-day groups was not significant.
A randomized controlled study compared one day and five
days of amoxicillin–clavulanate 1.2 g in 100 patients under-
going 108 lower-limb reconstruction procedures [892]. No
difference was seen in the postoperative SSI rate between
groups (9 patients [16%] and 12 patients [23%], respectively).
The study authors selected the agent based on extended
spectrum of activity and good tissue penetration. However,
they concluded that due to the high rate of infection observed,
the use of antimicrobial prophylaxis might not be as effective
as once thought.
A randomized controlled study compared ticarcillin–
clavulanate 3.1 g given as a single dose at induction of anes-
thesia with multiple doses given at induction and every 6 h
postoperatively until venous access lines were removed or a
maximum of 20 doses (total of five days) in patients under-
going open arterial procedures. [893] Significantly more SSIs
occurred in the single-dose group (28 [18%] of 153 patients)
compared with the multidose group (15 [10%] of 149 patients)
(relative risk, 2.00; 95% CI, - 1.02 to 3.92; p = 0.041). Ti-
carcillin–clavulanate has a short duration of action and is not
recommended as a routine agent for antimicrobial prophy-
laxis. Practice guidelines recommend single-dose prophylaxis
in vascular procedures or a maximum duration of therapy of
24 h postoperatively, regardless of the presence of invasive
drains [6,41].
Recommendations
The recommended regimen for patients undergoing vas-
cular procedures associated with a higher risk of infection,
including implantation of prosthetic material, is cefazolin
(Table 2). (Strength of evidence for prophylaxis =A.) Clin-
damycin and vancomycin should be reserved as alternative
agents as described in the Common Principles section of these
guidelines. If there are surveillance data showing that gram-
negative organisms are a cause of SSIs for the procedure,
practitioners may consider combining clindamycin or van-
comycin with another agent (cefazolin if the patient is not
b-lactam-allergic; aztreonam, gentamicin, or single-dose
fluoroquinolone if the patient is b-lactam-allergic), due to the
potential for gastrointestinal flora exposure.
Heart, lung, and heart–lung transplantation
Background
Solid-organ transplant recipients are at high risk for
infections due to the complexity of the surgical procedures,
donor- or recipient-derived infections, reactivation of recipient-
associated latent infections, preoperative recipient coloniza-
tion, exposure to community pathogens, and opportunistic
infections due to immunosuppression [894–897]. Infections
occur more frequently in the first year after transplantation,
due to aggressive immunosuppression. Transplant recipients
with infections are commonly asymptomatic or have non-
specific symptoms or sequelae of infection, which makes de-
tection and diagnosis of infections difficult [855,857,894].
Postoperative infections caused by bacterial, viral, and fungal
pathogens, including SSIs, UTIs, blood stream infections, and
pneumonia, are of greater concern within the first month after
transplantation [895–897]. Opportunistic infections that result
from immunosuppression typically occur after the first month
of transplantation. It is routine for transplant recipients to re-
ceive antimicrobial prophylaxis to prevent opportunistic infec-
tions [894–897]. A discussion of the prophylactic strategies for
prevention of cytomegalovirus (CMV) infection, herpes simplex
virus infection, pneumocystis, UTI in kidney transplant recipi-
ents, Aspergillus infection in lung transplant recipients, and
other opportunistic infections outside of the immediate post-
transplantation period is beyond the scope of these guidelines.
Few well-designed, prospective, comparative studies of
antimicrobial prophylaxis have been conducted with patients
undergoing solid-organ transplantation, and no formal rec-
ommendations are available from expert consensus panels or
professional organizations; however, there are reviews that
provide guidance [8,41,894].
The recommendations given for each of the solid-organ
transplant procedures are intended to provide guidelines for
safe and effective surgical prophylaxis based on the best
available literature. Antimicrobial surgical prophylaxis prac-
tice will vary considerably among transplantation centers
throughout the United States, based on the organ involved,
preexisting recipient and donor infections, and local antimi-
crobial susceptibilities [894–897].
Heart transplantation
Background. Heart transplantation is an option for se-
lected patients with end-stage cardiac disease. In 2007, the
United Network for Organ Sharing (UNOS) reported that
2,209 heart transplants were performed in the United States,
including 327 in children (< 18 years of age) [898]. The mean
graft survival rate 10 years after heart transplantation is ap-
proximately 49%. Infection continues to be an important cause
of morbidity andmortality after heart transplantation and is a
primary cause of death in approximately 14% of patients
within the first year after transplantation [899].
Despite the large number of heart transplantation proce-
dures performed, few studies have specifically examined
postoperative SSI rates in this population. General cardio-
thoracic procedures have been associated with SSI rates
ranging from 9% to 55% in the absence of antimicrobial
prophylaxis [214,900,901]. Studies of general cardiothoracic
procedures, including heart transplantation, found SSIs, par-
ticularly mediastinitis, in 3–6% of patients who received
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antimicrobial prophylaxis [170,902]. The frequency was
highest in heart transplant recipients. The SSI rates reported in
patients undergoing heart transplantation who received an-
timicrobial prophylaxis ranged from 5.8% to 8.8%, including
mediastinitis in 3%–7% of patients [903,904].
Several independent risk factors for SSIs after cardiac and
thoracic procedures have been identified (see the cardiac and
thoracic sections of this article). Heart transplantation has
been identified as an independent risk factor for SSIs [170].
Other independent risk factors for SSIs in heart transplanta-
tion include age [905], receipt of ciprofloxacin alone for pro-
phylaxis [906], positivewire cultures [907], a BMI of >30kg/m2,
female sex [908], previous cardiac procedures, previous left
VAD placement, and hemodynamic instability requiring ino-
tropic support [903,904]. Unfavorable functional outcomeswere
seen in patients who developed infections within the first year
after heart transplantation associated with lung, bloodstream,
and CMV infections [909]. Independent predictors of mortality
in heart transplant recipients included serum creatinine levels,
amyloid etiology, history of hypertension, pulmonary infection,
andCNS infection.Additional predisposing factors for infection
in heart transplantation include exposure to pathogens from the
donor or transplant recipient, the time from organ recovery to
reperfusion, and the immunosuppressive regimens used
[897,904,910]. Similar risk factors for infection are noted in pe-
diatric transplant recipients, with the addition of a naive im-
mune system to several pathogens, most notably viruses, as
well as incomplete primary immunization series [897].
Patients with an indwelling VAD at the time of heart
transplantation have additional prophylaxis concerns. Re-
cipients who do not have a driveline infection and have no
history of either colonization or infection should receive
prophylaxis as described for recipients without a VAD in
place. Patients with a history of colonization or previous in-
fection should have the antimicrobial sensitivities of that or-
ganism considered when choosing the SSI prophylactic
regimen administered, though the duration should still be less
than 24 h. Heart transplant recipients with an active VAD
driveline infection at the time of heart transplantation should
be given appropriate antimicrobials specifically for the treat-
ment of that infection. This intervention will usually deter-
mine the actual perioperative prophylaxis regimen as well as
the duration of therapy beyond the period of prophylaxis.
Patients requiring ECMO as a bridge to heart transplanta-
tion should be treated with a similar approach. If there is no
history of colonization or previous infection, then the general
recommendations for SSI antimicrobial prophylaxis for the
specific procedure should be followed. In ECMO patients
with a history of colonization or previous infection, changing
the preoperative antimicrobial prophylaxis to cover these
pathogens must be considered, weighing whether the path-
ogen is relevant to SSIs in the planned procedure.
Because heart transplantation is similar to other cardiac
and thoracic procedures, similar considerations regarding the
need for antimicrobial prophylaxis apply (see the cardiac and
thoracic sections) [911]. These guidelines do not address an-
timicrobial prophylaxis for infective endocarditis. Readers are
referred to the current guidelines for prevention of infective
endocarditis from AHA [11,228].
Organisms. As with other types of cardiothoracic proce-
dures, gram-positive organisms, mainly Staphylococcus
species, are the primary pathogens that cause SSI after
heart transplantation [902,905–907,912,913]. Methicillin-
resistant S. aureuswas reported in 12%–21% of SSIs in several
cohort studies [903,905,906]. Vancomycin-resistant E. faecalis
was noted in 15% of infections in one cohort study [903]. Other
gram-positive pathogens (e.g., coagulase-negative staphylo-
cocci, Enterococcus species) [903,905–907,913] and gram-
negative organisms (e.g., Enterobacteriaceae, P. aeruginosa,
Stenotrophomonas maltophilia) are also a concern for SSIs in
heart transplant recipients, as are Candida species [903,906].
Efficacy. Despite the paucity of literature on antimicro-
bial prophylaxis for the prevention of SSIs in heart trans-
plantation, the efficacy noted in other cardiac surgical
procedures has made it the standard of practice during
transplantation [896].
No randomized controlled trials have specifically ad-
dressed the use of antimicrobial prophylaxis in heart trans-
plantation. In an open-label noncomparative study, the SSI
rate was 4.5% among 96 patients administered cefotaxime
plus floxacillin preoperatively and for 72 h after cardiac pro-
cedures [912]. This rate of infection was similar to that seen in
other cardiothoracic, nonheart transplantation procedures in
which antimicrobial prophylaxis was used.
Choice of agent. Antimicrobial prophylaxis for heart
transplantation should be similar to that used for other
types of cardiothoracic procedures [911]. First- and second-
generation cephalosporins are considered to be equally effi-
cacious and are the preferred agents. There appear to be no
significant differences in efficacy among prophylactic regi-
mens using agents such as cefazolin and cefuroxime [914]. The
use of antistaphylococcal penicillins, either alone or in com-
bination with aminoglycosides or cephalosporins, failed to
demonstrate superior efficacy to that of cephalosporin
monotherapy (see the cardiac and thoracic sections) in other
cardiothoracic procedures.
Several cohort studies examined antimicrobial prophylac-
tic agents used for patients undergoing heart transplantation
but did not evaluate efficacy [902,903,905,906]. Ciprofloxacin
alonewas found to be an independent risk factor for incisional
SSI [906].
Duration. There is no consensus on the optimal duration
of antimicrobial prophylaxis in cardiothoracic procedures,
including heart transplantation. Cohort evaluations of pa-
tients undergoing heart transplantation reported durations of
antimicrobial prophylaxis with cefazolin or vancomycin of 24
or 48 h postoperatively [902,903,905]. Data from cardio-
thoracic procedures also support a range of prophylaxis
durations, from a single dose to 24 or 48 h postoperatively
[41,131]. The currently accepted duration for these proce-
dures, which do not include transplantation, is 24–48 h post-
operatively [41,59,131,201]. The duration of antimicrobial
prophylaxis for patients who do not have their chest primarily
closed is unclear; most centers continue prophylaxis until
the chest is closed, but there is no evidence to support this
practice.
Pediatric efficacy. No randomized controlled studies
have specifically addressed antimicrobial prophylaxis for
heart transplantation in pediatric patients. Infants are at risk
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for mediastinitis caused by gram-negative as well as gram-
positive organisms. Pediatric patients undergoing heart
transplantation should be treated according to recommen-
dations for other types of cardiothoracic procedures. The re-
commended regimen for pediatric patients undergoing
cardiothoracic procedures is cefazolin 25–50mg/kg i.v.
within 60 min before surgical incision and every 8 h for up to
48 h. Cefuroxime 50mg/kg i.v. within 60 minutes before
surgical incision and every 8 h for up to 48 hours is an ac-
ceptable alternative. Vancomycin 10–20mg/kg i.v. over 60–
120 min, with or without gentamicin 2mg/kg i.v., should be
reserved as an alternative on the basis of guidelines from
HICPAC for routine antimicrobial prophylaxis in institutions
that have a high prevalence of MRSA, for patients who are
colonized with MRSA, or for patients with a true b-lactam
allergy [8]. Additional doses may be needed intraoperatively
for procedures > 4 h in duration, for patients with major
blood loss, or for extended use of CPB depending on the half-
life of the prophylactic antimicrobial. Fluoroquinolones are
not routinely recommended in pediatric patients.
Recommendations. Based on data for other types of
cardiothoracic procedures, antimicrobial prophylaxis is indi-
cated for all patients undergoing heart transplantation (see
cardiac and thoracic sections). The recommended regimen is a
single dose of cefazolin (Table 2). There is no evidence to
support continuing prophylaxis until chest and mediastinal
drainage tubes are removed. Alternatives include vancomy-
cin or clindamycin with or without gentamicin, aztreonam, or
a single fluoroquinolone dose. (Strength of evidence for pro-
phylaxis =A.) The optimal duration of antimicrobial pro-
phylaxis for patients who do not have their chest primarily
closed is unclear. No recommendation is made for these pa-
tients. Patients who have left VADs as a bridge and who are
chronically infected might also benefit from coverage of the
infecting microorganism.
Lung and heart–lung transplantation
Background. Lung transplantation is an accepted option
for a variety of end-stage, irreversible lung diseases. The most
common diseases forwhich lung transplantation is performed
are idiopathic pulmonary fibrosis, chronic obstructive pul-
monary disease, emphysema, cystic fibrosis, a-1-antitrypsin
deficiency, and idiopathic pulmonary arterial hypertension
[915,916]. The UNOS reported that in the United States in
2007, 1,468 lung transplantations and three heart–lung
transplantations were conducted in adults, and 52 lung
transplantations and three heart–lung transplantations were
performed in children [898,917]. Ten-year survival rates were
reported as 29.7% of double-lung, 17.5% of single-lung, and
25.8% of heart–lung transplant recipients [899]. The reported
three-year survival rate for pediatric lung transplant recipi-
ents was 57% [897].
Infections are the most common complications after lung
and heart–lung transplantations [899,915,918,919]. In an
analysis of UNOS data over an 18-year period, infection was
the number one cause of death within the first year of trans-
plantation, occurring in 24.8% of lung and 18.3% of heart–
lung transplant recipients [899]. Among the top 10 primary
causes of death within the first year after lung and heart–lung
transplantations were sepsis, pneumonia, fungal infection
(lung only), and CMV infection [899]. A study of two cohorts
of patients undergoing heart, lung, and heart–lung trans-
plantations who received antimicrobial prophylaxis evalu-
ated the rate of SSIs andmediastinitis [904,908]. The rate of SSI
among all transplant recipients was 12.98%, with the majority
of infections (72%) being organ/space infections, followed by
deep incisional infections (17%) and superficial incisional in-
fections (10%) [908]. The overall rate of mediastinitis in a
similar cohort was 2.7%, with rates of 5.2% in heart–lung
transplant recipients and 3.2% in bilateral lung transplant
recipients [904]. Pneumonia was reported in 26.4% of trans-
plantation patients overall, with rates of 20.7% in lung trans-
plant recipients and 40% in heart–lung transplant recipients
[908]. A cohort of lung transplant recipients reported a rate of
2.2 episodes of pneumonia per patient during amedian follow-
up period of 412 days (range, 1–1,328 days) [920].
Bronchial anastomotic infections, especially fungal infec-
tions, can be serious and are potentially fatal in lung trans-
plant recipients [921,922]. The lung allocation score (LAS) is a
rating system adopted by the Organ Procurement and
Transplant Network and UNOS in 2005 to improve organ
allocation and transplantation outcomes. The LAS is based on
the risk of death while on the waiting list for transplantation
and the expected one-year survival after transplantation. Pa-
tients with a low LAS are unlikely to undergo transplantation.
A study of lung transplant recipients age 12 years or older
revealed a higher rate of infection and other morbidities and a
lower one-year survival rate in patients with a high LAS at the
time of transplantation than in patients with a low LAS at the
time of transplantation [923]. Thus, the potential for bronchial
anastomotic infection and a poor posttransplantation out-
come needs to be considered in patients undergoing lung
transplantation. Among lung transplantation patients, risk
factors for nosocomial infections included a-1-antitrypsin
deficiency and repeat transplantation. Risk factors for pneu-
monia included colonized or infected donor bronchus and
perfusate and preoperative colonization with gram-negative
rods. Risk factors for mortality among the transplant recipi-
ents were cystic fibrosis, nosocomial infection, and ventilation
before transplantation [908]. Risk factors for mediastinitis af-
ter heart, lung, and heart–lung transplantation were degree of
immunosuppression, impaired renal function, previous ster-
notomy, and reexploration due to bleeding [904]. There was a
positive association between pretransplantation colonizing
microorganisms from suppurative lung disease patients and
pneumonia after transplantation [920]. Transplantation alters
the physiological function of lungs, including the impairment
of mucociliary clearance and interruption of the cough reflex,
leading to a higher risk of pulmonary infections [896].
In patients requiring ECMO as a bridge to lung trans-
plantation who have no history of colonization or previous
infection, the general recommendations for SSI antimicrobial
prophylaxis for the procedure should be followed. In ECMO
patients with a history of colonization or previous infection,
changing the preoperative antimicrobial prophylaxis to cover
these pathogens must be considered, weighing whether the
pathogen is relevant to SSIs in the planned procedure.
Organisms. While gram-positive and gram-negative or-
ganisms are of concern in heart transplantation, there is in-
creased concern regarding gram-negative and fungal
pathogens in mediastinitis and pneumonia in patients
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undergoing lung transplantation [894,904,908]. The most
frequent organisms found in SSIs or mediastinitis in two co-
hort studies were P. aeruginosa [904,908], Candida species, S.
aureus (including MRSA) [908], enterococci, coagulase-
negative staphylococci (e.g., S. epidermidis), Burkholderia cepa-
cia [904], E. coli, and Klebsiella species.
Patients undergoing lung transplantation are also at risk for
bacterial or fungal pneumonia due to colonization or infection
of the lower and upper airways of the donor, recipient, or both
[915]. Organisms reported to cause pneumonia in lung
transplantation patients include P. aeruginosa [894,896,904,
908,920], S. aureus (including MRSA) [894,896,904,908], B.
cepacia [896,904,908], Enterobacter species [908], S. maltophilia,
Klebsiella species [904,908], S. epidermidis [904], E. coli, Asper-
gillus species [920], and VRE [894]. Similarly, organisms fre-
quently seen in pediatric lung infections are nonfermenting
gram-negative bacteria, such as Pseudomonas species, Steno-
trophomonas species, Alcaligenes species, and fungi, including
Aspergillus species [897].
The donor lung appears to be a major route of transmission
of pathogens; 75%–90% of bronchial washings from donor
organs are positive for at least one bacterial organism
[920,924,925]. Organ recipients may also be the source of in-
fection of the transplanted organ. This is particularly true in
patients with cystic fibrosis because of the frequent pres-
ence of P. aeruginosa in the upper airways and sinuses be-
fore transplantation [896,919]. These pathogens are often
multidrug-resistant, likely due, in large part, to frequent
administration of broad-spectrum antimicrobials during the
course of the disease. Multidrug-resistant strains of B. cepacia
and S. maltophilia may be a problem in cystic fibrosis patients
in some transplantation centers [919,926].
Efficacy. Although much has been published about
general infectious complications associated with lung trans-
plantation, no randomized controlled trials regarding anti-
microbial prophylaxis for lung or heart–lung transplantation
have been published; however, antimicrobial prophylaxis is
considered standard practice in these patients [896]. Anti-
microbial prophylaxis is routinely administered to patients
undergoing lung or heart–lung transplantation, with the aim
of preventing pneumonia as well as SSIs. The rate of pneu-
monia within the first two weeks postoperatively has re-
portedly been decreased from 35% to approximately 10% by
routine antimicrobial prophylaxis [927–929]. Improvements
in surgical technique and postoperative patient care are also
important factors in the apparently lower rates of pneumonia
after lung transplantation.
Choice of agent. No formal studies have addressed op-
timal prophylaxis for patients undergoing lung transplanta-
tion. Antimicrobial prophylaxis for lung and heart–lung
transplantation should generally be similar to that used for
other cardiothoracic procedures (see the cardiac and thoracic
sections). First- and second-generation cephalosporins are
considered equally efficacious and are the preferred agents for
these procedures. However, prophylactic regimens should be
modified to include coverage for any potential bacterial
pathogens, including gram-negative and fungal organisms,
that have been isolated from the recipient’s airways or the
donor lung through preoperative cultures [894,896,904,908,
915,920]. Patients with end-stage cystic fibrosis should receive
antimicrobials on the basis of the known susceptibilities of
pretransplant isolates, particularly P. aeruginosa, B. cepacia
complex, and Aspergillus species.
Antimicrobial prophylaxis regimens reported in cohort
evaluations of thoracic transplantation, including lungs, have
varied [904,908,920]. One study used ceftazidime, floxacillin,
tobramycin, and itraconazole in these patients [908]. In addition,
all patients received nebulized amphotericin B and oral itraco-
nazole as antifungal prophylaxis. Another cohort study used
cefepime for lung transplant recipients without known coloni-
zation; for thosewith known colonization, the selection of agents
was based on organism susceptibility [920]. A third cohort re-
ported use of metronidazole and aztreonam as prophylaxis for
patients with a septic lung (positive sputum culture) [904].
Antifungal prophylaxis should be considered, especially
when pretransplantation cultures reveal fungi in the donor
lung [915] or the recipient’s airway. There is no consensus on
the appropriate antifungal agent for lung transplant recipients
[894,896,930]. Selection is recommended based on patient risk
factors for infection (e.g., cystic fibrosis) and colonization,
pretransplantation and posttransplantation cultures, and local
fungus epidemiology [894,896,897,930]. Because of the serious
nature of fungal infections in the early posttransplantation
period and the availability of antifungal agents, prophylaxis
should be considered when Candida or Aspergillus species are
isolated from the donor lung [915] or recipient’s airway.
Duration. No well-conducted studies have addressed the
optimal duration of antimicrobial prophylaxis for lung or
heart–lung transplantation. In the absence of positive cultures
from the donor or the recipient, prophylactic regimens of
48–72 h and no longer than 7 d have been reported [896,904,
905,931]. In patients with positive pretransplantation cultures
from donor or recipient organs or patients with positive cul-
tures after transplantation, postoperative antimicrobial treat-
ment for 7–14 d or longer has been reported, particularly for
patients with cystic fibrosis and previous P. aeruginosa and
multidrug-resistant infections [896,915,919]. Such antimicro-
bial administration is viewed as treatment and not as surgical
prophylaxis. Treatment may include additional antibacterial
agents or antifungal agents.
Recommendations. Based on data from other types of
cardiothoracic procedures, all adult patients undergoing lung
transplantation should receive antimicrobial prophylaxis,
because of the high risk of infection. Patients with negative
pretransplantation cultures should receive antimicrobial
prophylaxis as appropriate for other types of cardiothoracic
procedures.
The recommended regimen is a single dose of cefazolin
(Table 2). There is no evidence to support continuing pro-
phylaxis until chest and mediastinal drainage tubes are re-
moved. Alternatives include vancomycin with or without
gentamicin, aztreonam, and a single fluoroquinolone dose.
(Strength of evidence for prophylaxis =A.) The optimal du-
ration of antimicrobial prophylaxis for patients who do not
have their chest primarily closed is unclear. No recommen-
dation is made for these patients.
The prophylactic regimen should be modified to provide
coverage against any potential pathogens, including gram-
negative (e.g., P. aeruginosa) and fungal organisms, isolated
from the donor lung or the recipient pretransplantation. The
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prophylactic regimen may also include antifungal agents for
Candida and Aspergillus species based on patient risk factors
for infection (e.g., cystic fibrosis) and colonization, pre-
transplantation and posttransplantation cultures, and local
fungus epidemiology. Patients undergoing lung transplanta-
tion for cystic fibrosis should receive treatment for at least
seven days with antimicrobials selected according to pre-
transplantation culture and susceptibility results. (Strength of
evidence for prophylaxis =B.)
Liver transplantation
Background
Liver transplantation is a lifesaving procedure for many
patients with end-stage hepatic disease for whom there are no
other medical or surgical options [932,933]. In 2007, UNOS
reported that 6,494 liver transplantations were performed in
the United States, 96% ofwhich had a cadaveric donor and 4%
had a living-related donor source. [934] These liver trans-
plantations were performed in 5,889 adults and 605 pediatric
( < 18 years old) patients. Reported one-year patient survival
rates for adults ranged from 76.9% to 95% [932,935–938] and
from 80% to 91.7% for pediatric patients [934,939–942]. Sur-
vival at three and five years ranged from 68.5% to 80.9% [934]
and from 61.6% to 76.5% [932,933] in adult patients, respec-
tively. In pediatric patients, three- and five-year survival
ranged from 73.2% to 86% [897,934,941] and from 69.2% to
80.1% [934], respectively. One-year graft survival rates ranged
from 74.2% to 94% in adults [934–936,938] and from 72.1% to
86.1% in pediatric patients [934,941,942]. Graft survival at
three and five years ranged from 58.9% to 75.5% and from
51.6% to 70.5%, respectively, in adults and from 62.5% to
77.6% and from 68.4% to 71.4%, respectively, in pediatric
patients [934,941]. No significant differences were noted in
graft or patient survival between cadaveric and living-related
donors in adult and pediatric liver transplant recipients [934].
Infection remains a major cause of morbidity and mortality in
liver transplant recipients. Infections may occur in 31–83% of
patients within three months of transplantation and are the
cause of death in 4–53% of patients [934,936,940,943–950].
These rates are highly variable and do not seem to have
changed despite advances in surgical technique and medical
management. SSIs within 30 days after transplantation ran-
ged from 4% to 48%with antimicrobial prophylaxis in several
cohort and controlled studies [935–938,941,942,948,949,951–
964]. Superficial SSIs are seen most often within the first two
to three weeks postoperatively, whereas organ/space infec-
tions and deep infections are seen after three to four weeks.
Liver transplantation is often considered to be the most
technically difficult of the solid-organ transplantation proce-
dures. Surgical procedures lasting longer than 8–12 hours
have been consistently identified as one of the most impor-
tant risk factors for early infectious complications, including
SSIs, intraabdominal infections, and biliary tract infections
[896,938,939,945,947,957]. Other important risk factors for
infectious complications related to liver transplantation sur-
gery include previous hepatobiliary surgery [896,939,945,
947,952,963], previous liver or kidney transplantation
[937,951,952,965], and surgical complications such as anasto-
motic leakage [896,938,939,945,947,951,952]. Patient-related
risk factors for infection after liver transplantation include
antimicrobial use within three to four months before trans-
plantation [935,954], low pretransplantation serum albumin
concentration [938,958,963], high pretransplantation serum
bilirubin concentration [939,945,947], ascites [938], obesity
[963], diabetes, and hemochromatosis [966]. Procedure-re-
lated risk factors for infection include transfusion of > 4 units
of red blood cells [896,951], bacterial contamination due to
entry into the gastrointestinal tract [963], surgical incision
method [963], and use of muromonab-CD3 within the first
week after transplantation [938].
Organisms
The pathogens most commonly associated with early SSIs
and intraabdominal infections are those derived from the
normal flora of the intestinal lumen and the skin. Aerobic
gram-negative bacilli, including E. coli [935,937,939,940,
942,945,947–949,951,967,968], Klebsiella species [933,936,937,
939,940,945,947–949,967–969], Enterobacter species [936,939,
940,942,945,947,952,959,964,967,968], A. baumannii [935–937,
942,951], and Citrobacter species [939,940,945,947,952,959,
967,968], are common causes of SSIs and intraabdominal in-
fections and account for up to 65% of all bacterial pathogens.
Infections due to P. aeruginosa may also occur but are much
less common in the early postoperative period [936,937,939,
940,942,945,947,948,952,959,969]. Enterococci are particularly
common pathogens and may be responsible for 20–46% of
SSIs and intraabdominal infections [894,933,935,937,938,
940,943,945–947,951,952,955,964,965,969]. Staphylococcus aureus
(frequently MRSA) and coagulase-negative staphylococci
are also common causes of postoperative SSIs [936–938,
940,942,943,945–949,955,957–961,964,965,970,971]. Candida
species commonly cause both early and late postoperative
infections [933,936,937,940,942,943,945–947,949,951,969].
Several studies have noted increasing concern about anti-
microbial resistance based on detection of resistant organ-
isms, including E. coli [935,937], Enterococcus species
[933,937,964,965], Enterobacter species [964], Klebsiella species
[933,937], coagulase-negative staphylococci [937,964], and S.
aureus [937,948,957–961,970]. General information on antimi-
crobial resistance is provided in the Common Principles
section of these guidelines. Of specific concern to the
transplantation community is the emergence of multidrug-
resistant A. baumannii [972], carbapenem-resistant Entero-
bacteriaceae [973,974], K. pneumoniae carbapenemase-
producing organisms [975], and C. difficile [976–978].
Efficacy
Although there remains a high rate of infection directly
related to the liver transplantation procedure, there are few
well-controlled studies concerning optimal antimicrobial
prophylaxis. In evaluating the efficacy of prophylactic regi-
mens, it is important to differentiate between early infections
(occurring within 14–30 days after surgery) and late infections
(occurring more than 30 days after surgery). Infections oc-
curring in the early postoperative period are most com-
monly associated with biliary, vascular, and abdominal
surgeries involved in the transplantation procedure itself and
are thus most preventable with prophylactic antimicrobial
regimens [939,940,943,945]. The frequency of these infections
varies from 10% to 55% despite antimicrobial prophylaxis
[939,940,943,945,979]. It is difficult to assess the efficacy of
prophylactic regimens in reducing the rate of infection,
120 SURGICAL PROPHYLAXIS GUIDELINES
because prophylaxis has been routinely used in light of the
complexity of the surgical procedure; therefore, reliable rates
of infection in the absence of prophylaxis are not available. No
controlled studies have compared prophylaxis with no pro-
phylaxis.
Choice of agent. Antimicrobial prophylaxis should be
directed against the pathogens most commonly isolated from
early infections (i.e., gram-negative aerobic bacilli, staphylo-
cocci, and enterococci). Traditional prophylactic regimens
have therefore consisted of a third-generation cephalosporin
(usually cefotaxime, because of its antistaphylococcal activi-
ty) plus ampicillin [936,937,943,944,946–948,951,952,954,962,
965,967,979]. The use of cefoxitin and ampicillin–sulbactam,
cefotaxime and ampicillin–sulbactam and gentamicin [957–
959], cefuroxime and metronidazole [971], ceftriaxone and
metronidazole [980], cefotaxime and metronidazole [953],
ceftriaxone and ampicillin [949], ceftizoxime alone [955], ce-
fotaxime and tobramycin [956], cefoxitin alone [960,961], ce-
fazolin alone [951], amoxicillin–clavulanate and gentamicin
[970], amoxicillin–clavulanate alone [951], glycopeptides and
antipseudomonal penicillin [951], fluoroquinolone and
amoxicillin–clavulanate or glycopeptide [951], vancomycin
and aztreonam [951,981], and piperacillin–tazobactam
[964,970] has also been reported. Alternative prophylaxis
regimens for b-lactam-allergic patients have included cefurox-
ime and metronidazole [970], clindamycin and gentamicin or
aztreonam [948,960–962], ciprofloxacin and metronidazole
[970], and vancomycin or ciprofloxacin [936]. Imipenem-cilas-
tatin alone was used in one study for patients with renal failure
[956]. The efficacy of these regimens comparedwith cefotaxime
plus ampicillin is difficult to assess due to different definitions
of infection used in the available studies and variability of
study design (many single-center cohort studies) in different
countries. One prospective nonrandomized study found no
difference in the frequency of SSIs in orthotopic liver transplant
recipients with cefazolin alone and amoxicillin–clavulanic acid
alone, both given one hour before surgical incision, with a
second dose given in cases of significant bleeding or surgery
lasting over six hours, as antimicrobial prophylaxis [935]. The
study did find a significantly higher rate of A. baumannii in the
cefazolin group than the amoxicillin–clavulanic acid group.
The routine use of vancomycin as antimicrobial prophylaxis
is not recommended because of the risk of developing
vancomycin-resistant organisms [8,950], but vancomycin may
be reserved for centers with an MRSA or MRSE cluster
[8,950,957–959]. No randomized controlled studies have been
conducted to compare the efficacy of other antimicrobial pro-
phylactic regimens in the prevention of early postoperative
infections. For patients known to be colonized with MRSA,
VRE, or resistant gram-negative pathogens, it is reasonable to
consider prophylaxis specifically targeted at these organisms.
See the Common Principles section for further discussion.
Postoperative infections with Candida species after liver
transplantation are common, particularly in the abdomen,
and are frequently considered organ/space SSIs. For this
reason, the use of antifungal prophylaxis in the perioperative
period has become common. Efficacy has been demonstrated
for fluconazole [964–984], lipid complex amphotericin B
[985–987], and caspofungin [988]. Finally, one meta-analysis
found a decreased risk of fungal infection and death associ-
ated with fungal infection, though not overall mortality,
among patients given antifungal prophylaxis [989]. Universal
antifungal prophylaxis is probably not necessary, since the
risk of invasive candidiasis is low in uncomplicated cases.
Instead, prophylaxis is generally reserved for patients with
two ormore of the following risk factors: need for reoperation,
retransplantation, renal failure, choledochojejunostomy, and
known colonization with Candida species [15]. Risk is also
increased with prolonged initial procedure or transfusion of
> 40 units of cellular blood products, but this cannot be pre-
dicted before the procedure.
Selective bowel decontamination to eliminate aerobic gram-
negative bacilli and yeast from the bowel before the trans-
plantation procedure has been evaluated in several studies
and a meta-analysis [936,943,949,955,956,967,968,980,990,991].
These studies used combinations of nonabsorbable antibacte-
rials (aminoglycosides, polymyxin B or E), antifungals (nysta-
tin, amphotericin B), and other antimicrobials (cefuroxime in
suspension) administered orally and applied to the oropha-
ryngeal cavity in combination with systemically administered
antimicrobials. Results are conflicting, with no differences in
patient outcomes (e.g., infection rates, mortality) or cost and
concerns of increasing gram-positive infections with potential
resistance in several studies [939,955,956,980,991] and others
with positive results [936,949]. Two randomized controlled
studies found significantly fewer bacterial infections with
early enteral nutrition plus lactobacillus and fibers [971,980].
Based on currently available data, the routine use of selective
bowel decontamination or lactic acid bacteria and fibers in pa-
tients undergoing liver transplantation is not recommended.
Duration. No studies have assessed the optimal duration
of antimicrobial prophylaxis in liver transplantation. Al-
though antimicrobials have been administered in studies for
five days [937,944,946,949,957–959] and seven days [964], the
majority of recent studies have limited the duration of pro-
phylaxis to 72 h [981], 48 h [936,943,945,952,955,956,960,961,
967,970,979,980,991], 36 h [981], 24 h [935,948,962,970], and a
single dose [963], with no apparent differences in early in-
fection rates. A prospective, nonrandomized, controlled study
found no difference in bacterial infections within the first
three months after liver transplantation in patients receiving
cefotaxime and ampicillin as short-term antimicrobial pro-
phylaxis for two to three days, compared with long-term
prophylaxis for five to seven days [954]. Of note, five of the 11
patients in the long-term prophylaxis group had detectable
C. difficile toxin B in the feces and developed enteritis. No
patients in the short-term group had detectable C. difficile.
Two recent review articles noted that antimicrobial prophy-
laxis duration should be less than three days [896,950].
Pediatric efficacy
There are few data specifically concerning antimicrobial
prophylaxis in liver transplantation in pediatric patients. The
combination of cefotaxime plus ampicillin has been reportedly
used in children undergoing living-related donor liver trans-
plantation; the efficacy of this regimen appeared to be favor-
able [946]. A small, retrospective, single-center cohort study
reported outcomes of children undergoing liver, heart, small
bowel, or lung transplantation receiving piperacillin–tazo-
bactam120–150mg/kg/day beginning before surgical incision
and continuing for 48 h postoperatively and found favorable
results, with a superficial SSI rate of 8% and no deep SSIs [992].
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Recommendations
The recommended agents for patients undergoing liver
transplantation are (1) piperacillin–tazobactam and (2) cefo-
taxime plus ampicillin (Table 2). (Strength of evidence for
prophylaxis =B.) For patients who are allergic to b-lactam
antimicrobials, clindamycin or vancomycin given in combi-
nation with gentamicin, aztreonam, or a fluoroquinolone is a
reasonable alternative. The duration of prophylaxis should be
restricted to 24 h or less. For patients at high risk of Candida
infection, fluconazole adjusted for renal function may be
considered. (Strength of evidence for prophylaxis =B.)
Pancreas and pancreas–kidney transplantation
Background
Pancreas transplantation is an accepted therapeutic inter-
vention for type 1 diabetes mellitus; it is the only therapy that
consistently achieves euglycemia without dependence on
exogenous insulin [993–997]. Simultaneous pancreas–kidney
(SPK) transplantation is an accepted procedure for patients
with type 1 diabetes and severe diabetic nephropathy. In 2007,
UNOS reported that 469 pancreas transplantations and 862
SPK transplantations were performed in the United States, of
which 60 and four patients, respectively, were under age 18
years [998]. Pancreas graft one-year survival rates ranged
from 70.2% to 89%, and the three-year rates ranged from 48%
to 85.8% [998–1002]. Patient survival with pancreas trans-
plantation has been reported between 75% and 97% at one
year and between 54% and 92.5% at three years [998]. Allo-
graft survival is higher in recipients of SPK transplantations,
with allograft survival rates of 86.1–95.1% at one year and
54.2–92.5% at three years. Reported patient survival rates in
SPK are 91.7–97.6% at one year and 84.4–94.1% at three years.
During pancreas transplantation, surgical complications with
portal-hepatic drainage significantly decreased the one-year
and three-year survival rates to 48% and 44%, respectively, in
one cohort study [999].
Infectious complications are a major source of morbidity
and mortality in patients undergoing pancreas or SPK trans-
plantation; the frequency of SSI is 7%–50%with antimicrobial
prophylaxis [993–997,1000–1009]. The majority of SSIs oc-
curred within the first 30 d to three months after transplan-
tation [1000–1002,1005,1008,1009]. Urinary tract infections are
also a significant concern during the same time frame, with
rates ranging from 10.6% to 49% in pancreas transplant recip-
ients who received antimicrobial prophylaxis, and are much
more common in recipients with bladder drainage compared
with enteric drainage [1000–1008].
Pancreas and SPK transplantation patients may be at in-
creased risk of SSIs and other infections because of the com-
bined immunosuppressive effects of diabetes mellitus and the
immunosuppressive drugs used to prevent graft rejection
[995,1000]. Other factors associated with increased SSI rates
include prolonged operating and ischemic times ( > 4 h), organ
donor age of > 55 years, and enteric rather than bladder
drainage of pancreatic duct secretions [895,995,1000]. Pro-
longed organ preservation time ( > 20 h) was shown to in-
crease the risk of complications, including duodenal leaks and
decreased graft survival in cadaveric pancreas transplant re-
cipients [1003]. Risk factors for UTI are reviewed in the kidney
transplant section.
Organisms
A majority of superficial SSIs after pancreas or SPK trans-
plantation are caused by Staphylococcus species (both coagu-
lase-positive and coagulase-negative) and gram-negative
bacilli (particularly E. coli and Klebsiella species) [993–
997,1000–1002,1004–1006,1009–1011]. Deep incisional SSIs
also are frequently associated with gram-positive (Enterococcus
species, Streptococcus species, andPeptostreptococcus species) and
gram-negative organisms (Enterobacter species, Morganella
species, andB. fragilis), aswell asCandida species [993–997,1000–
1002,1004–1006,1009–1011]. Although anaerobes are occasion-
ally isolated, the necessity for specific treatment of anaerobes
in SSIs after pancreas transplantation remains unclear.
Efficacy
Although no placebo-controlled studies have been con-
ducted, several open-label, noncomparative, single-center
studies have suggested that antimicrobial prophylaxis sub-
stantially decreases the rate of superficial and deep SSIs after
pancreas or SPK transplantation. SSI rates were 7–33% with
various prophylactic regimens [995,1000–1002,1004,1005],
compared with 7–50% for historical controls in the absence of
prophylaxis [1009,1010]. The reason for the wide disparity in
infection rates observed with prophylaxis is not readily appar-
ent but may include variations in SSI definitions, variations in
antimicrobial prophylaxis, immunosuppression protocols, and
variations in surgical techniques [999–1002,1005,1007,1008].
Choice of agent. Because of the broad range of potential
pathogens, several studies have used multidrug prophylactic
regimens, including imipenem–cilastatin plus vancomycin
[995]; tobramycin, vancomycin, and fluconazole [1010]; cefo-
taxime, metronidazole, and vancomycin [1012]; cefotaxime,
vancomycin, and fluconazole [1008]; ampicillin and cefotaxime
[1007]; and piperacillin–tazobactam and fluconazole [1006].
The HICPAC recommendations for SSI prevention include
limiting the use of vancomycin unless there is an MRSA or
MRSE cluster or as an alternative for b-lactam-allergic pa-
tients, though transplantation procedures were not specifi-
cally covered in the guidelines [8]. Limited data are available
on the use of vancomycin as antimicrobial prophylaxis in
kidney or pancreas transplantation, or both. A small, ran-
domized, active-controlled, single-center study evaluated the
impact of vancomycin-containing antimicrobial prophylaxis
regimens in kidney and pancreas (alone or SPK) transplant
recipients on the frequency of gram-positive infections [1004].
Renal transplantation patients received either vancomycin
and ceftriaxone or cefazolin, and pancreas transplantation
patients received either vancomycin and gentamicin or cefa-
zolin and gentamicin. There was no statistically significant
difference in the risk of developing gram-positive infections
between antimicrobial prophylaxis regimens with and with-
out vancomycin. The study was not powered to detect a dif-
ference in efficacy between the antimicrobial regimens. For
patients known to be colonized with MRSA, VRE, or resistant
gram-negative pathogens, it is reasonable to consider pro-
phylaxis targeted specifically for these organisms. See the
Common Principles section for further discussion.
An evaluation of the surgical complications of pancreas
transplant recipients with portal-enteric drainage found
an intraabdominal infection rate of 12% in the 65 patients
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undergoing SPK transplantation and no cases in those under-
going pancreas transplantation alone [999]. All patients re-
ceived either cefazolin 1 g i.v. every eight hours for one to three
days, or vancomycin if the patient had a b-lactam allergy.
One study evaluated SSI rates in SPK transplantation after
single-agent, single-dose prophylaxis with cefazolin 1 g i.v. to
donors and recipients, as well as cefazolin 1 g/L bladder and
intraabdominal irrigation in the recipient [1009]. Superficial
SSIs developed in two patients (5%), and deep SSIs associated
with bladder anastomotic leaks or transplant pancreatitis oc-
curred in four additional patients (11%). This study reported
similar SSI rates as with multidrug, multidose regimens.
Based on the regularity of isolation of Candida species from
SSIs after pancreas transplantation and the frequent coloni-
zation of the duodenum with yeast, fluconazole is commonly
added to prophylactic regimens. Although never studied in a
randomized trial, a lower fungal infection rate was found in
one large case series with the use of fluconazole (6%) com-
pared with no prophylaxis (10%) [1013]. Although enteric
drainage of the pancreas has been identified as a risk factor for
postoperative fungal infections, many institutions use fluco-
nazole for prophylaxis with bladder-drained organs as well.
In settings with a high prevalence of non-albicans Candida
species, a lipid-based formulation of amphotericin B has been
recommended in infectious diseases guidelines from the
American Society of Transplantation and the American So-
ciety of Transplant Surgeons [15].
Duration. Studies evaluating the use of antimicrobial
prophylaxis regimens in pancreas and SPK transplantation,
summarized above, ranged from a single preoperative
dose of cefazolin to multidrug regimens of 2–5 d duration
[995,1005,1009,1010,1012]. More recent studies reported
monotherapy regimens with cefazolin or vancomycin [999],
amoxicillin–clavulanic acid [1001,1002], and piperacillin–
tazobactam [1000–1002] 1–7 d in duration, with the majority
using the regimen 48–72 h after transplantation. The duration
of fluconazole ranged from 7 to 28 d [1002].
Recommendations
The recommended regimen for patients undergoing pan-
creas or SPK transplantation is cefazolin (Table 2). (Strength of
evidence for prophylaxis=A.) For patients who are allergic
to b-lactam antimicrobials, clindamycin or vancomycin given
in combination with gentamicin, aztreonam, or a fluor-
oquinolone is a reasonable alternative. The duration of pro-
phylaxis should be restricted to 24 hours or less. The use of
aminoglycosides in combinationwith other nephrotoxic drugs
may result in renal dysfunction and should be avoided unless
alternatives are contraindicated. (Strength of evidence for
prophylaxis=C.) For patients at high risk of Candida infection,
fluconazole adjusted for renal function may be considered.
Kidney transplantation
Background
In 2007, UNOS reported that 16,628 kidney transplanta-
tions were performed in the United States; of these, 796 pa-
tients were younger than 18 years [998]. The rate of
postoperative infection after this procedure has been reported
to range from 10% to 56%, with the two most common in-
fections being UTIs and SSIs [1004,1014–1024]. Graft loss due
to infection occurs in up to 33% of cases [1017,1023]. One
study of adult and pediatric kidney transplant recipients
(both living-related and cadaveric donor sources) found pa-
tient survival rates at seven years after transplantation of
88.9% and 75.5%, respectively, and graft survival of 75%
and 55.5%, respectively [1025]. No patients developed an
SSI. Mortality associated with postoperative infections is
substantial and ranges from approximately 5% to 30%
[1015,1017,1019,1022,1026,1027].
The frequency of SSIs in kidney transplant recipients
has ranged from zero to 11% with antimicrobial prophylaxis
[1023–1025,1028,1029] to 2% to 7.5% without systemic pro-
phylaxis [1030,1031]. The majority of these infections were
superficial in nature and were detected within 30 days after
transplantation [1023,1028–1030]. Risk factors for SSI after
kidney transplantation include contamination of organ per-
fusate [1027]; pretransplantation patient-specific factors, such
as diabetes [1029,1030], chronic glomerulonephritis [1030],
and obesity [1027,1030,1032]; procedure-related factors, such
as ureteral leakage and hematoma formation [1027]; immu-
nosuppressive therapy [1024,1027,1029]; and postoperative
complications, such as acute graft rejection, reoperation, and
delayed graft function [1030]. In one study, the frequency of
SSI was 12% in patients receiving immunosuppression with
azathioprine plus prednisone but only 1.7% in patients re-
ceiving cyclosporine plus prednisone [1033]. A significant
difference in SSI rates was noted after kidney transplantation
between immunosuppression regimens including mycophe-
nolate mofetil (45 [3.9%] of 1150 patients) versus sirolimus (11
[7.4%] of 144 patients) [1029]. Sirolimus-containing immuno-
suppression was found to be an independent risk factor for
SSIs. These recommendations refer to kidney transplant re-
cipients; recommendations for living kidney donors can be
found in the discussion of nephrectomy in the urologic section.
Organisms
Postoperative SSIs in kidney transplant recipients are
caused by gram-positive organisms, particularly Staphylo-
coccus species (including S. aureus and S. epidermidis) and
Enterococcus species, gram-negative organisms, E. coli, En-
terobacter species, Klebsiella species, P. aeruginosa, and yeast
with Candida species [1004,1014–1021,1023,1024,1026,1028,
1030,1034]. One study site in Brazil reported a high level of
antimicrobial resistance [1030]. Organisms recovered from
infections included MRSA (77%), methicillin-resistant coag-
ulase-negative Staphylococcus (53.5%), extended-spectrum
b-lactamase-producing K. pneumoniae (80%), and carbape-
nem-resistant P. aeruginosa (33.3%). Another center in Brazil
reported a significant difference in resistance to broad-
spectrum antimicrobials in pathogens isolated in UTIs from
cadaveric kidney transplant recipients (n= 21, 19.1%) com-
pared with living-related donor kidney transplant recipients
(n= 2, 3.7%) (p = 0.008) [1024]. One center in the United States
reported 94% susceptibility to vancomycin of Enterococcus
species within the first month after transplantation, while E.
coli, cultured most commonly more than six months after
transplantation, was 63% resistant to sulfamethoxazole–tri-
methoprim [1023]. This resistance may be related to the rou-
tine use of sulfamethoxazole–trimethoprim in prophylaxis of
Pneumocystis jerovici pneumonia and UTI.
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Efficacy
A number of studies have clearly demonstrated that anti-
microbial prophylaxis significantly decreases postoperative
infection rates in patients undergoing kidney transplantation.
These have included at least one randomized controlled trial
[1014] and many prospective and retrospective studies com-
paring infection rates with prophylaxis and historical infection
rates at specific transplantation centers [1015–1018,1021,1033–
1035]. Based on the available literature, the routine use of sys-
temic antimicrobial prophylaxis is justified in patients under-
going kidney transplantation.
Two studies that evaluated a triple-drug regimen consist-
ing of an aminoglycoside, an antistaphylococcal penicillin,
and ampicillin found infection rates of < 2%, compared with
10–25% with no antimicrobial prophylaxis [1018,1019]. More
specifically, infection rates in patients without antimicrobial
prophylaxis (45 cadaveric and 44 living-related donors) were
10.1% in total (8.9% and 11.4%, respectively), compared with
1.5% in total (1.5% and zero, respectively) with antimicrobial
prophylaxis [1018]. Infection rates were as high as 33% in
living-related patients with no antimicrobial prophylaxis and
zero to 1% in both cadaveric and living-related transplant
recipients with antimicrobial prophylaxis [1021]. Piperacillin
plus cefuroxime was also shown to be efficacious; infection
rates were 3.7%, compared with 19% in cadaveric transplant
recipients not receiving prophylaxis [1018]. Several studies
have shown that single-agent prophylaxis with an anti-
staphylococcal penicillin [1029,1034], a first-generation cepha-
losporin [1016,1017,1023,1024,1029], a second-generation
cephalosporin [1028,1035,1036], or a third-generation cephalo-
sporin (e.g., cefoperazone, cefotaxime, ceftriaxone) [1024,1029,
1033,1037] can reduce postoperative infection rates to zero to
8.4%. All studies included cadaveric transplant recipients,
whereas living-related transplant recipients were also included
in select studies [1017,1024,1028,1036]. Where compared di-
rectly, infection rates between cadaveric and living-related
transplant recipients receiving antimicrobial prophylaxis were
not statistically different [1024].
Choice of agent. The available data do not indicate a
significant difference between single-drug and multidrug
antimicrobial regimens [1014,1018,1021]. In addition, there
appears to be no significant differences between single-agent
regimens employing antistaphylococcal penicillins and first-,
second-, or third-generation cephalosporins [1016,1017,1033–
1035,1037]. Studies have directly compared antimicrobial
regimens in a prospective, controlled fashion. Single-agent
prophylaxis with both cefazolin and ceftriaxone has been re-
ported to result in SSI rates of zero [1016,1024,1037].
A survey of 101 kidney transplant centers in 39 countries
reported that 65% of the centers used single antimicrobial
prophylaxis regimens, 20.8% used two-drug regimens, and
3% used three drugs; no prophylaxis was used in 11% of
centers [1036]. Cephalosporins were used in 68 centers (55
alone, 7 in combination with penicillin, and 6 with other an-
timicrobials). Penicillins were used by 28 centers (13 alone, 7
with cephalosporin, and 8 with other antimicrobials). Other
antimicrobials (specifics were not reported) were used in two
centers as the single agent.
As noted above, HICPAC recommendations for SSI pre-
vention include limiting the use of vancomycin to situations in
which there is an MRSA or MRSE cluster or as an alternative
for b-lactam-allergic patients [8]. Transplantation procedures
were not specifically covered in the guidelines.
Duration. Studies have used various prophylactic regi-
mens, ranging from a single-drug cephalosporin regimen,
administered as a single preoperative dose or for up to 24 h
postoperatively, to multidrug regimens of two to five days’
duration [981,1004,1014–1018,1021,1023,1024,1028,1029,1033,
1036,1038]. Cefazolin for 24 h was equivalent to seven days of
surgical prophylaxis in living-related kidney transplant donors.
[1039] There appear to be no significant differences in SSI rates
between single-dose, 24-h, and multidose regimens; therefore,
the duration of antimicrobial should be restricted to 24 h.
Pediatric efficacy
Although pediatric patients were included in studies
demonstrating the efficacy of antimicrobial prophylaxis, there
are few data specific to pediatric patients. One cohort of 96
pediatric patients who underwent 104 renal transplants (63%
cadaveric and 37% living-related donors) ranged in age from
six months to 18 years (mean age, 8.2– 5.5 years) [1040]. Anti-
microbial prophylaxis included one dose of cefotaxime 30-mg/
kg i.v. bolus at the start of the procedure and cefotaxime 90mg/
kg/day in three divided doses during the intensive care unit
stay, which averaged one to two days. No SSIs were reported.
Recommendations
The recommended agent for patients undergoing kidney
transplantation is cefazolin (Table 2). (Strength of evidence for
prophylaxis =A.) For patients who are allergic to b-lactam
antimicrobials, clindamycin or vancomycin given in combi-
nation with gentamicin, aztreonam, or a fluoroquinolone is a
reasonable alternative. The duration of prophylaxis should be
restricted to 24 h or less. The use of aminoglycosides in
combination with other nephrotoxic drugs may result in renal
dysfunction and should be avoided unless alternatives are
contraindicated. (Strength of evidence for prophylaxis =C.)
For patients at high risk of Candida infection, fluconazole ad-
justed for renal function may be considered.
Plastic surgery and breast procedures
Background
Plastic surgery encompasses a broad range of procedures
focused on reconstructive, dermatological, and cosmetic
procedures [1041]. The primary goal of these procedures is to
restore function to the affected area, with a secondary goal of
improving appearance. The scope of procedures ranges from
simple primary surgical site closure, skin grafts, and skin flaps
to composite tissue transplantations. Composite tissue trans-
plantation for tissue reconstruction of the knee joint, larynx,
uterus, abdominal wall, hand, face, and penis has been per-
formed in a small number of patients [1042,1043].
Most dermatological, breast (reduction and reconstruc-
tive), clean head and neck, and facial procedures have an
associated SSI rate of < 5% [1044–1053]. Oral procedures, such
as wedge excision of lip or ear, flaps on the nose [1046,1054],
and head and neck flaps, have SSI rates of approximately
5–10% [1053,1055–1060]. In addition to general risk factors as
described in the Common Principles section, factors that in-
crease the risk of postoperative infectious complications
124 SURGICAL PROPHYLAXIS GUIDELINES
for plastic surgery procedures include implants [1061], skin
irradiation before the procedure, and procedures below the
waist [1062,1063].
Organisms
The most common organisms in SSIs after plastic surgery
procedures are S. aureus [1045,1049,1050,1053,1054,1056,
1063–1068], other staphylococci, and streptococci [1045,
1054,1064,1066,1067]. Procedures involving macerated, moist
environments (e.g., under a panus or axilla of an obese indi-
vidual), below the waist, or in patients with diabetes are as-
sociated with a higher rate of infection with gram-negative
organisms such as P. aeruginosa, [1068] Serratia marcescens, or
Enterobacteriaceae, including E. coli [1065,1068], Klebsiella
species [1068], and P. mirabilis [1065].
Efficacy
The efficacy of antimicrobial prophylaxis in select plastic
surgery procedures has been investigated in several clinical
trials and cohort studies. Most placebo-controlled and retro-
spective studies for many clean plastic surgery procedures
have found that antimicrobial prophylaxis does not signifi-
cantly decrease the risk of infection. These studies have
evaluated head and neck procedures (facial bone fracture,
tumor excision and reconstruction, radical neck dissection,
rhinoplasty) [1049], flexor tendon injury repairs [1051], aug-
mentation mammoplasty using periareolar submuscular
technique [1052], carpal tunnel [1069], and breast procedures
(reduction mammoplasty, lumpectomy, mastectomy, axillary
node dissection) [1056,1058,1070,1071].
However, a Cochrane review of seven randomized,
placebo-controlled trials of 1984 patients undergoing breast
cancer procedures (axillary lymph node dissection and pri-
mary nonreconstructive surgery) evaluated the effectiveness
of preoperative or perioperative antimicrobial prophylaxis
(n = 995) compared with placebo or no treatment (n = 989) in
reducing the rate of postoperative infections [1072]. Pooled
study results revealed a significant difference in SSI rates
with antimicrobial prophylaxis (80 [8%] of 995), compared
with 10.5% (104 of 989) for no antimicrobial prophylaxis
(relative risk, 0.72; 95% CI, 0.53–0.97). Review authors con-
cluded that antimicrobial prophylaxis is warranted to de-
crease the risk of SSIs in nonreconstructive breast cancer
procedures.
Guidelines also support no antimicrobial prophylaxis in
patients undergoing clean facial or nasal procedures without
an implant [7]. For patients undergoing facial or nasal pro-
cedures with an implant, antimicrobial prophylaxis should be
considered [7].
A randomized, double-blind, controlled trial of 207 pa-
tients evaluated the use of three antimicrobial prophylaxis
regimens in patients undergoing abdominoplasty procedures
[1066]. The reported SSI rates were 13% for patients receiving
no antimicrobial prophylaxis, 4.3% for those receiving pre-
operative antimicrobials only, and 8.7% for those receiving
one preoperative dose and three days of postoperative anti-
microbials. There was a significantly lower infection rate in
the group receiving preoperative antimicrobials only com-
paredwith the placebo group (p < 0.05). The infection rate was
slightly but not significantly higher in patients who received
postoperative antimicrobials.
Choice of agent. There is no consensus on the appropri-
ate antimicrobial agent to use for prophylaxis in plastic sur-
gery procedures [1055,1073]. Agents with good gram-positive
coverage and, depending on the site of surgery, activity
against common gram-negative organisms are recommended
for patients undergoing clean plastic surgery procedures with
risk factors (listed in the Common Principles section and the
background discussion of this section) or clean-contaminated
procedures. Cefazolin or ampicillin–sulbactam is sufficient in
most cases, with clindamycin and vancomycin as alternatives
for patients with b-lactam allergy. There are no studies as-
sessing the impact of MRSA on patients undergoing plastic
surgery procedures or regarding the need to alter prophylaxis
regimens in patients without known colonization with
MRSA. When vancomycin or clindamycin is used and if a
gram-negative organism is highly suspected, practitioners
should consider adding cefazolin if the patient is not b-lactam
allergic; if the patient is b-lactam allergic, the addition of az-
treonam, gentamicin, or single-dose fluoroquinolone should
be considered. If the surgical site involves the ear, an anti-
pseudomonal fluoroquinolone may be considered to cover
Pseudomonas species [1045].
Although oral agents such as cephalexin, amoxicillin,
clindamycin, and azithromycin have been recommended
in reviews of antimicrobial prophylaxis in clean dermatolog-
ical surgery, there is no evidence that supports their use
[13,1045,1046,1054].
Duration. Antimicrobial prophylaxis should be limited
to the shortest duration possible to prevent SSIs (even if
a drain or a catheter is left in place or an implant is inserted),
limit adverse events, and prevent antimicrobial resistance
[8,512,1047,1048,1054,1056]. Multiple studies have found no
significant differences in SSI rates after breast surgery with
single-dose preoperative cephalosporin compared with ex-
tended-duration regimens that last from one to five days
postoperatively [1048,1054,1056].
A randomized, single-blind, controlled trial of 74 patients
undergoing surgical ablation of head and neck malignancies
with immediate free-flap reconstruction found no significant
differences in SSI rate between clindamycin 900mg i.v. every
eight hours for three doses compared with 15 doses [1057].
Both groups were given clindamycin 900mg i.v. immediately
preoperatively, in addition to the postoperative regimens.
In a controlled study, 200 patients undergoing septorhi-
noplasty were randomized to a single preoperative dose of
amoxicillin–clavulanate 2.2 g i.v. administered 30 min before
surgical incision only (n= 100) or in combination with post-
operative oral amoxicillin–clavulanic acid 1000mg twice
daily for seven days [533]. There was no significant difference
in infection rates between the group receiving only a preopera-
tive dose (zero) and the combination group (3%). There was a
higher rate of adverse events (nausea, diarrhea, skin rash,
and pruritus) among the combination group comparedwith the
group receiving only a preoperative dose (p=0.03). The study
authors recommended the use of a single preoperative i.v. dose
of amoxicillin–clavulanate for endonasal septorhinoplasty.
Pediatric efficacy
Limited data on antimicrobial prophylaxis are available for
pediatric patients undergoing plastic surgery procedures.
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There is no consensus among surgeons regarding the use of
antimicrobial prophylaxis in the repair of cleft lip and
palate [1074]. The occurrence of postoperative infections
after these procedures is 1.3% [1075]. No controlled trials
have evaluated the use of antimicrobial prophylaxis in these
procedures.
Recommendations
Antimicrobial prophylaxis is not recommended for most
clean procedures in patients without additional postoperative
infection risk factors as listed in the Common Principles sec-
tion of these guidelines and the background discussion of this
section. Although no studies have demonstrated antimicro-
bial efficacy in these procedures, expert opinion recommends
that patients with risk factors undergoing clean plastic pro-
cedures receive antimicrobial prophylaxis. The recommen-
dation for clean-contaminated procedures, breast cancer
procedures, and clean procedures with other risk factors is a
single dose of cefazolin or ampicillin–sulbactam (Table 2).
(Strength of evidence for prophylaxis =C.) Alternative agents
for patients with b-lactam allergy include clindamycin and
vancomycin. If there are surveillance data showing that gram-
negative organisms cause SSIs for the procedure, the practi-
tioner may consider combining clindamycin or vancomycin
with another agent (cefazolin if the patient is not b-lactam-
allergic; aztreonam, gentamicin, or single-dose fluoro-
quinolone if the patient is b-lactam-allergic). Postoperative
duration of antimicrobial prophylaxis should be limited to
less than 24 h, regardless of the presence of indwelling cath-
eters or drains.
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Appendix A. National Healthcare Safety Network Criteria
for Classifying Wounds35
Clean
An uninfected operative wound in which no inflam-
mation is encountered and the respiratory, alimen-
tary, genital, or uninfected urinary tracts are not entered.
In addition, clean wounds are primarily closed and, if
necessary, drained with closed drainage. Operative
incisional wounds that follow nonpenetrating (blunt)
trauma should be included in this category if they meet the
criteria.
Clean-contaminated
Operative wounds in which the respiratory, alimentary,
genital, or urinary tracts are entered under controlled con-
ditions and without unusual contamination. Specifically,
operations involving the biliary tract, appendix, vagina, and
oropharynx are included in this category, provided no evi-
dence of infection or major break in technique is encoun-
tered.
Contaminated
Open, fresh, accidental wounds. In addition, operations
with major breaks in sterile technique (e.g., open cardiac
massage) or gross spillage from the gastrointestinal tract and
incisions in which acute, nonpurulent inflammation is en-
countered are included in this category.
Dirty or infected
Includes old traumatic wounds with retained devitalized
tissue and those that involve existing clinical infection or
perforated viscera. This definition suggests that the organisms
causing postoperative infection were present in the operative
field before the operation.
Appendix B. National Healthcare Safety Network Criteria
for Defining a Surgical-Site Infection (SSI)8,36
Superficial incisional SSI
Occurs within 30 days postoperatively and involves skin or
subcutaneous tissue of the incision and at least one of the
following: (1) purulent drainage from the superficial incision,
(2) organisms isolated from an aseptically obtained culture of
fluid or tissue from the superficial incision, (3) at least one of
the following signs or symptoms of infection: pain or ten-
derness, localized swelling, redness, or heat, and superficial
incision is deliberately opened by surgeon and is culture-
positive or not cultured (a culture-negative finding does not
meet this criterion), and (4) diagnosis of superficial incisional
SSI by the surgeon or attending physician.
Deep incisional SSI
Occurs within 30 days after the operative procedure if no
implant is left in place or within one year if implant is in place
and the infection appears to be related to the operative proce-
dure, involves deep soft tissues (e.g., fascial and muscle layers)
of the incision, and the patient has at least one of the following:
(1) Purulent drainage from the deep incision but not from the
organ/space component of the surgical site, (2) a deep incision
spontaneously dehisces or is deliberately opened by a surgeon
and is culture-positive or not cultured and the patient has at
least one of the following signs or symptoms: fever (>38 C) or
localized pain or tenderness (a culture-negative finding does
not meet this criterion), (3) an abscess or other evidence of
infection involving the deep incision is found on direct exam-
ination, during reoperation, or by histopathologic or radiologic
examination, and (4) diagnosis of a deep incisional SSI by a
surgeon or attending physician.
Organ/space SSI
Involves any part of the body, excluding the skin incision,
fascia, or muscle layers, that is opened or manipulated during
the operative procedure. Specific sites are assigned to organ/
space SSI to further identify the location of the infection (e.g.,
endocarditis, endometritis, mediastinitis, vaginal cuff, and
osteomyelitis). Organ/space SSI must meet the following cri-
teria: (1) Infection occurs within 30 days after the operative
procedure if no implant is in place or within one year if implant
is in place and the infection appears to be related to the operative
procedure, (2) infection involves any part of the body, excluding
the skin incision, fascia, or muscle layers, that is opened or
manipulated during the operative procedure, and (3) the patient
has at least one of the following: (a) purulent drainage from a
drain that is placed through a stabwound into the organ/space,
(b) organisms isolated from an aseptically obtained culture of
fluid or tissue in the organ/space, (c) an abscess or other evi-
dence of infection involving the organ/space that is found on
direct examination, during reoperation, or by histopathologic or
radiologic examination, and (d) diagnosis of an organ/space SSI
by a surgeon or attending physician.
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